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Myelinoids: three-dimensional human pluripotent stem cell-derived cultures 
comprising CNS-patterned cells and demonstrating compact myelination as a model 
to study human myelin development and disease. Myelinating oligodendrocytes in 






Myelination is essential for central nervous system (CNS) formation, health, and 
function. Its development is an adaptive and regulated process that, when perturbed, 
leads to disease. However, our understanding of myelin formation in health and 
disease is limited by the paucity of human models of myelination. I sought to develop 
a human stem cell-derived in vitro model of myelination that would enable studies of 
myelin development in the context of pharmacological, physiological, or genetic 
perturbations. 
Three-dimensional human induced pluripotent stem cell-derived, spinal cord 
organoids were generated containing NF-H+ neurons, GFAP+ astrocytes, PDGFRα+ 
oligodendrocyte progenitor cells, and MBP+ oligodendrocytes. With prolonged culture, 
myelin formation was evident, demonstrated by (i) thick MBP+ tubular structures co-
localising with NF-H+ axons; (ii) organisation of myelinated axon domains, as 
determined by appropriate clustering of paranodal and nodal proteins; and (iii) 
compact myelin lamellae visualised by transmission electron microscopy. iPSC 
‘myelinoids’ demonstrate temporal development of myelination, with both myelin 
sheath length and compaction increasing over time. The morphology of individual 
myelinating oligodendrocytes could also be analysed, and exposure to a 
pharmacological cytoskeletal modulator potentiated myelin sheath number per cell, 
as expected. Furthermore, a novel automated pipeline to quantify myelin volume 
across entire myelinoids was developed, which showed that myelin volume—specific 
to myelinated axons—increased over time. Automated analysis of 
oligodendrogenesis and myelin formation was demonstrated as an alternative method 
for investigating the effects of small molecules or trophic factor signalling on 
oligodendrogenesis and myelin development. 
Neuronal activity can regulate myelination by oligodendrocytes in model organisms. 
However, whether myelination by human oligodendrocytes is responsive to neuronal 
activity has not previously been investigated. I found that blocking synaptic vesicle 
release via tetanus toxin (TeNT) impaired myelin sheath generation by individual 
oligodendrocytes and led to a reduction in total myelin volume across myelinoids. 
 viii 
These results demonstrate that human myelinating oligodendrocytes respond to 
changes in neuronal activity.  
An advantage of iPSC-based models is the generation of patient-derived cultures that 
enable aspects of human disease to be modelled in vitro. In order to demonstrate that 
myelinoids could be used to model disorders of myelin, myelinoids were generated 
from a patient with a homozygous recessive mutation in the gene for Neurofascin 
(NFASC). This nonsense mutation is predicted to specifically affect the glial-
expressed form of Neurofascin, Nfasc155 (a component of the paranodal axoglial 
junction assembly expressed by glia), the deficiency of which results in a 
neurodevelopmental disorder characterised by hypotonia, amimia, and areflexia. 
Patient-derived myelinoids demonstrated impaired formation of paranodal axoglial 
junctions, while nodal Neurofascin remained intact, recapitulating the major pathology 
of this disease.  
Finally, oligodendrocyte pathology is prevalent in amyotrophic lateral sclerosis (ALS), 
a rapidly progressing neurodegenerative disorder of both upper and lower motor 
neurons. However, the mechanism by which oligodendrocytes contribute to disease 
is not yet understood. TDP-43 is a critical DNA/RNA binding protein involved in RNA 
metabolism whose cytoplasmic misaccumulation and aggregation in neurons and glia 
is a pathological hallmark of ALS. Disease causing mutations in the encoding gene, 
TARDBP, account for 5-10% of familial forms of ALS. To determine whether mutant 
TDP-43 affects myelin development, myelinoids were generated from both patient-
derived and CRISPR/Cas9 gene-corrected iPSCs. I found that myelinoids derived 
from mutant and gene-corrected iPSCs showed no difference in oligodendrogenesis 
or myelin formation. 
Collectively, this work shows that iPSC myelinoids provide a robust platform for 






Communication within the brain and between the brain and the rest of the body, 
occurs via electrical signals that travel along nerve cells called neurons. 
Approximately half of these neurons are covered in a dense insulating sleeve, called 
myelin, which is made by cells called oligodendrocytes. Much like insulation on an 
electrical wire, myelin enables signals between different parts of the brain and other 
body parts to be carried by neurons up to ten times more quickly than they could travel 
otherwise. Myelin plays other important roles too, helping to provide the optimal 
chemical environment for neuron function. It is unsurprising then that damage to, or 
loss of, myelin (or oligodendrocytes) has drastic consequences on neuron function 
and can cause these cells to die. This happens in disorders such as the 
leukodystrophies, multiple sclerosis, and motor neuron disease. Moreover, there is 
some evidence that subtle changes to myelin development might be involved in 
causing psychiatric conditions such as schizophrenia. 
Currently, most of our understanding of myelin development in health and disease 
has come from animal models. Such studies are an integral part of biomedical and 
drug discovery research. However, the development of new therapies to treat human 
disease is very inefficient, particularly for brain disorders. Recent studies have 
identified important differences between mice and human cells that might be 
contributing to inefficient drug development. In order to address this, many have 
turned to human stem cells: ‘ground-state’, embryonic-like cells that have the potential 
to be made into any cell in the body. Stem cells can be derived by reprogramming 
skin cells or blood cells, making it possible to source stem cells from healthy adults 
as well as people with neurological disorders. We can grow these cells into the cell 
type of our choice and use them to study how disease-causing mutations effect 
cellular processes and to test the effectiveness of different drugs on rescuing any 
disease-associated defects.  
Human stem cell-derived oligodendrocytes can be made through a process 
sometimes referred to informally as ‘chemical cookery’. However, unlike the same 
cells from rodents, human oligodendrocytes do not readily form myelin when placed 
together with neurons. Therefore, in order to study human myelin development using 
 x 
healthy and patient-derived oligodendrocytes, I first aimed to find the right conditions 
that would support human stem cell-derived myelin formation in the lab. I found that 
cultures of stem cells that were grown as three-dimensional spheres generated both 
neurons and oligodendrocytes and that myelin wrapping around neurons could be 
seen after maintaining these cultures for long periods of time. I characterised myelin 
development in these cultures and found that myelinating spheres, or ‘myelinoids’, 
demonstrated the expected characteristics of mature, compactly wrapped myelin. I 
also showed that, when exposed to different drugs, the number and morphology of 
myelinating oligodendrocytes changed predictably, providing evidence that human 
stem cell-derived myelin looked and behaved as we would expect.  
Next, I asked whether human oligodendrocytes could respond to changes in neuronal 
activity. Studies in animal models have shown that neurons with either higher or lower 
levels of electrical activity had either more or less myelin along their lengths and also 
affected the amount of myelin made per oligodendrocyte. This has important 
implications for the idea of ‘plasticity’, which refers to a range of physical and 
functional changes in the brain that accompany certain tasks, for example, learning 
to juggle, play the piano or learning a second language. Human brain imaging studies 
have shown structural changes in response to learning specific motor tasks that are 
suggestive of changes in myelin. However, it has not yet been possible to test whether 
human myelinating oligodendrocytes are responsive to neuronal activity. I found that 
reducing neuronal activity led to a reduction in myelin formation. These findings show, 
for the first time, that human oligodendrocytes respond to changes in neuronal activity.  
Subsequently, using patient-derived stem cells that carry a defective gene involved in 
myelin formation, I show that myelinoids acquire the same myelination defect that was 
observed in the patient and animal models of this particular disease. This validates 
this platform for modelling neurological disorders. Finally, I investigated whether a 
disease-causing mutation that results in motor neurone disease (MND) had an impact 
on myelin development. To do so, I used stem cells from someone with MND and, 
using the CRISPR/Cas9 ‘genetic scissors’ approach to cut and repair the disease-
causing mutation, created gene-corrected stem cells that can be used to compare 
against the unhealthy ‘cell line’. Using these two stem cell lines, I show that the 
presence of the MND-causing mutation does not affect myelin formation in stem cell 
derived myelinoids. 
 xi 
Collectively, this work shows that human stem cells can be used to generate a model 
of myelination for the study human myelin development and the factors that regulate 
it, as well as to study myelination in the context of human disease, through the use of 
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Chapter 1 Aims 
 
  
  2 
The overarching aim of this thesis is to establish a robust and efficient in vitro model 
of myelination using human induced pluripotent stem cells that recapitulates the three-
dimensional architecture of myelinated axons. This will enable future studies of 
human myelin development and the factors that regulate it, as well as provide a 
platform from which to investigate myelin formation in the context of human disease. 
Specifically, I aim to: 
a) Establish an in vitro human stem cell derived myelination model by exploring 
co-culture and three-dimensional organoid models.   
 
b) Interrogate whether human myelination responds to pharmacological and 
physiological cues, including neuronal activity.  
 
c) Develop an automated method of quantifying in vitro myelin that enables 
higher experimental throughput.  
 
d) Investigate whether human disorders of myelin can be recapitulated in an in 
vitro model of myelination using patient-derived iPSCs.   
 
  








Chapter 2 Introduction 
 
  
  4 
Myelination is a remarkable example of reciprocal communication between two very 
different cell-types. This process profoundly affects axon function and has had 
considerable bearing on the expansion and connectivity of the central nervous system 
(CNS) over time (Zalc et al. 2008). Ensheathment of axons by specialised glial cell 
membrane leads to the formation of a dynamic axo-myelin unit that is associated with 
substantial rearrangement of ion channels and cytoskeletal proteins, modified signal 
propagation and altered metabolic support (Sherman & Brophy 2005; Hartline & 
Colman 2007; Simons & Nave 2015). Many axons are myelinated in the CNS and 
disruption to or loss of myelin has dramatic consequences on CNS health and function 
as a whole. 
Myelin related disorders may be inherited or acquired, appear in young and old age 
and are a source of substantial economic burden (Powers 2004; Noseworthy 2000). 
Currently however, our understanding of myelin pathology in human disorders is 
limited by the paucity of human models of myelination. Induced pluripotent stem cell 
technology has enabled researchers to generate distinct CNS-derived cells, including 
oligodendrocytes, from both healthy individuals and those with neurological disorders, 
in vitro (Livesey et al. 2016). However, only transplantation studies using the 
dysmyelinating shiverer mouse model has faithfully recapitulated the appropriate 
three-dimensional architecture of myelinated axons by human oligodendrocytes so 
far (Windrem et al. 2017). In this thesis I will establish a robust method of generating 
iPSC-derived myelin with appropriate architecture and nodal organisation using 
organoid-like cultures and will characterise myelin development therein. I will 
demonstrate that human myelin formation is sensitive to pharmacological 
manipulation and that regulation of synaptic vesicle release modulates myelinating 
oligodendrocyte morphology as well as global levels of myelin. Finally, I will show that 
patient-derived cultures recapitulate key features of a disorder of myelinated axon 
organisation (Nfasc155 deficiency) and that presence of the ALS-causing mutation, 
TARDBPG298S, does not impact myelin formation in these cultures. 
In this introduction, I will summarise the functions of myelin as well as its development 
and pathology in disease. I will discuss recent evidence outlining the role of neuronal 
activity in modulating several aspects of myelin formation and emphasise the 
importance of studying human oligodendroglia by summarising species-specific 
differences related to myelin development. Lastly, I will discuss the models used to 
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study oligodendroglia and their contemporary equivalents, making the case that iPSC-
derived organoids are well-suited to the study of complex interactions between human 
CNS-derived cells in vitro. 
  
  6 
2.1 Myelin form and function 
 
The acquisition of myelinated fibres in a subset of vertebrates 425 million years ago 
is considered to be a major contributing factor to the evolution of nervous systems 
with greatly enhanced information processing capacity (Zalc et al. 2008). The reason 
for this lies in the propagation of electrical impulses. 
Action potential propagation along the axons of neurons relies on a strongly 
maintained negative charge on the intracellular surface of the axolemma. The 
initiation involves membrane depolarization beyond a certain threshold that results in 
a conformational change in nearby voltage-gated sodium channels, which are 
dispersed throughout the axolemma, and an influx of sodium cations. In turn, the 
change in voltage is extended into neighbouring areas, opening sodium channels 
further down the axolemma, generating a unidirectional depolarization wave, which 
travels down the axon at a rate of approximately 1m/s. The culmination of this process 
is the arrival of the depolarization wave at the presynaptic terminal and release of 
neurotransmitter containing vesicles onto another neuron (Hartline & Colman 2007). 
Increasing conduction velocity is thought to have been advantageous for both 
predatory and escape behaviours and has been achieved in two ways: axon gigantism 
and the acquisition of myelin. In non-myelinated axons, the longitudinal resistance to 
electric current is inversely proportional to the square root of the fibre diameter, 
resulting in faster propagation in larger fibres. Axon gigantism is seen across taxa and 
primarily involved in circuits related to escape responses (Hartline & Colman 2007). 
Alternatively, myelin—a dense, lipid rich and multilamellar membrane that ensheaths 
axons in a tightly wound helix—acts as an insulator that reduces the transverse 
capacitance of the axolemma, preventing the build-up of charge and membrane 
depolarization. Sodium channels are instead sequestered to gaps (~1µm) in the 
myelin sheath termed nodes of Ranvier where the axolemma is free to depolarise, 
resulting in an influx of sodium cations (Salzer 2003). Due to the increased membrane 
resistance inferred by myelin internodes, cations flow longitudinally through the 
cytoplasm towards the next node of Ranvier to propagate the depolarization wave 
(Figure 2.1). This saltatory (meaning ‘to leap’, from the Latin, saltare) conduction of 
action potentials at nodes of Ranvier increases the speed of propagation tenfold for 
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axons greater than 1µm. It is also more energetically efficient as the active transport 
of ions that restores the resting membrane potential of the axolemma occurs only at 
nodes. Finally, by avoiding the need for axon gigantism, myelin has enabled the 
development of large neural circuits with an economic use of space, as the same ten-
fold increase in conduction velocity would require 100-times thicker axons. 
  





Figure 2.1 Myelin form and function 
A) Schwann cells in the peripheral nervous system (PNS) form a single internode per cell 
and oligodendrocytes in the CNS myelinate many axons per cell (modified from Salzer et 
al., (2016) Current Biology).  
B) Illustration of saltatory conduction along myelination axons (modified from 
apusbiology.org, Copyright Pearson Education). 
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In the CNS, myelin is laid down by oligodendrocytes and is predominantly found in 
white matter (WM), which in humans, makes up approximately 40–50% of intracortical 
brain volume (Ge et al. 2002). In contrast to grey matter (GM), where local networks 
between neurons are established with relatively sparse myelination, white matter 
contains both short and long-range axonal projections, which are heavily myelinated 
and typically gathered into bundles that link different cortical areas with each other 
and with subcortical structures (Schmahmann et al. 2008; Quan Wen 2005; Ouyang 
et al. 2017) . Deep, long-range, white matter tracts are the first to be myelinated with 
somatosensory pathways preceding motor tracts, reflecting the temporal sequence of 
their functional maturation (Geng et al. 2012). GM myelination in the frontal and 
temporal cortices takes place during adolescence and continues well into adulthood 
(Westlye et al. 2010; Walhovd et al. 2005; Benes 1989). White matter myelin 
contributes to processing speed in infants between 2 and 5 and is also correlated with 
cognitive decline later in life (Deoni et al. 2015; Grydeland et al. 2013; Deary et al. 
2006; Lu et al. 2013). 
However, many axons remain unmyelinated and there is tremendous variation in the 
length, thickness, and distribution of myelin across others. Discontinuously 
myelinated axons are found in the juvenile and adult CNS (Tomassy et al. 2014; 
Hughes et al. 2018; Hill et al. 2018) and are believed to reflect local control of signal 
transduction and a mechanism to fine-tune circuit function. Indeed, changes to myelin 
sheath parameters including internodal length, thickness, and node length have been 
demonstrated to influence conduction velocity (Arancibia Carcamo et al. 2017; Brill et 
al. 1977). Even subtle changes have potentially dramatic effects on neural circuit 
function by affecting synchronicity and oscillation frequency (Pajevic et al. 2014). This 
supports the growing appreciation that precise timing of conduction, rather than 
maximal velocity, may represent the optimal state for the function of certain circuits 
(Suminaite et al. 2019). Thalamocortical afferents for example display selective 
myelination to ensure consistent latency across a range of travelling distances 
(Salami et al. 2003). Intriguingly, discontinuous myelination has also been 
demonstrated along individual axons in sound localization circuitry within the 
brainstem (Seidl & Rubel 2015; Ford et al. 2015). Here, coincident detection of signals 
at medial superior olivary (MSO) neurons on either side of the brain is essential for 
circuit function. This is achieved, in part, through differential internode lengths along 
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ipsilateral and contralateral bifurcations of single axons projecting from each cochlear 
nucleus (Seidl & Rubel 2015). Thus, precise myelination, even along single axons, 
supports optimal CNS function and suggests that myelin sheath length optimisation 
is regulated via local adaptive mechanisms. That myelin not only modulates signal 
transduction but is reciprocally regulated in an activity-dependent process is further 
discussed in Chapter 2.5.  
Myelin has also been recently attributed with additional functions in the metabolic 
support of axons (Figure 2.2). Axons can reach very long lengths of up to 1m in human 
adults and lack significant energy stores, which makes them vulnerable to increased 
neuronal activity due to the energetic demands of re-establishing the membrane 
potential via Na+/K+ channels (Thomas Philips 2017). Extra-axonal supply of lactate 
(or pyruvate) is considered a mechanism by which these energy demands are met. 
This was demonstrated in acute optic nerve preparations whereby the rapid 
deterioration of evoked compound action potentials (CAPs) observed in aglycemic 
conditions was rescued by bath application of L-lactate (Brown et al. 2004). Astrocyte-
vasculature coupling and astrocytic glycogen stores are integral to the metabolic 
support of axons, and astrocytes may shuttle monocarboxylates to axons directly. 
However, panglial coupling of astrocytes and oligodendrocytes via gap junctions 
enables the diffusion of metabolites into oligodendrocytes, which are well placed to 
support the metabolic demands of axons, particularly in densely myelinated tracts. 
Axo-myelin metabolic coupling involves the release of pyruvate and lactate via 
oligodendroglial monocarboxylate transporter 1 (MCT1) into the internodal space. 
Subsequent take-up by axons for mitochondrial ATP production fuels neuronal energy 
homeostasis (Y. Lee, Morrison, Y. Li, Lengacher, Farah, Hoffman, Y. Liu, Tsingalia, 
Jin, Zhang, Pellerin, Magistretti & Rothstein 2012a; Fünfschilling, Supplie, Mahad, 
Boretius, Saab, Edgar, Brinkmann, Kassmann, Tzvetanova, Möbius, Diaz, Meijer, 
Suter, Hamprecht, Sereda, Moraes, Frahm, Goebbels & Nave 2012a; Saab et al. 
2013; Thomas Philips 2017). It is also thought that axonal glutamate release and 
activation of N-methyl-D-aspartate receptors (NMDAR) on oligodendrocytes regulates 
this process, thereby coupling neuronal activity and metabolic supply (Saab et al. 
2016) (Figure 2.2). 
Interestingly, a distinct mode of axo-myelin metabolic coupling was identified in the 
corpus callosum, which rather than being fully myelinated, displays a large proportion 
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(60-70%) of non-myelinated axons (Mack et al. 1995). When mouse coronal sections 
were placed in aglycemic conditions, L-lactate perfusion was not sufficient to sustain 
the rapidly deteriorating evoked CAPs within the corpus callosum (Meyer et al. 2018). 
Rather, loading of individual oligodendrocytes (and not astrocytes) with glucose was 
able to rescue the loss of CAPs. This effect was abolished by reducing glial network 
coupling or by pharmacological blockade of MCTs and glucose transport. That 
alternate modes of metabolic coupling exist between different WM tracts underlines 
the importance of oligodendrocytes in supporting neuronal function but leaves open 
further questions about the generalisability of axo-myelin metabolic coupling across 
the CNS and the functional heterogeneity of myelinating oligodendrocytes across 
different regions. A failure to support axon metabolism is thought to underlie several 
neurodegenerative disorders, discussed in Chapter 2.4. 
  







Figure 2.2 Oligodendrocyte metabolically support axons 
A) Astrocytes couple the vasculature to both oligodendrocytes and axons by shuttling glucose 
or its glycolytic products to other cell-types.  
B) Glycolytic oligodendrocytes import glucose and shuttle lactate (or pyruvate) to the 
underlying axon, which is thought to be modulated by activity dependent release of glutamate.  
C) Glycolytic substrates are shuttled to the axon via MCT1 on the inner tongue of 
oligodendrocytes and subsequently taken up by the axon via MCT2 on the axonal surface, 
where it can be used in oxidative phosphorylation to generate ATP.   
Image adapted from Phillips and Rothstein, (2017) The Journal of Clinical Investigation. 
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2.2 Oligodendrocyte development 
 
Myelinated fibres were first identified by van Leeuwenhoek in 1717 but it wasn’t until 
the 1920s and the work of Rio-Hortega and Penfield that oligodendrocytes were 
confirmed to be the myelinating cell of the CNS (Boullerne 2016). In contrast to the 
myelinating Schwann cells of the PNS, which form only one internode per cell, 
oligodendrocytes extend several processes to form as many as 50–60 internodes per 
cell (Figure 2.1). With internodal lengths varying between 20 and over 200 µm, and 
up to 100 myelin wraps per internode, oligodendrocytes generate an estimated 5-
50,000µm2 of membrane area per cell, which is significantly more than any other cell 
type (Mikael Simons 2016). 
Oligodendrocytes first appear in the cervical spinal cord around mid-gestation in 
humans and just prior to birth in both mice and rats. They arise from the pMN domain 
of the ventral spinal cord, which is patterned into multiple domains in the ventral-dorsal 
axis by contrasting gradients of sonic hedgehog (SHH) and bone morphogenetic 
proteins (BMP) released by the floor plate and roof plate, respectively (Fu et al. 2002; 
Lai et al. 2016) (Figure 2.3). Whilst a second, minor wave of oligodendrogenesis 
occurs in the dorsal spinal cord and three separate waves of cortical 
oligodendrogenesis arise from the ganglionic eminences, this thesis relates only to 
the derivation of pMN-derived oligodendrocytes. The key stages of differentiation, 
however, are shared across all oligodendroglial cells. 
In the developing neural tube, the positioning of neural progenitor cells along the 
ventral-dorsal axis determines their exposure to particular concentrations of SHH and 
BMP. This induces the expression of unique combinations of transcription factors and, 
in turn, define the cellular subtypes derived from each domain. Each population of 
progenitors first gives rise to neurons and then glial cells. The pMN domain is defined 
by the expression of OLIG2, which is critical for the transcription of genes related to 
both motor neuron and oligodendrocyte generation. Olig2-dependent expression of 
Ngn2 and Lhx3 trigger motor neuron generation and the ratio of Ngn2 relative to Olig2 
in progenitor cells acts as a gate for timing the switch between neurogenesis and 
gliogenesis, and appropriate cell production (S.-K. Lee et al. 2005). However, the 
exact mechanisms by which pMN progenitors switch from neurogenesis to 
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gliogenesis is not precisely known. Live imaging of developing zebrafish revealed that 
in fact distinct progenitors drove the sequential generation of motor neurons (MNs) 
and oligodendrocyte progenitor cells (OPCs). Radial migration of MN progenitors 
away from the spinal cord lumen was followed by ventral migration of dorsally 
positioned progenitor cells, which initiate Olig2 expression in response to higher SHH, 
replenishing the pMN domain with progenitors destined to be OPCs (Andrew M 
Ravanelli 2015). Thus, spatial and temporal patterning mediated by SHH signalling 
drives diversification of neural cell types within the developing neural tube. 
  







Figure 2.3 Oligodendrocyte development and differentiation 
A gradient of Floor Plate derived Sonic Hedgehog establishes discrete domains along the 
dorsal-ventral axis of the developing spinal cord. Oligodendrocytes are generated from 
the pMN domain after the generation of motor neurons. Antagonistic actions of Olig2 and 
Ngn2 control the temporal switch to gliogenesis. PDGFRα+ OPCs differentiate into pre-
myelinating oligodendrocytes expressing O4 and PLP. Maturation of differentiated 
oligodendrocytes is denoted by the expression of MBP. Image modified from Rowitch et 
al., (2004) Nature Reviews Neuroscience. 
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Whilst Olig2 expression is maintained throughout oligodendroglial production, 
differentiation and myelination, a number of stage-specific markers have been 
identified which enable the study of the temporal development of oligodendrocytes. 
OPCs are identified by their expression of NG2, platelet derived growth factor receptor 
(α subunit, PDGFRα) and Sox10, a key transcription factor that regulates the 
expression of myelin genes and is necessary for terminal oligodendrocyte 
differentiation. pMN domain derived OPCs are highly migratory and repulse one 
another to achieve unique territories throughout spinal cord grey and white matter 
(Hughes et al. 2013). Interestingly, not all OPCs go on to differentiate and represent 
approximately 5% of the total cells in the adult CNS. They comprise the majority of 
proliferative cells in the adult CNS, respond to injury and have been implicated in axo-
glial communication by the discovery of bona fide synapses between OPCs and axons 
(Hughes et al. 2013; Bergles et al. 2000). It was recently shown that non-
differentiating OPCs may arise from distinct progenitors through an expanded 
programme of progenitor recruitment outlined above. In zebrafish, sequential initiation 
of Olig2 expression in distinct spinal cord progenitors appeared to first gives rise to 
motor neurones, then rapidly myelinating oligodendrocytes followed by OPCs that 
persisted without differentiation (Ravanelli et al. 2018).  
Terminal differentiation of OPCs into pre-myelinating oligodendrocytes is associated 
with translocation of the Olig1 transcription factor to the cytosol, an increase in 
morphological complexity, and induction of the transcription factor myelin gene 
regulatory factor (MRF) which has been shown to be critical for the expression of late 
myelin genes, including MOG (Ben Emery et al. 2009; Niu et al. 2012). Three highly 
conserved signalling pathways have been associated with oligodendrocyte 
differentiation including Wnt/β-catenin, PI3K/AKT/mTOR, and ERK/MAPK (Jenna M 
Gaesser 2016). Further detail regarding the transcription factors (Ben Emery 2015), 
epigenetic modifications (J. Liu et al. 2016), microRNAs (Dylan A Galloway 2016), 
and signalling pathways (Jenna M Gaesser 2016) involved in oligodendroglial lineage 
progression have been reviewed. 
Surprisingly, oligodendrocytes are over-produced during development with the 
majority of newly differentiated oligodendrocytes undergoing programmed cell death 
(Barres et al. 1992; Hughes et al. 2018). Recently it was shown that this process is 
regulated, in part, by the expression of transcription factor EB (TFEB) in 
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premyelinating oligodendrocytes and that suppression of TFEB leads to ectopic 
myelination (Sun et al. 2018; Meireles et al. 2018). Whilst the factors that regulate 
TFEB expression are poorly understood, it is well established that axonal contact and 
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2.3 Myelin formation 
 
Individual oligodendrocytes can myelinate multiple axons of varying diameters and 
demonstrate a range of myelin sheath lengths and thickness per cell. However, myelin 
sheath lengths are also precisely distributed along certain axons to fine-tune action 
potential conduction velocities, suggesting that the physical dimensions of individual 
myelin sheaths are locally regulated (Waxman & Sims 1984). Remarkably however, 
oligodendrocytes establish each of their internodes (up to ~60 in the mammalian 
cortex) across different axons in concert. This process is rapidly completed following 
the initiation of myelination (5 hours for zebrafish spinal cord oligodendrocytes 
(Czopka et al. 2013) and, in the intact CNS, fluctuations in sheath number or sheath 
length following this critical period are minimal. 
Non-cell autonomous and cell-intrinsic regulation of myelination 
Myelin formation follows in a stepwise manner of oligodendrocyte process extension, 
axoglial contact, membrane outgrowth and axonal wrapping, trafficking of membrane 
proteins, compaction, and node formation (Simons & Nave 2015). Several axonally-
regulated signals have been identified to positively and negatively regulate these 
distinct processes. For example, oligodendrocyte processes are sensitive to axon 
calibre and a minimum threshold of ~1µm for PNS axons and ~0.2µm for CNS axons 
exists, below which it is thought myelin ensheathment is unlikely to confer significantly 
enhanced conduction velocity (Voyvodic 1989; Mayoral et al. 2018; Sherman & 
Brophy 2005). In the PNS, unmyelinated small diameter axons can be stimulated to 
grow in calibre, which leads to their myelination (Voyvodic 1989). This is thought to 
be signalled through increased expression of Neuregulin 1 (Nrg1) type III expression 
on the surface of axons. Larger calibre axons express more Nrg1 than smaller axons 
and overexpression of Nrg1 leads to increased myelin sheath thickness and induced 
myelination of typically non-myelinated peripheral axons (Taveggia et al. 2005; 
Michailov et al. 2004). In the CNS, Nrg1 has been shown to support the survival of 
newly differentiated oligodendrocytes but its role in myelination is largely dispensable 
(Fernandez et al. 2000; Brinkmann et al. 2008). Integrin signalling via Lamininα2 has 
been shown to be important in regulating oligodendrocyte number, enhancing myelin 
membrane formation in vitro and its absence leads to dysmyelination in both mice and 
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humans (Buttery & ffrench-Constant 1999; Colognato et al. 2002; Jones et al. 2001; 
Chun et al. 2003). Several inhibitory cues of oligodendrocyte differentiation and 
myelination have also been found. Lingo-1, a transmembrane protein expressed by 
neurons and oligodendrocytes inhibits oligodendrocyte differentiation with Lingo-1 
knockout mice demonstrating increased numbers of mature oligodendrocytes and 
myelination (Mi et al. 2005). JAM2 is a somatodendritic protein that inhibits myelin 
wrapping and whose knockout leads to ectopic myelination of neuronal cell bodies 
(Redmond et al. 2016). Increasing evidence also demonstrates neuronal activity as 
an important regulator of oligodendrocyte differentiation and myelination, discussed 
further in 2.5. Finally, intrinsic properties of oligodendrocytes also regulate myelination 
as myelin sheath length around inert microfibres were found to differ between cortical 
and spinal cord-derived oligodendrocytes (Bechler et al. 2015). 
Myelin wrapping 
The mode of myelin wrapping has proven to be an elusive process to define with 
several hypotheses put forward over the years. With the advent of techniques such 
as live in vivo imaging and serial section electron microscopy analysis, a clearer 
picture has begun to form. Oligodendrocyte processes appear to first encircle axons 
before the bilateral growth of outer myelin layers (Snaidero et al. 2014). F-actin 
polymerisation at the leading edge of the oligodendrocyte process drives its continued 
wrapping of the underlying axon. F-actin disassembly and bilateral elongation of 
myelin membrane follows, resulting in a stepwise reduction in myelin thickness 











Figure 2.4 Myelin wrapping and compaction 
A) Illustration of myelin wrapping. The active growth zone (green) proceeds to encircle the 
axon as sheath elongation occurs at the distal ends of nascent sheaths. 
B) Cross-sectional illustration of myelinated axon shows that MBP is pivotal to compaction of 
myelin lamellae, which is achieved by extruding CNP+ cytoplasm. Images taken from Chang 
et al., (2017) Nature Neuroscience.  
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The myelin sheath is biochemically distinct to that of plasma membrane at the 
oligodendrocyte cell soma and is segmented into compact and non-compact domains 
(Krämer et al. 2001; Morell & Quarles 1999). The biochemical composition of myelin 
by dry weight consists of 70% lipid (predominantly galactoceramide and cerebroside) 
with most (80%) of the remaining mass accounted for by two proteins, myelin basic 
protein (MBP) and proteolipid protein (PLP/DM20) (Morell & Quarles 1999; Krämer et 
al. 2001). Precise localisation of these proteins to compact myelin and others, 
including 2’3’-cyclic nucleotide 3’-phosphodiesterase (CNP), myelin-associated 
glycoprotein (MAG) and myelin-oligodendrocyte glycoprotein (MOG) to uncompacted 
regions or the border between these two domains (e.g. CLAUDIN-11) requires 
organised synthesis, sorting and trafficking of myelin components. Several pathways 
have been implicated in myelin membrane trafficking including directed transport, 
transcytosis or ‘bulk flow’ of myelin membrane, exocytosis of vesicles that deliver new 
myelin to the inner tongue via the cytoplasmic channels of non-compacted myelin and 
the assembly of myelin rafts, which involves lipid-protein interactions and delivery via 
cytoplasmic adapter molecules (Snaidero et al. 2014; Krämer et al. 2001). The 
delivery of PLP appears largely dependent on myelin rafts (Simons et al. 2000). MBP, 
however, is locally translated at the cell periphery following the translocation of Mbp 
mRNA in microtubule-associated granules to sites of myelin growth. This suggests 
that sheath growth can be locally regulated. Indeed, nascent myelin sheaths engaged 
with electrically active axons in vitro demonstrate increased expression of newly 
synthesized MBP (Wake, Lee & Fields 2011a).  
MBP is a small, positive protein that interacts with membranes by binding to negatively 
charged lipid head groups, which then leads to conformational changes and the 
formation of ordered α-helices and β-sheets (Aggarwal et al. 2011). During myelin 
compaction it is thought MBP neutralises the repulsive charges on opposing 
membranes to create a ‘zipper’ type effect that extrudes cytoplasmic proteins such as 
CNP (Snaidero & Simons 2017) (Figure 2.4B). This is exemplified in CNP+/  and in 
MBP+/  mice that show either advanced or delayed intracellular compaction, 
respectively (Snaidero et al. 2014). 
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Node formation 
Myelinated axon function requires two specializations: the compaction of myelin 
lamellae around axons to reduce transverse capacitance and the organisation of 
nodal and paranodal proteins into discrete domains to enable saltatory conduction of 
action potentials.  
Mature myelinated axons are morphologically divided into discrete domains that 
include the node of Ranvier (NoR), paranodal axoglial junctions (PNJ), 
juxtaparanodes (JXP) and internodes. The intricate formation of these domains is an 
extraordinary demonstration of reciprocal communication between axons and glia, 
involving extracellular matrix proteins, cell adhesion molecules and cytoskeletal 
scaffolds. Figure 2.5 is an illustrated representation of a myelinated axon cut along its 
sagittal axis, adapted from (Derfuss et al. 2010). 
  








Figure 2.5 Organisation of myelinated axon sub-domains 
Sagittal section of a myelinated axon depicting distinct domains. NoR: node of 
Ranvier; PNJ: paranodal junction; JXP: juxtaparanode. Adapted from Derfuss et al., 
(2010) Journal of Molecular Medicine. 
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The nodes of Ranvier are composed of a diverse arrangement of voltage-gated Na+ 
channels, which mediate ion flow across the membrane and, together with K+ 
channels, regulate action potential propagation. In addition, the NoR contains a 
number of scaffolding proteins essential to its assembly and maintenance. Flanking 
the nodes of Ranvier are PNJ, which tether the myelin sheath to the axolemma via 
specialised septate-like junctions. The PNJ serves as a major boundary that 
constrains electrical activity to the node of Ranvier and prevents lateral diffusion of 
axonal membrane proteins. The JXP domain highlights a dense cluster of Kv1 K+ 
channels, which are thought to function as delayed rectifier K+ channels that maintain 
internodal resting potential. Finally, the internode is where dense layers of compact 
myelin can be viewed in cross-section. Several cell adhesion or scaffolding proteins 
are involved in establishing myelinated axon domain organisation, which are useful 
markers used to determine the formation of these structures.  
The PNJ is a specialised axoglial contact between the axolemma and the spiralling 
cytoplasmic loops of myelin lamellae located at the distal ends of myelin sheaths. The 
septate-like junctions formed at this site constitute the largest known intercellular 
junctions in vertebrates (Rasband & Peles 2015). The PNJ is composed of the cell 
adhesion molecules CASPR and CONTACTIN, expressed on the surface of axons, 
which form a complex that binds with the 155-kDa isoform of Neurofascin, Nfasc155, 
expressed on the surface of oligodendrocytes. The heterotrimeric complex formed 
bridges the two cell-types together.  
Neurofascins are a family of proteins, encoded by alternative transcripts of the NFASC 
gene, involved in the assembly of the axon initial segment (AIS) and NoR in 
myelinated axons. The two major isoforms, Nfasc155 and Nfasc186 (named 
corresponding to their molecular weight in kDA) are differentially expressed by 
myelinating glia and axons, respectively. Nfasc186 is central to and initiates NoR 
assembly by recruiting Ankyrin-G, a large cytoskeletal protein that acts as a 
multivalent organiser in the assembly and maintenance of both the AIS and NoR 
(Dzhashiashvili et al. 2007; Gasser et al. 2012).  
Myelin wrapping is also demonstrated by CLAUDIN-11, otherwise known as 
oligodendrocyte-specific protein (OSP). CLAUDIN-11 forms tight-junctions between 
the cytoplasmic loops of myelin lamellae, which is distinct from, but structurally 
  25 
overlaps with, the PNJ. CLAUDIN-11 also demarcates Schmidt-Lantermann incisures 
of the CNS, which are cytoplasmic channels that spiral through compact CNS myelin, 
permitting the trafficking of products to the inner myelin tongue (Gow et al. 1999; 
Blakemore 1969; Pérez-Cerdá et al. 2015) (Figure 2.6).  
 
  







Figure 2.6 The myelinic channel  
Claudin-11 labels tight junctions between terminal myelin lamellae at the PNJ as well as the 
outer myelinic channel and Schmidt-Lanterman incisure (uncompacted structures beneath the 
outer myelin loop that spirals through compact myelin towards the axon at regular intervals). 
Adapted from Gow et al., (1999) Cell. 
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2.4 Disorders of myelin 
 
The evidence provided above supports the notion that oligodendrocytes are not 
simply passive members of the CNS whose sole purpose is to insulate axons but are 
instead dynamic modulators of neural circuits and axon function. This is best 
exemplified by inherited and acquired disorders of myelin such as the 
leukodystrophies and multiple sclerosis, demonstration that cell-autonomous defects 






Figure 2.7 Oligodendrocyte mutations impact on axonal health 
Mutations in oligodendrocyte-specific genes have differing effects on myelinated axon health. 
MBP-null mutations lead to uncompacted myelin without affecting axonal health. PLP-, 
CNPase- and MCT1-null mutations lead to neurodegeneration. Image adapted from Phillips 
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Mouse models 
Mice that lack the myelin proteins proteolipid protein (PLP), myelin associated 
glycoprotein (MAG) or 2'3'-cyclic nucleotide 3'-phosphodiesterase (CNP) generate 
compact myelin sheaths but exhibit widespread axonal swellings and degeneration 
(Griffiths et al. 1998; Lappe-Siefke et al. 2003; Pan et al. 2005). Shiverer mice, 
discussed below, lack the structural protein myelin basic protein (MBP) and so fail to 
generate compact myelin, leading to tremors, convulsions and early death (Chernoff 
1981). Knockout mutations in the genes encoding oligodendrocyte-specific gap 
junction proteins Cx32 and Cx47 exhibit extensive myelin pathology and loss of axons 
(Menichella et al. 2003). Mice lacking expression of the myelin tight junction protein 
Claudin-11 show neurotransmitter imbalances in the absence of neurodegeneration, 
which lead to perturbed auditory processing and neuropsychiatric disease-associated 
phenotypes (Maheras et al. 2018). These data underlie the importance of myelin in 
global CNS health and point towards additional functions of oligodendrocytes besides 
accelerating signal conduction (Figure 2.7). 
 
Inherited and acquired disorders of myelin 
The leukodystrophies are a group of heritable metabolic disorders that result from 
defective myelination of the CNS (Schiffmann & van der Knaap 2009; Powers 2004). 
Several types of leukodystrophies exist and have been classified accordingly: 
hypomyelinative disorders are those in which the CNS myelin is not properly formed. 
They arise from mutations in myelin related genes and include Pelizaeus Merzbacher 
disease (PMD), which arises from mutations in the gene for PLP (Gow et al. 1998). 
Metabolic demyelinating diseases such as Krabbe disease arise from enzymatic 
deficiency and lipid misaccumulation (Svennerholm et al. 1980) and 
leukoencephalopathy disorders such as vanishing white matter disease display gross 
tissue loss (Leegwater et al. 2001). Myelin abnormalities are also found in several 
disorders of perinatal injury, including cerebral palsy, where hypoxia-ischaemia 
events lead to oligodendrocyte injury (Haynes et al. 2003). 
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Multiple sclerosis 
The most common acquired disorder of myelin is multiple sclerosis (MS), a chronic 
autoimmune inflammatory disease of the CNS that leads to myelin destruction and 
progressive neurodegeneration. Approximately 85% of MS patients present with a 
relapse-remitting form of the disorder in which exacerbations of clinical symptoms are 
followed by periods of remission, which are thought to reflect resolution of 
inflammation and/or remyelination (Goldenberg 2012). However, the majority of 
patients after c.10 years will move into the progressive phase of disease characterised 
by accumulating and irreversible disability due to underlying neurodegeneration. In 
addition, 10–15% of patients have a purely progressive form of the disease from the 
outset. MS is thus the most common form of neurodegeneration in younger adults 
(majority of patients present with the relapse-remitting form between 20 and 40 years 
of age) with a prevalence of 100–200 per 100,000 in the UK. A complex disease, that 
affects woman c.2.5 x more than men, both genetic and environmental factors have 
been identified to play a part (Noseworthy et al. 2000; Visser et al. 2012; Patrikios et 
al. 2006). Inflammatory-mediated demyelination detrimentally impacts conduction 
speed. Interestingly however, remyelination of denuded axons by newly differentiated 
oligodendrocytes restores conduction speeds and is associated with functional 
recovery of the affected circuits, albeit remyelinated sheaths appear thinner and 
shorter in length (Blakemore 1974; Smith et al. 1979; Franklin & ffrench-Constant 
2008). In contrast to the development of many effective disease modifying treatments 
for the inflammatory dominant relapse – remitting phase of disease there are no 
effective treatments for the progressive phase of disease. There is therefore an unmet 
need for neuroprotective therapies (discussed further in Chapter 7). 
 
Neuropsychiatric disorders 
Considerable interest has also been placed on white matter pathology in several 
neuropsychiatric disorders including autism, schizophrenia, bipolar disorder and 
major mental illness where changes in white matter integrity have been observed 
(Haroutunian et al. 2014; Roussos & Haroutunian 2014; Fields 2008; Nave & 
Ehrenreich 2014; J. Liu et al. 2012; Sehmbi et al. 2019). Genome-wide association 
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studies of neuropsychiatric conditions regularly highlight dysregulated expression of 
myelin-related genes (Hakak et al. 2001; Witt et al. 2017) and, in some cases, white 
matter alterations precede the onset of psychosis (Carletti et al. 2012).  
Neuropsychiatric conditions such as schizophrenia typically present during 
adolescence between the second and third decade of life, a period of time that 
overlaps with the development of inhibitory pathways and myelination of the pre-
frontal cortex (Insel 2010). This has led many to suggest that disrupted connectivity 
and aberrant modulation of synaptic efficacy underlies the pathogenesis of this 
disorders (Friston et al. 2016). Indeed others have speculated on the convergence of 
interneuron and white matter abnormalities in schizophrenia (Stedehouder & Kushner 
2016). Further work is needed to determine cell-intrinsic deficits and dysfunctional 
interactions between different neural cells in schizophrenia. Several studies have 
already highlighted the utility of iPSCs to probe oligodendrocyte dysfunction in 
schizophrenia (Vasistha et al. 2019; de Vrij et al. 2019). 
 
Amyotrophic laterals sclerosis 
Oligodendrocyte dysfunction is also prevalent in amyotrophic lateral sclerosis (ALS), 
a rapidly progressing neurodegenerative disease characterised by the selective death 
of motor neurons. Though the majority (90%) of ALS cases are sporadic, several 
mutations have been identified to cause ALS, including in the gene for TDP-43 
(TARDBP) (Kabashi et al. 2008; Sreedharan et al. 2008; Lagier-Tourenne et al. 2010). 
TDP-43 is a DNA/RNA binding protein that plays critical roles in RNA splicing, 
translation and transport (Ratti & Buratti 2016) and also represents a defining 
pathological hallmark for the majority of ALS cases by the accumulation of large TDP-
43+ cytoplasmic aggregates in both neurons and glial cells (Neumann et al. 2006; Arai 
et al. 2006; Mackenzie et al. 2010). TDP-43 mislocalization and aggregation is present 
in oligodendrocytes in spinal cord grey matter of human ALS (Rohan et al. 2014; 
Philips et al. 2013) and demyelination in both the spinal cord and grey matter regions 
of the motor cortex has been observed (S. H. Kang et al. 2013). The SOD1G93A mouse 
model of ALS is a well characterised model in which expression of mutant human Cu, 
Zn superoxide dismutase (SOD1; which accounts for ~2% of familial ALS) leads to 
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MN degeneration (Gurney et al. 1994). Here, enhanced proliferation of NG2+ 
oligodendrocyte progenitor cells and degeneration of new-born oligodendrocytes was 
observed (S. H. Kang et al. 2013). In addition, selective depletion of mutant SOD1 
from oligodendrocytes delayed disease onset in SOD1G93A mice, suggesting a 
deleterious non-cell autonomous effect on motor neuron survival (S. H. Kang et al. 
2013).  
A possible mechanism by which oligodendrocyte integrity might negatively impact 
neuronal survival is via MCT1 and the shuttling of glycolytic substrates from the myelin 
sheath to the underlying axon to be used in oxidative phosphorylation (Fünfschilling, 
Supplie, Mahad, Boretius, Saab, Edgar, Brinkmann, Kassmann, Tzvetanova, Möbius, 
Diaz, Meijer, Suter, Hamprecht, Sereda, Moraes, Frahm, Goebbels & Nave 2012a; Y. 
Lee, Morrison, Y. Li, Lengacher, Farah, Hoffman, Y. Liu, Tsingalia, Jin, Zhang, 
Pellerin, Magistretti & Rothstein 2012b; Saab et al. 2013) (Figure 2.2). Spinal cord 
MNs depend on MCT1 for survival and MCT1 was shown to be downregulated in the 
motor cortex of ALS patients (Fünfschilling, Supplie, Mahad, Boretius, Saab, Edgar, 
Brinkmann, Kassmann, Tzvetanova, Möbius, Diaz, Meijer, Suter, Hamprecht, Sereda, 
Moraes, Frahm, Goebbels & Nave 2012b; Y. Lee, Morrison, Y. Li, Lengacher, Farah, 
Hoffman, Y. Liu, Tsingalia, Jin, Zhang, Pellerin, Magistretti & Rothstein 2012b). 
The exact mechanism by which oligodendrocyte dysfunction and disease 
exacerbation occurs is unclear. One suggestion centres around dysfunctional RNA 
metabolism. Myelin proteins, including MBP, are locally translated in the cell periphery 
(Campagnoni et al. 1980; Colman et al. 1982) and can be bound and sequestered by 
TDP-43 (Jia Wang et al. 2018). Additionally, translocation of myelin mRNAs is 
regulated by the activity of a number of trans-acting factor heterogeneous nuclear 
ribonucleoprotein (hnRNP) RNA binding proteins (Barton et al. 2019; White et al. 
2008), which in turn are regulated by TDP-43 (Deshaies et al. 2018; Highley et al. 
2014). Finally, it was recently shown that increasing concentrations of TDP-43 in the 
cytoplasm leads to formation of long-lived liquid droplets of cytosolic TDP-43 that 
accumulate a number of nucleocytoplasmic transport proteins as well as hnRNPA1, 
thereby disrupting normal RNA trafficking (Gasset-Rosa et al. 2019). A possible 
framework therefore is established whereby stress-related imbalances in 
posttranscriptional regulation of oligodendroglial mRNAs may lead to reduced 
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oligodendrocyte integrity, dysfunction, demyelination and neurodegeneration (Hoch-
Kraft et al. 2019). 
Whilst the exact role of TDP-43 in oligodendrocytes remains unclear, it was recently 
shown that selective depletion of TDP-43 from mature oligodendrocytes (Cnp+) 
resulted in a shortened lifespan, progressive motor deficits, progressive myelin 
disruption, degeneration of mature oligodendrocytes and enhanced 
oligodendrogenesis, though no loss of spinal cord MNs or muscle denervation 
observed (Jia Wang et al. 2018). Further studies investigating endogenous 
expression of mutant TDP-43 are needed to unpick oligodendrocyte pathophysiology 
in this disease. 
Finally, the importance of axon-oligodendrocyte coupling has resulted in a shift in how 
we perceive axonal physiology and raises the possibility that oligodendrocytes are 
important contributors to the pathogenesis of other neurodegenerative disorders that 
display white matter and oligodendrocyte pathology including Alzheimer’s disease, 
multiple system atrophy and Huntington’s disease (Alexandra I et al. 2018; J. Zhang 
et al. 2018; B. Huang et al. 2015; Nasrabady et al. 2018). 
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2.5 Activity regulated myelination 
 
White matter volume steadily increases until the fifth decade of life (Westlye et al. 
2010), is positively correlated with intelligence (Grydeland et al. 2013) and can be 
potentiated by learning novel motor tasks including juggling (Scholz et al. 2009), piano 
playing and following musical training (Bengtsson et al. 2005), riding a unicycle 
(Weber et al. 2019) and also by bilingualism (Schlegel et al. 2012; Anderson et al. 
2018). It has also been shown that social isolation or enrichment likewise modulates 
the extent of cortical myelination (J. Liu et al. 2012; Hughes et al. 2018; Makinodan et 
al. 2012). Experience-dependent structural changes in both grey and white matter 
relative to task performance is an indication of the plasticity of the CNS and one which 
highlights physical activity as a potential intervention for modulating cognitive and 
brain functions (Weber et al. 2019; Erickson et al. 2011; Colcombe et al. 2006). 
However, the cellular mechanisms underlying these changes are not completely 
understood (Zatorre et al. 2012).  
Magnetic resonance imaging (MRI) can be used to investigate both the structural and 
functional integrity of white matter in vivo. The latter makes use of the constrained 
diffusion of water molecules along similarly oriented fibres, creating a directional 
‘anisotropy’ of water diffusion that reveals microstructural properties of the brain 
(Alexander et al. 2007). It was estimated that a single white matter 100 x 100 x 100 
µm voxel contains between 1,000 and 13,000 axons and is occupied by approximately 
48% myelin volume and 48% astrocyte membrane volume. Oligodendrocytes 
outnumber astrocytes 4:1 and the number of microglia and OPCs were less and in 
equal proportions (Walhovd et al. 2014). Changes in fractional anisotropy (FA) or 
mean diffusivity may reflect modifications to each or several of these compartments 
(Cassandra Sampaio-Baptista 2017). However, histological examination of myelin 
has been shown to correlate with in vivo measurements, supporting the use of in vivo 
imaging to reflect myelin-specific changes (Blumenfeld-Katzir et al. 2011; Sampaio-
Baptista et al. 2013). 
Understanding how neuronal activity modulates myelin development has interested 
researchers for decades: since the identification that dark reared mice demonstrate 
reduced myelination of optic nerve tracts (Gyllensten & Malmfors 1963). The role of 
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axons in regulating oligodendrocyte development was eluded to following the 
observation that neonatal optic nerve transection reduces the number of proliferating 
OPCs (Barres & Raff 1993). Furthermore, pharmacological suppression of neuronal 
activity within the optic nerve—via tetrodotoxin (TTX)-mediated blockade of voltage 
gated Na+ channels—reduced OPC proliferation and the number of myelinating 
oligodendrocytes (Barres & Raff 1993; Demerens et al. 1996). TTX was also found to 
reduce the number of myelinated fibres in optic nerve cultures. In contrast, 
potentiation of neuronal activity via α-scorpion-toxin (Na+ channel activator) had an 
opposite effect by greatly increasing the number myelinated fibres (Demerens et al. 
1996). 
In vivo, electrical stimulation of the dorsal corticospinal tract in adult mice selectively 
promoted the proliferation and differentiation of oligodendrocyte progenitor cells (Q. 
Li et al. 2010). However, white matter changes are also associated with pathological 
perturbations of electrical activity, including accelerated myelin development following 
epileptic seizures (Goldsberry et al. 2011) and oligodendrocyte injury due to 
glutamate receptor-mediated excitotoxicity in hypoxia-ischemia (Follett et al. 2000).  
More recently, sophisticated genetically encoded modulators of neuronal activity have 
been used to address this question. Using transgenic mice expressing 
channelrhodopsin 2 under the control of the Thy 1 promoter, optogenetic-mediated 
enhancement of neuronal activity in the mouse premotor cortex increased OPC 
proliferation, differentiation and myelination with functional behavioural changes in 
normal gait (Gibson et al. 2014). In another study, optogenetic activation of toxin-
induced demyelinated lesions increased OPC numbers, enhanced oligodendrocyte 
differentiation, promoted remyelination and aided functional recovery (Ortiz et al. 
2019). Using Designer Receptors Exclusively Activated by Designer Drugs 
(DREADD)-based modulation of neuronal activity, stimulation of the somatosensory 
cortex led to increased OPC proliferation and differentiation in the underlying white 
matter, a myelination bias for activated axons and thicker myelin sheaths on activated 
axons (Mitew et al. 2018). DREADD-activated parvalbumin+ interneurons in the 
medial prefrontal cortex also led to selectively increased myelination mediated by 
enhanced axonal arborisation and the number of internodes (Stedehouder et al. 
2018). These data highlight the potential of neuronal activity to regulate OPC 
proliferation, differentiation and/or myelination during development, learning and 
  35 
disease. Interestingly, blocking the formation of new oligodendrocytes impaired the 
learning of complex running tasks (Xiao et al. 2016), further supporting the role of 
oligodendrocytes in regulating CNS plasticity and learning.  
The mechanisms underlying activity regulated myelination are not completely 
understood. However, a number of key observations have been made that have 
begun to explain this phenomenon. A landmark paper discovered that OPCs form 
bona fide synapses with axons of hippocampal pyramidal neurons with AMPA 
receptor-mediated calcium responses produced by local release of glutamate-filled 
synaptic vesicles (Bergles et al. 2000). Indeed, many of the canonical postsynaptic 
constituents have been shown to be express by OPCs, including PSD-95 (Almeida & 
Lyons 2014). Vesicular release of glutamate also occurs along unmyelinated callosal 
axons during action potential propagation, which activates Ca2+-permeable AMPA 
receptors at OPC-axon synapses within the corpus callosum, as identified by 
VGLUT1+ puncta at axon-NG2+ cell junctions (Ziskin et al. 2007; Kukley et al. 2007). 
ATP is also released by electrically active DRG axons and activity-induced 
differentiation of OPCs and myelination in co-culture was shown to be mediated by 
adenosine (Stevens et al. 2002). These studies have led to a leading hypothesis that 
OPC-axon synapses represent a mechanism for activity-dependent signalling that 
modulates OPC behaviour to promote myelination of electrically active axons, thereby 
modulating the speed and efficiency of signal propagation.  
Evidence that nonsynaptic release of neurotransmitter is mediated via exocytosis of 
vesicles—rather than membrane channels (Fields 2011)—was demonstrated by 
Wake et al. who showed botulinum neurotoxin (BoNT/A)-mediated blockade of 
vesicular release significantly reduced Ca2+ responses in OPCs when co-cultured with 
DRGs (Wake, Lee & Fields 2011a). The authors also identify a reduction in the 
number of myelin segments per cell in BoNT/A-treated cultures, preferential myelin 
targeting to a subset of neurons that had not been pre-treated with BoNT/A, and 
preferential translation of MBP on OPC processes in contact with electrically active 
axons (Wake et al. 2015; Wake, Lee & Fields 2011b).  
Further evidence for the role of vesicle exocytosis in mediating myelin development 
in vivo came from live imaging of transgenic zebrafish reporter lines expressing the 
tetanus toxin (TeNT) light chain. TeNT is another clostridial neurotoxin that blocks 
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synaptic transmission via proteolytic cleavage and inactivation of Synaptobrevin 1/2 
(VAMP2), one of three neuronal SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor) proteins that mediate rapid exocytosis of 
neurotransmitter containing synaptic vesicles at the pre-synaptic terminal, in all known 
synapses (Söllner et al. 1993). Clostridial neurotoxin exposure blocks both 
spontaneous and action-potential-evoked synaptic vesicle release (Y. I. Kim et al. 
1984). TeNT-expressing zebrafish showed a 40% reduction in the number of 
myelinated axons, which was accounted for by individual oligodendrocytes 
myelinating fewer (30% reduction) axons per cell (Mensch et al. 2015). In a parallel 
study, (Hines et al. 2015) identified under normal conditions, the motility of synaptic 
vesicles was reduced at points of myelin ensheathment. Additionally, selective TeNT 
expression in Phox2b+ neurons reduced the stabilisation of nascent sheaths and total 
myelin along these neurons. Importantly, it was recently shown that social isolation 
reduces the number of myelin sheaths per cell, providing evidence that experience 
dependent changes can also negatively modulate oligodendrocyte morphology in vivo 
(Swire et al. 2019; Mensch et al. 2015).  
Finally, neuronal activity has also been shown to be important in driving myelin repair. 
Using organotypic brain slices from a rat model of toxin-induced demyelination, 
recruited OPCs were found to form de novo synapses with demyelinated axons in the 
corpus callosum (Gautier et al. 2015). Furthermore, activity-dependent myelination 
(mediated by newly born oligodendrocytes) also occurs in the adult mammalian CNS 
(Gibson et al. 2014; Mitew et al. 2018). As such, experience-dependent plasticity has 
been suggested as a tractable method for the management of multiple sclerosis 
(Jensen & Yong 2016). It is inconclusive however, whether established 
oligodendrocytes and their myelin sheaths are capable of activity regulated 
adaptation. Myelin remodelling by established oligodendrocytes was recently 
demonstrated in zebrafish following selective ablation of oligodendrocytes. The 
sparse loss of internodes along myelinated axons led to radial growth of neighbouring 
myelin sheaths to cover the portion of denuded axon (Auer et al. 2018). Whether or 
not this process may be modulated by neuronal activity remains to be seen. It is more 
likely that adaptation by established oligodendrocytes will involve changes in myelin 
thickness. However, this remains to be determined. 
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2.6 The argument for complementary human models 
 
The understanding of human development and disease would ultimately be best 
served by the study of living human models that are experimentally tractable. Animal 
models provide accessible and genetically amenable tools with which to investigate 
cellular mechanisms and disease-associated pathogenesis. Moreover, their use in 
preclinical studies of therapeutic interventions and drug safety is integral to the drug 
discovery process. However, the underlying pathology for many neurological 
disorders are still not fully understood and there is high attrition in the development of 
new therapies, particularly for neurological disorders (Garner 2014; McGraw et al. 
2017). Both disease- and species-specific differences have been suggested to 
contribute to the attrition of drug development and suggests that human models of 
development and disease may complement existing capacities for both mechanistic 
and drug discovery/validation purposes. This is also true for myelin development and 
disease. Here, I will summarise the differences in neuroanatomy as well as in the 
temporal development, signalling pathways and transcriptional profile of 
oligodendroglial cells and emphasise the potential of human stem cell-derived 
cultures to study the biology and pathology of myelin development.  
Evolutionary divergences in the density of glial cells are surprisingly minimal across 
clades with absolute numbers of nonneuronal cells best explained by the average 
mass of glial cells and the relative neuronal mass (Mota & Herculano-Houzel 2014). 
However, the relative proportion of white matter within the cerebral cortical volume 
differs significantly between species as it increases relative to brain size and is linked 
to the degree of cortical folding in mammals (Hofman 1985; Schoenemann et al. 2005; 
Smaers et al. 2010; Mota et al. 2019). As I will describe below, however, species-
specific differences are primarily attributed to functional differences, rather than in the 
distribution and types of cells.  
Human myelin development is a particularly protracted process, even amongst 
primates (Miller et al. 2012; Bakken et al. 2016). The phylogenetically close 
chimpanzee, for example, demonstrates a more rapid acquisition of neocortical 
myelin relative to developmental stage (Miller et al. 2012). Additionally, whilst 
myelination peaks in the chimpanzee around the time of sexual maturity, human 
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myelin development extends past adolescence into adulthood and steadily increases 
until the fourth or fifth decade of life (Miller et al. 2012; Westlye et al. 2010; Yeung et 
al. 2014). This distinction has important implications for the development of 
neuropsychiatric conditions in humans, which appear during an intense period of 
neocortical myelination. Indeed, perturbed myelin development is a leading 
hypothesis for the development of disorders including autism, schizophrenia, and 
bipolar disorder (Haroutunian et al. 2014; Roussos & Haroutunian 2014; Fields 2008; 
Nave & Ehrenreich 2014; J. Liu et al. 2012).  
Currently, there is some contradictory evidence over the turnover rate of 
oligodendrocytes in the adult CNS, whether mature oligodendrocytes can contribute 
to remyelination and whether species-specific differences may exist. 
Retrospective 14C birth-dating takes advantage of the enormously elevated 14C 
content in all biological material synthesized during the atomic bomb testing of the 
early 1960s and the fallout thereafter to identify the respective age of cellular material 
(Spalding et al. 2005). Using this technique on autopsied human brains, the majority 
of oligodendrocytes of the human corpus callosum were found to be nearly as old as 
the individual, supporting very long survival of integrated oligodendrocytes, similar to 
what was recently indicated in mice (Yeung et al. 2014; Hughes et al. 2018). However, 
fractionally isolated myelin of the same region appears to be relatively contemporary, 
indicating myelin turnover occurs in long-lived oligodendrocytes (Yeung et al. 2014). 
Additionally, the authors identify an annual ‘turnover rate’ (which may also reflect new 
additional oligodendrocytes) of 0.3% for WM oligodendrocytes after the age of 5, 
which is at least 100-fold lower than mice at comparable ages. Indeed, while over 
98% of human callosal oligodendrocytes were established by 9 years of age, as many 
as 20% of callosal oligodendrocytes in the mouse are born during adulthood (Rivers 
et al. 2008). Given the recently established paradigm of activity regulated 
myelination—whereby experience dependent elevations in myelination are 
dependent on the integration of newly differentiated oligodendrocytes (McKenzie et 
al. 2014; Hughes et al. 2018)—the authors suggest that the rate of 
oligodendrogenesis in human white matter could not account for the increase in 
myelin content observed during learning (determined by proxy using FA) and that 
mature oligodendrocytes might instead contribute to myelin plasticity in the human 
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adult CNS (Yeung et al. 2014). However, the changes observed by FA in humans 
have not yet been corroborated at the level of oligodendrocyte/myelin ultrastructure. 
The apparent plasticity of human myelinating oligodendrocytes was further developed 
in the context of remyelination in MS. Yeung et al. once again employed 14C dating to 
show that a greater proportion of recently generated OPCs and oligodendrocytes exist 
in normal appearing white matter (NAWM) of a subset of MS patients with a severe 
course of disease, compared to unaffected individuals. Significantly, oligodendrocytes 
residing in shadow plaques (believed to be indicative of lesions undergoing 
remyelination), were found to be old in ‘age’ and could not have been generated from 
neighbouring progenitor cells (Yeung et al. 2019). This suggests that 
oligodendrocytes that survive demyelination may contribute to remyelination in 
humans. Support for this notion recently came from large animal models of 
remyelination, where mature oligodendrocytes were found associated with both thick 
and thin myelin sheaths (indicative of remyelination) in the cat spinal cord following 
irradiated food induced demyelination; and also from a model of vitamin B12 
deficiency in the rhesus monkey which resulted in demyelination, survival of 
oligodendrocytes, and association with thin myelin sheaths (Duncan et al. 2018). This 
is in contrast to the rodent, where pre-existing mature oligodendrocytes were shown 
not to contribute to remyelination (Crawford et al. 2016). Whilst not generalizable 
across models of demyelination, these results indicate species-specific differences in 
myelin repair and, at the very least, highlight an important consideration for the 
development of future therapies that aim to promote remyelination. 
Further insight into species-specific differences has come from transcriptomic 
analysis of mouse and human cells. A study by the Allen Institute for Brain Science 
used single-nuclear RNA sequencing of mouse cerebral cortex and the middle 
temporal gyrus (MTG) of autopsied human tissue to show that, despite a 65 million 
year old common ancestor, many cell-types matched up 1:1 with no major class of 
cell missing a homolog (Hodge et al. 2019). However, divergent gene-expression was 
identified between mouse and human and—most notably—in nonneuronal cells and 
in genes associated with connectivity and signalling, indicating that evolutionary 
adaptations in humans have focussed on cell-cell interactions within a relatively 
comparable cellular architecture. A similar conclusion was drawn from another single 
nuclear RNA sequencing study comparing mouse, rat, and human cerebellar 
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transcriptomes (Xu et al. 2018). They conclude that, whilst cell-type specific genes 
are highly conserved across species, a significant number of genes demonstrate 
divergent expression profiles not defined by any particular gene ontology pathway, 
including in OPCs and oligodendrocytes. Promoter chromatin accessibility was 
identified as a potential driver of evolutionary differences and changes in the 
expression of cell-type specific transcription factors was suggested to underlie the 
common failure of mouse models to recapitulate features of human disease (Xu et al. 
2018). In addition, divergent DNA sequences was found to underlie the difference in 
activity-dependent gene-responsiveness of mouse and human ESC-derived cortical 
neurons (Qiu et al. 2016).  
Substantial evidence indicates that human astrocytes are functionally and 
morphologically specialised compared with rodent, demonstrating different laminar 
distributions, up to tenfold difference in size, different gene expression profiles and 
altered cytokine responses (Y. Zhang et al. 2016; Oberheim et al. 2009; Hodge et al. 
2019; Du et al. 2017). Their role in regulating aspects of myelination and remyelination 
are beginning to be uncovered (Molina-Gonzalez & Miron 2019). However, species-
specific differences have also been identified in oligodendroglial cells. The study by 
Hodge et al. identified 14% of genes expressed by OPCs to be highly divergent 
between mouse and human (Hodge et al. 2019). Additionally, comparisons between 
mouse and human fetal A2b5+ cells, isolated by magnetic sorting, showed significant 
differences in their gene expression profiles (Sim et al. 2009). After filtering out 
astrocyte-related genes, an OPC-enriched dataset identified 92 differentially 
expressed genes between mouse and human and over 200 genes not identified in 
mouse. Furthermore, proteomic analysis of mouse and human myelin identified 
shared and differentially expressed proteins (308 proteins shared, 167 mouse-
specific, and 370 human-specific). However, the authors conclude these differences 
may be overestimated by the technical limitations of their study (Ishii et al. 2009). 
More in-depth investigation by single cell RNA sequencing of isolated oligodendroglial 
cells revealed surprising heterogeneity within oligodendrocytes. Based on their gene 
expression profiles, Marques et al., identified 13 subpopulations of cells across the 
juvenile and adult mouse CNS that included 6 distinct populations of mature 
oligodendrocytes (Marques et al. 2016). Jäkel et al. showed that a similar scenario 
exists in the human brain, where 7 subpopulations of oligodendrocytes were 
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identified. Whilst a comparison of oligodendrocyte heterogeneity between healthy 
mice and humans is currently lacking, the authors demonstrated altered heterogeneity 
between control human and MS brains. Additionally, comparison between MS brains 
and cells isolated from the EAE mouse model of the disease showed only partly 
overlapping populations (Jäkel et al. 2019). This research supports the need for 
human models of myelin development, especially in the context of disease. An 
interesting consequence of this work will be to determine whether different subtypes 
of mature oligodendrocytes identified by RNA sequencing show differential responses 
to physiological cues and whether comparable oligodendrocyte subtypes behave 
equally across species. This is yet to be investigated. 
Finally, species-specific differences have also been identified regarding the behaviour 
and function of oligodendroglial cells. For example, fibroblast growth factor 2 (FGF2) 
is a trophic factor that promotes mouse—but not human—OPC specification and 
proliferation (Chandran et al. 2004) and the transcription factor ASCL1 regulates the 
induction of mouse—but not human—OPC genes (Jing Wang et al. 2014). 
Additionally, the expression pattern of muscarinic receptor (MR) subtypes is different 
between mouse and human OPCs, which has implications for the development of pro-
myelinating therapeutics as MR antagonism is frequently identified from rodent-based 
drug screens of oligodendrocyte differentiation (Welliver et al. 2018). 
Intrinsic differences have also been identified in the proliferation, colonisation and 
myelination of the demyelinated mouse CNS by either transplanted human fetal or 
mouse glial progenitor cells (Sim et al. 2009; Windrem et al. 2008; Windrem et al. 
2014; Mozafari et al. 2015; Buchet et al. 2011; Chanoumidou et al. 2019) with human 
cells showing increased proliferation for a prolonged period of time before 
differentiation and myelination begins. Given that human oligodendrocyte 
differentiation occurs comparatively quicker in vitro, this suggests that human and 
mouse OPCs differentially respond to the same niche-derived signals and that rodent 
models of remyelination therefore may not accurately reflect the dynamics of human 
OPC-mediated repair (Dietz et al. 2016). 
Altogether, these findings demonstrate significant differences in the dynamics and 
degree of human myelination, the transcriptomic signature of oligodendroglial cells 
and that novel disease-associated states of oligodendroglia are not recapitulated by 
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mouse models. In light of this, the development of a humanised model of myelination 
is warranted, as it would support our understanding of normal and pathogenic myelin 
formation whilst maintaining appropriate interactions with neurons and astrocytes 
(whose species-specific differences are well documented) and provide confidence 
that any potential disease-modifying treatments have a desired effect in human cells.   
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2.7 Modelling myelin development   
 
The use of tissue culture as a tool to study developmental and pathological processes 
has become an integral component of biomedical research. Since the demonstration 
that tissue explants derived from embryonic sources could be cultivated and 
propagated ex vivo in the earliest twentieth century, tissue culture techniques have 
been used to study developmental events in detail (Harrison et al. 1907; Carrel 1912; 
Ambrose 2017). Furthermore, access to the cellular environment permits 
pharmacological manipulation and physiological evaluation of cellular processes. 
 
Two dimensional cultures: primary oligodendrocytes and co-cultures 
Oligodendrocyte progenitor cells may be specifically isolated from the rat or mouse 
cerebral cortex and have been instrumental in understanding the behaviour and 
function of these cells (McCarthy & de Vellis 1980). Interestingly, in the absence of 
neurons, oligodendrocyte differentiation is not impeded. However, without a substrate 
to myelinate, large, flat, leaf-shaped sheets of myelin membrane are generated 
(Szuchet et al. 1987). Surprisingly, it was found that oligodendrocytes could myelinate 
both inert microfibres that mimic the physical dimensions of myelinated axons in vivo 
and fixed axons, demonstrating that myelin formation is not dependent on neuron-
derived signals (Althaus et al. 1984; Rosenberg et al. 2008; Bechler et al. 2015). 
However, the extent of wrapping is much greater in the presence of live axons and 
the factors that regulate non-cell autonomous induction of myelination in neuron co-
cultures has been of considerable interest (Allamargot et al. 2001; Brinkmann et al. 
2008; Câmara et al. 2009; Ishibashi et al. 2006; Demerens et al. 1996; Wake et al. 
2015). Indeed, two-dimensional co-cultures derived from dissociated CNS explants 
were highly informative and used to conclude that myelin is only targeted to axons, 
that the number of processes per cell was equivalent to that in vivo, that individual 
oligodendrocytes myelinate multiple axons in concert, and that myelination typically 
occurred in areas of high axonal density (S. U. Kim 1972; Lubetzki et al. 1993).  
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Another well-established method of studying myelin formation in vitro is through co-
culture with dorsal root ganglion (DRG) neurons. DRG neurons are pseudo-unipolar 
sensory neurons that project an axon both to the periphery and to the spinal cord and 
so are myelinated both by oligodendrocytes and schwann cells in vivo (Wood et al. 
1980). Wide-spread myelination occurs 10–14 days after the addition of OPCs (Chan 
et al. 2004; J. K. Huang et al. 2011). Due to the independent preparations of DRGs 
and OPCs, the ability to tightly control and manipulate each compartment prior to their 
co-culture provides a highly flexible model for studying both cell autonomous and non-
cell autonomous regulators of myelination (Jarjour et al. 2012).  
 
Three-dimensional cultures: organotypic and aggregate cultures 
Cultures that more closely mimic the in vivo environment have also be devised. Crain 
and colleagues showed that organotypic slice cultures of embryonic spinal cord 
develop a high degree of electrophysiological and biochemical maturity with 
prolonged culture (Crain 1966). Given the preservation of histotypical architecture and 
neuronal circuitry in brain organotypic slice cultures, they became—and remain—a 
powerful model for investigating neuronal physiology and function in a physiologically 
relevant environment. Organotypic cultures have also been extensively used to study 
myelination and helped to elucidate which cells were responsible for myelin formation 
(Jarjour et al. 2012; Field et al. 1969). A robust response to chemically induced 
demyelination with a substantial and well-defined time course of repair makes them 
well suited to study the process of remyelination and the factors that regulate it (Miron 
et al. 2013). 
Another interesting and relevant culture method to this thesis, that was popularised 
during the 1970s, is that of CNS aggregate cultures. Interest in recapitulating 
developmental processes ex vivo led to the demonstration that enzymatic digestion 
and mechanical dissociation of limb buds from the chick embryo would aggregate and 
self-organise in vitro and re-establish the expected tissue architecture with continued 
differentiation (Moscona & Moscona 1952). This method was soon applied to fetal 
cortical tissue, which gave rise to numerous spherical cultures displaying neural 
rosette formation, typical of the developing neural tube (Moscona 1957). Indeed, CNS 
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aggregate cultures became popular with optimised conditions yielding diverse 
neuronal and glial differentiation, synapse formation, expression of multiple 
neurotransmitters and, significantly, myelination (Seeds & Vatter 1971; Matthieu et al. 
1978; Trapp et al. 1979). Aggregate cultures were used to study modulators of 
myelination (Almazan et al. 1985), as well as de- and remyelination (de Rosbo et al. 
1990; Duvanel et al. 2001; Diemel et al. 2004), and were also generated using human 
fetal material (Pulliam et al. 1988). Aggregate cultures were advantageous due to the 
full complement of CNS cells present and their ability to mirror both the temporal 
maturation of the in vivo brain and appropriate cell-cell interactions therein. Aggregate 
cultures were often referred to as organoids (i.e. resembling an organ) and represent 
the methodological foundation to contemporary organoid cultures, which have been 
loosely defined as “derived from primary sourced material or pluripotent stem cells to 
generate restricted or diverse cell-types to study developmental and pathological 
processes in a 3D environment” (Lancaster & Knoblich 2014b).  
 
Pluripotent stem cells  
The derivation of embryonic stem cell lines from the mouse and human blastocyst 
was a landmark event that enabled the propagation and differentiation of mammalian 
cells in vitro and led to the generation of experimental mammalian genetics (Evans & 
Kaufman 1981; Martin 1981). Then came the seminal discovery that somatic cells 
both from mouse and human could be reprogrammed to a comparably pluripotent 
state via the transduction of 4 transcription factors (Oct3/4, Sox2, Klf4, c-Myc), 
revolutionising the field and bypassing the ethical controversy of using human ES cell 
lines (Takahashi & Yamanaka 2006; Takahashi et al. 2007). So called ‘induced’ 
pluripotent stem cells (iPSC) promised the ability to generate patient and disease-
specific cell lines to understand developmental and disease mechanisms, for drug 
screening and toxicology purposes and for application in regenerative medicine.  
Furthermore, another major advancement in recent years was the development of 
gene editing tools—most notably of CRISPR/Cas9—that enabled accessible and 
precise targeting of the genome. In particular, for iPSC research, targeted gene-
correction of known genetic mutations in patient-derived iPSCs has provided 
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researchers with a valuable tool to create isogenic cell lines for investigating 




Developmental studies of the 20th century provided the foundation and necessary 
information to induce precise differentiation of pluripotent stem cells into defined 
germ-layers and cell-types (Rossant 2011) (Figure 2.8). The generation of stem cell-
derived oligodendrocytes was viewed as an attractive method to study normal as well 
as dysfunctional oligodendrocyte development in disease, as a screening tool to find 
chemical inducers of oligodendrogenesis to treat demyelinating disorders and as a 
potential cell-based therapeutic intervention for childhood leukodystrophies and 
cerebral palsy (Billon et al. 2002; Goldman & Kuypers 2015; Goldman et al. 2012). 
Oligodendrocytes were first derived from mouse ES cells (Fraichard et al. 1995) and 
then from human ES (S.-C. Zhang et al. 2001) inefficiently amongst a mix of neuronal 
cell-types. However, protocol optimisation eventually led to efficient generation of 
oligodendrocytes from human ES cells (S. M. Kang et al. 2007) and iPSC cells 
(Ogawa et al. 2011; Su Wang et al. 2013; Livesey et al. 2016; Douvaras et al. 2014) 
using the principle technique of reproducing the temporal signalling environment 
exposed to neuroepithelial cells as they differentiate into oligodendrocyte in vivo. This 
involves neural induction via retinoic acid, proliferation of NPCs via FGFs, 
ventralisation via sonic hedgehog signalling, expansion of OPCs via PDGF and 
exposure to insulin and thyroid hormone to support oligodendrocyte differentiation, 
survival and maturation (Goldman & Kuypers 2015; Barres et al. 1993).  
Stem cell-derived oligodendrocytes demonstrate the appropriate maturation-specific 
physiological features that were first reported in rodent systems, including a 
progressive reduction in voltage-gated sodium and potassium channels, an increase 
in the activity of inwardly rectifying potassium channels and modifications to AMPA 
receptor composition (Livesey et al. 2016). Additionally, a number of studies have 
used this model to study the development of oligodendrocytes in response to factors 
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including small molecules and different oxygen tensions (Stacpoole et al. 2013; 








Figure 2.8 In vitro generation of different germ layers from pluripotent stem cells 
Pluripotent stem cells can be differentiated into different cell-types across all three germ layers 
(motor neurons: ectoderm, erythropoietic: mesoderm and intestinal cells: endoderm) using 
precise patterning factors. Adapted from Zhu and Huangfu, (2013), Development. 
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iPSC-derived myelin 
The critical function of oligodendrocytes is to myelinate and there exists a limited 
number of methods to study iPSC-derived myelin formation. The most robust of which 
involves transplantation of iPSC derived OPCs into the dysmyelinating shiverer 
mutant mouse. First described in 1973 (by Biddle et al in the F38 generation of Swiss 
Vancouver stock), the shiverer mouse contains an autosomal recessive mutation in 
the gene for myelin basic protein (MBP) (Chernoff 1981). As a result of the large 
deletion, shiverer mice do not express MBP mRNA and have trace amounts of 
compact myelin in the CNS, while peripheral myelin is intact. Consequently, 
transplantation of exogenous OPCs into either the neonatal mouse brain, or 
organotypic slice cultures derived from the shiverer mouse, leads to oligodendrocyte 
differentiation and myelination, which can be ascribed to the transplanted cells by their 
expression of MBP. This technique has been used to investigate the myelinating 
potential of normal and patient-derived iPSC-derived oligodendrocytes (Su Wang et 
al. 2013; Douvaras et al. 2014; Osipovitch et al. 2018; Windrem et al. 2017; Vasistha 
et al. 2019).  
Whilst useful for demonstrating the potential of human oligodendrocyte to form myelin, 
the constrained circumstances by which human cells must replace endogenous 
oligodendrocytes that fail to compactly myelinate the shiverer mouse, as well as the 
inherent variability of transplantation studies and the restrictive conditions of an in vivo 
environment highlight the need for a reliable, accessible, in vitro human-based model 
of myelination. 
In vitro assays of myelination are readily available using rodent material, involving co-
culture between primary rat OPCs and either retinal or dorsal root ganglion cells 
(Svenningsen et al. 2003). So far, similar efforts using strictly iPSC-derived cell-types 
has failed to give rise to myelin formation (Su Wang et al. 2013). Recently, mixed-
species approaches have been more successful, where co-culture of iPSC-derived 
oligodendrocytes with rat DRGs does lead to myelin formation (Nevin et al. 2017). 
Whilst suitable for analysis of cell-autonomous defects in human oligodendrocytes, 
the longevity of co-cultures is low, thereby limiting maturation of iPSC-derived myelin 
(e.g. assembly of nodal domains). Furthermore, there may be differences in axonally-
regulated signals between human and rat that are not accounted for in this system. 
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This may be particularly important in the context of modelling familial human diseases 
in vitro as such gene mutations will be globally expressed throughout the CNS.  
In order to model myelin disorders in vitro or to inform accurately on the factors that 
regulate human myelination, an improved in vitro model of myelination is needed that 
demonstrates robust, compact myelin development and which mirrors the in vivo 
physiological maturity of myelin. 
 
Pluripotent stem cell-derived organoids 
Until recently, the emphasis on refining iPSC-based protocols was placed on deriving 
more homogenous populations of defined cell-types to attribute any phenotype 
accordingly. However, though a reductionist approach is often warranted, it has long 
been established that cells behave differently in the presence of other cell-types. Most 
notably, astrocytes promote CNS synaptogenesis via thrombospondin-gabapentin 
receptor signalling (Christopherson et al. 2005; Eroglu et al. 2009). This has led to a 
resurgence in three-dimensional cultures that aim to preserve appropriate cell-cell 
interactions in vitro as a more physiologically relevant model system to study organ 
development. 
As indicated to earlier, organoids represent the methodological evolution of both 
pluripotent stem cell-derived embryoid bodies and aggregate cultures derived from 
dissociated embryonic tissue (Lancaster & Knoblich 2014b; Clevers 2016). They have 
been defined as “collections of organ-specific cells types that develop from stem cells 
or organ progenitors and self-organise through cell sorting and spatially restricted 
lineage commitments in a manner that is similar to in vivo” (Lancaster & Knoblich 
2014b). The advent of human pluripotent stem cells brought with it the possibility of 
modelling human organ development in vitro. In 2013, Madeline Lancaster 
demonstrated an organoid model of the developing brain that recapitulated species-
specific differences in cortical volume and outer radial glial cell number, compared to 
mouse ES-derived organoids. Furthermore, cerebral organoids generated from 
patient-derived iPSCs recapitulated the major hallmarks of primary microcephaly 
(Lancaster et al. 2013). Cerebral organoids develop a variety of regional identities that 
self-organised into discrete domains and opened up the possibilities of modelling 
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other neurodevelopmental conditions to study the pathogenesis of disease (Kelava & 
Lancaster 2016a).  
Over the following years a number of protocols have established slightly more 
restrictive, CNS region-specific cultures, made up of multiple, developmentally 
associated cell-types that avoids the unrestricted differentiation observed in cerebral 
organoids. A useful figure to illustrate the spectrum of stem cell-derived neural 
cultures with regard to cellular complexity is shown in Figure 2.9 (taken from Kelava 
& Lancaster 2016b). This depicts the trade-off between homogeneity and cellular 
complexity across different types of cultures, which is controlled by the degree of 
patterning factors supplemented into the medium and how the cells are handled. 
Whilst neural stem cells can be maintained in a highly pure population by controlling 
their growth and limiting their differentiation, spheroid cultures are exposed to 
inductive cues that pattern neuroepithelial cells to defined domains of the developing 
CNS. The complexity of whole-brain organoids is due to the absence of inductive 
cues. This results in highly heterogenous cultures that are established by intrinsic 
differentiation cues, which leads to regionalisation of different CNS domains. So far, 
region-specific organoids have been generated to resemble the dorsal and ventral 
forebrain, midbrain and hypothalamus (Birey et al. 2017; Qian et al. 2016). Of note, 
the term organoid has more recently become associated with any three-dimensional 
culture derived from either stem cells or primary tissue and is increasingly used 
interchangeably with ‘spheroid’ cultures. 
Techniques have emerged to study neuronal function and network formation (Paşca 
et al. 2015; Giandomenico et al. 2019) and the cellular composition of forebrain 
organoids has been shown to resemble that of the human fetal brain (Velasco et al. 
2019). Importantly, organoids give rise to cells that are functionally more mature than 
through conventional differentiation protocols, which is exemplified by the dynamic 
cell-cell interactions observed between astrocytes and neurons in cortical spheroids 











Figure 2.9 Complexity and homogeneity in stem cell-derived spheroids and 
organoids 
An inverse relationship between homogeneity and complexity exists in stem cell-derived 
neural cultures. Increasing cellular diversity is evident between neural stem cell and 
spheroids cultures with cerebral organoids demonstrating grater complexity again.  
(s)VZ : (sub)-ventricular zone.  
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Recently, several studies have investigated oligodendrogenesis in spheroid/organoid 
cultures (Madhavan et al. 2018; Marton et al. 2019; H. Kim et al. 2019). Given the 
heterogenous mixture of neurons and astrocytes, advanced functional maturity and 
the enhanced longevity of organoid culture (Lancaster & Knoblich (2014a) were the 
first to demonstrate cultures maintained for over 1 year) — organoids are an attractive 
model to study human myelin development. Evidence of oligodendrocyte-axon 
interaction and compaction has been shown in three-dimensional human stem cell-
derived cultures (Madhavan et al. 2018; Marton et al. 2019; H. Kim et al. 2019). 
However, wide-spread myelin formation and organisation of myelinated axon domains 
(eg. node of Ranver) have not been recapitulated in vitro, highlighting the immaturity 
of currently available model systems.  
Against this background, this thesis set out to develop a robust and physiologically 
mature model of myelination derived from human pluripotent stem cells in order to 
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3.1 Materials 
 
Advance DMEM/F12 (Life Technologies, 12634-010)  
Accutase (Sigma, A6964)  
Antibiotic-Antimycotic (Life Technologies, 15240062)  
Murine bFGF (Peprotech, 450-33)  
GFR BD Matrigel basement membrane matrix (SLS, 354230)  
Laminin (Sigma, L2020-1MG)   
DPBS (Ca-/Mg-) (Life Technologies, 14190-094)  
DMSO (Sigma, D2438)   
Activin Inhibitor (R & D Sytems, 1614/1)  
LDN193189 (Stratech, S2618)  
IMDM (Life Technologies 21980-32)  
F12 (Life Technologies 31765-027)  
BSA (Europa EQBAC62 0050)   
CD Lipid 100x (Life technologies) 11905-031)   
Monothioglycerol (Sigma M6145)  
Insulin  (Roche 1376497)  
Transferrin (Roche 10652202001)  
Glutamax (Life Technologies, 35050-038)  
B27 (Life Technologies 17504-044)  
N2 (Life Technologies, 17502-048)  
BDNF (R & D Systems248-BD-025)  
GDNF (R & D Systems212-GD-050)  
Forskolin (R & D Systems1099/10)  
Retinoic acid (Sigma R2625)  
Puromorphamine (Merck 540220-5MG)  
Heparin (Sigma H3149)  






















1 mg/ml 50 µg/ml 
 
Method: iPSC maintenance  
 
All iPSC lines used in this study were obtained under full Ethical/Institutional Review 
Board approval from the University of Edinburgh. CS02iCTR-NTn1 (iPSC1), 
CS25iCTRL-18n2 (iPSC2) were obtained from Cedars-Sinai and the CS00iNK-n1 and 
/ CS00iNK-n2 lines (Nfasc155 / ) were generated in collaboration with Professor Peter 
Brophy and Cedars-Sinai. The two ALS patient-derived cell lines used, harbouring 
either the G298S or M337V TARDBP mutations, were provided as fibroblasts from 
Professor Chris Shaw, King’s College London and reprogrammed to iPSCs by Dr 
Karen Burr and Dr Bilada Bilican via either episomal or retroviral-based methods.  
All iPSCs were maintained on Matrigel (BD Biosciences)-coated plates in Essential 8 
medium (Life Technologies) at 37°C and 5% CO2. Medium was replenished every 
day until cells had reached 80% to 90% confluency. To passage, cells were washed 
in 1 mL of DPBS before being lifted from the surface of the plate with 1 mL of a 1:1 
ratio of Dispase: Collagenase and incubated at 37˚C for 15–25 min. 1 mL of DPBS is 
added to the cell solution and used to flush remaining colonies from the surface of the 
plate. Cells were transferred to a 15mL falcon tube, gently separated by pipetting and 
allowed to settle. The supernatant was removed by aspiration and the pellet 
resuspended in 5 mL of DPBS to wash the cells, which were again left to settle. The 
supernatant was removed once more, the pellet was resuspended in E8 medium + 
PSF, and the cells were split accordingly.  
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Method: Generation of iPSC derived oligodendrocytes  
 
iPSC-derived oligodendrocytes were generated using the protocol published by 
(Livesey et al. 2016). On day 0, confluent iPSC colonies were lifted using 
Dispase/Collagenase (similarly to passaging iPSCs) and, after washing the cells 
without breaking the colonies up, were reconstituted in 10mL phase 1 medium, 
transferred to 90mm plastic dishes and placed on rotating shakers to encourage 
embryoid body and neurosphere formation. Phase 1 medium contains LDN and 
Activin inhibitor to direct cells towards a neuroectoderm fate by blocking BMP and 
TGF-β respectively (dual SMAD inhibition) and was replenished every 2–3 days. On 
day 7, the medium was changed to phase 2 medium, which contains the caudalising 
agent retinoic acid (RA) to pattern the cells towards the spinal cord. On day 14, 
neurospheres were plated on to laminin-coated 6 well plates for 2–3 days to allow for 
adhesion to the plate surface. Since only viable spheres attached to the plate surface, 
this process enriched the cultures for healthy spheres. In addition, non-neuralised 
spheres that did not show neural rosettes or any neural precursor cells (NPCs) 
migrating out of attached spheres were selectively removed using a p200 pipette. 
Neurospheres were lifted from 6 well plates using a cell scraper, transferred to 90mm 
dishes and cultured for a further 7 days in phase 3 medium containing the ventralising 
agent purmorphamine, to pattern the cells towards the pMN domain of the ventral 
telencephalon, and FGF2 to support the proliferation of NPCs. After 7 days, 
neurospheres were transferred to phase 3 medium-FGF for a further 14 days to 
prevent further growth of the spheres and promote differentiation of NPCs. Following 
this phase, spheres were transferred to oligodendrocyte proliferation medium, which 
contains the mitogens PDGF-α and FGF2, to promote oligodendrocyte progenitor 
generation and proliferation; smoothened agonist (SAG), as an additional ventralising 
factor; IGF; and T3, which support oligodendrocyte differentiation. Oligodendrocyte 
progenitor spheres were mechanically dissociated at this stage to enrich the OPC 
population and maintained for a further 3–4 weeks with regular pruning of any 
aggregated spheres.  
 
For two-dimensional analysis of oligodendrocyte differentiation, oligodendrocyte 
progenitor spheres were dissociated using the papain kit (Worthington Biochemical). 
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0.5 mL of spheres are collected in a 15 mL falcon tube and allowed to settle. A 
Papain/DNase solution is added to the cells and returned to the incubator for 15–20 
minutes. Using a P1000 pipette, spheres were gently dissociated into a single cell 
suspension and centrifuged at 2500 rpm for 2.5 minutes to remove the supernatant. 
The cell pellet was reconstituted in an inhibitor/DNase solution and gently layered on 
to 1mL of Ovomucoid inhibitor in a fresh falcon tube. This allowed for larger clumps 
of cells to sink to the bottom of the discontinuous density gradient. Using a P1000, 
the upper layer of cells was carefully removed from the gradient, centrifuged at 2.5rpm 
for 3 minutes, and the was supernatant removed. The pellet was resuspended in 
oligodendrocyte proliferation medium and the cells counted using a haemocytometer 
and 40 µl of cells at 1000 cells per µl was added as a droplet onto the centre of pre-
coated coverslips. After 2 hours, the cells had adhered to the surface and the well 
was flooded with oligodendrocyte proliferation medium. The next day, half the medium 
was changed with oligodendrocyte differentiation medium. Cultures were maintained 
for 3–4 weeks with medium changes every 2–3 days. Cultures were fixed in 4% PFA, 
washed in PBS, and used for immunocytochemistry. 
 
Method: coating coverslips 
To coat coverslips for oligodendrocyte plate down, acid-treated and autoclaved 
coverslips were submerged in a 1% polyornithine solution (in embryo transfer water) 
overnight at room temperature. The next day, coverslips were washed three times in 
Embryo Transfer Water. A 40 µl droplet of coating reagents laminin, matrigel, and 
fibronectin (LMF) was added and the coverslips were stored at 4°C for up to 7 days 
or placed in an incubator at 37 °C for 2–3 hours prior to plate down.  
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Method 
iPSC derived MNs were provided by Dr Bhuvaneish Selvaraj and were generated via 
the protocol published (Selvaraj et al. 2018). In a 40µl droplet, 20,000 MNs were 
added to the LMF-coated coverslips. After 1 hour, 25 µl of media was removed and 
replaced with 25 µl of a single cell suspension of OPCs. Between 35,000 and 125,000 
cells were added per well. After a further 2 hours, the well was flooded with MN co-
culture medium. Co-cultures were maintained for 3 weeks and the medium was 
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3,3′,5-Triiodo-L-
thyronine sodium salt 
(T3) 
T6397 




Dr Marie Bechler in the ffrench-Constant lab provided technical support in establishing 
DRG cultures. DRGs were dissected from E15 rats and were incubated in 1 ml of 
papain digestion mix (1 ml MEM, 1.2 U/ml papain (Worthington), 0.24 mg/ml L-
cysteine solution (Sigma) and 40µg/ml of DNase (Sigma) for 1 hour at 37ºC. DRG 
medium supplemented with NGF was used to quench the reaction and, after washing 
once in DRG medium, the cell pellet was dissociated. Between 1.7 and 2.0 x 106 cells 
were added as a 200 µl droplet onto Poly-D-Lysine and matrigel-coated 22 mm wide 
coverslips. The next day, each well was flooded with DRG medium supplemented 
with NGF and FdU. Cells were maintained in DRG medium supplemented with NGF 
for 21 days and were exposed to a total of three doses of FdU every other media 
change. After 21 days, DRGs were slowly exposed to DRG co-culture medium by 
gradual incorporation over 3 days. Subsequently, between 50,000 and 250,000 iPSC 
derived OPCs were added and maintained for 4 weeks. Cultures were fixed in 4% 
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discarded and the DNA pellet was washed in 70% EtOH. DNA was resuspended in 
10-20 µl of buffer EB and used in a PCR reaction to test for presence of full-length 
MBP gene.  
 
Method: Preparing organotypic slice cultures and OPC co-cultures 
The brains of homozygous shiverer MBP /  mice were dissected in cold EBSS and 
placed in plastic moulds containing pre-heated 4% low-melting agarose (Lonza). 
Once hardened, 300 µm sections of forebrain were cut using a vibratome and up to 
three sections each were transferred to PTFE-coated cell culture inserts in serum 
containing slice culture medium. Between days 1 and 7, the medium was slowly 
replaced with increasing concentration of serum free slice culture medium. Between 
10 to 20,000 OPCs were added onto organotypic slice cultures in 1–2 µl. Alternatively, 
whole spheroids that had not been dissociated were transferred onto slice cultures 
using a p200 pipette. Cultures were maintained in serum free slice culture medium for 
2–8 weeks. Cultures were fixed in 4% PFA by adding 1ml below and 1ml above each 
insert, washed in PBS, and used for immunocytochemistry. 
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were added to each insert and maintained in myelination medium for 4–12 weeks (1 
ml of medium was replaced every 2–3 days). To pharmacologically modulate myelin 
development, blebbistatin (10 µM, Sigma), TeNT (3 nM, Sigma), and BDNF (10 ng/µl) 
were added to myelination medium at MI and maintained throughout the remainder of 
the culture period. Myelinoids were exposed to 15 mM KCl (myelination medium 
supplemented with 10mM KCl) for 2 hours at a time, either once or three times per 
week, before being returned to normal medium. 
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3.5 CRISPR/Cas9 gene targeting 
 
In order to correct the TDP-43 G298S mutation in patient-derived iPSCs, a 
CRISPR/Cas9 gene targeting approach was used to induce a double stranded DNA 
break near the mutation site and a single stranded oligo DNA nucleotide (ssODN) was 
supplied with the correct gene sequence as a substrate for homology directed repair 
(HDR). A schematic overview of the targeting strategy is provided in Figure 7.2A. 
 
Testing gRNA targeting efficiency 
Dr Bhuvaneish Selvaraj designed guide RNAs (gRNA) targeting the mutant allele 
using the gRNA design resource at http://crispr.mit.edu/. gRNAs were cloned into the 
pMTL23 vector, which was used to drive expression of CRISPR RNA, transactivating 
CRISPR RNA and gRNA via the U6 promoter. The targeting efficiency of each gRNA 
was tested via a T7 assay on transfected cells. To do so, patient-derived iPSCs were 
lifted using accutase, pelleted, washed, and reconstituted in E8 medium + Rock 
inhibitor. Once counted, 800,000 iPSCs were reconstituted with a transfection solution 
containing a pMTL23 plasmid to drive expression of each gRNA, the pspCas9-2A-
GFP plasmid that drove expression of the Cas9 mRNA and an EGFP-PUROMYCIN 
plasmid that enabled positive selection of transfected cells. The Lonza 4D 
nucleofector (programme CA137) and P3 Primary Cell 4D-Nucleofector kit was used 
was used to transect iPSCs in a total of 500 µl. Per well, 250 µl of cells were plated in 
E8 medium + Rock inhibitor per well. The next day, the medium was replaced and 
supplemented with 0.5 µg/ml puromycin for 24 hours. DNA was isolated from the 
transfected cells after a further 5 days of culture using the Promega kit (Wizard 
Genomic DNA Purification Kit). 
 
T7 surveyor assay 
Following Cas9-mediated DNA cleavage, the dominant repair process is non-
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hFOXG1 R2 CCGTCGTAAAACTTGGCAAAG   
hFOXG1 F2 CCGCACCCGTCAATGACTT 65 133bp 
hOtx2 F AGAGGACGACGTTCACTCG   
hOtx2 R TCGGGCAAGTTGATTTTCAGT 66 115bp 
hHoxB4 ex1 F GTGAGCACGGTAAACCCCAAT   
hHoxB4 ex2 R CGAGCGGATCTTGGTGTTG 67 243bp 
hGbx2 R CGCCTTGTCGAAGTTACCG   
hGbx2 F CTCACCTCTACGCTCATGGC 67 126bp 
hPax6RT F ATGTGTGAGTAAAATTCTGGGCA   
hPax6RT R GCTTACAACTTCTGGAGTCGCTA 65 103bp 
hNkx2.2 R GCGCTTCATCTTGTAGCGG   
hNkx2.2 F CGGCGAGTGCTTTTCTCCAA 68 165bp 
SYT1 F TCATCTGATGCAGAATGGTAAGAGG  
SYT1 R GTAGCCCACAAAGACTTTGCC 67 199bp 
PSD95 F GGGAGAAGCAGCTCAACTCCAATCC  
PSD95 R CCAGCAAGGCCTGGAAGAG 70 180bp 
VAMP2 F GTGGATGAGGTGGTGGACAT   
VAMP2 R TTCTCTAGGCAGGGCAGACT 68 267bp 
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3.7 Immunocytochemistry 
 
MI-4, MI-8, and MI-12 myelinoids were fixed by submerging in 4% PFA (myelinoids: 
2 hours at room temperature (RT), co-cultures: 15–20 minutes RT). Cells were 
washed twice in PBS and stored at 4°C until they were ready for processing. For 
analysis of myelin sheath length and myelin volume across the spheroid, whole 
spheroids were stained as follows. Membranes containing myelinoids were cut out 
from each insert and placed in 24 well plates with fresh PBS. Cells were permeabilised 
with 0.3% Triton-X-100 in PBS for 45 minutes and then placed in blocking solution for 
2 hours (10% normal goat serum, 0.3% Triton-X-100 in PBS) at RT. For CNP staining, 
antigen retrieval was performed by transferring membranes into 1.5 mL eppendorfs 
containing 1mL of citrate buffer pH 6 and placed in a shaking heatblock at 95°C for 
20 minutes. Myelinoids were then washed in PBS and placed in blocking solution for 
another 1 hour. Primary antibodies were diluted in blocking solution and added to 
myelinoids for overnight incubation at 4°C. The next day, spheres were washed in 
PBS + 0.1% Tween-20 (PBS-T) and incubated with secondary antibody (all 1/1000) 
for 2 hours at RT. DAPI was used at a dilution of 1:20,000 and incubated for 15 
minutes. After further washing in PBS-T, membranes containing myelinoids were 
mounted onto microscope slides (Thermo Scientific) with FluorSave (Calbiochem) 
and No. 1.5 coverslips (Thermo Scientific). 
Where cryosections were used, myelinoids were fixed (as before) and immersed in a 
30% sucrose solution overnight at 4°C. The next day, myelinoids were transferred to 
a 1:1 solution of 30% sucrose and OCT and frozen in a bath of isopentane over dry 
ice. Cryosections of 10µM were cut and stored at –20°C until ready for staining. To 
stain cryosections, slides were immersed in 0.3% Triton-X-100 in PBS for 30 minutes 
and blocked using the same blocking solution as above for 1 hour. For CNP staining, 
slides were immersed in citrate buffer pH 6 and placed in a microwave for 4 minutes 
at full power, then for 3 minutes at 80% power, and washed in PBS. The sections 
were incubated with primary antibody in blocking solution overnight at RT. The next 
day, sections were washed in PBS-T and incubated with secondary antibodies for 2 
hours. DAPI was added to the sections for 7 minutes, which were washed in PBS-T 
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3.8 Confocal microscopy and image analysis 
 
A Zeiss 710 confocal was used for each of the following: for cell counts, two z-stacks 
per myelinoid were acquired with a 40X (1.3 NA) objective. For manual tracings of 
individual oligodendrocytes, a 40X objective was used to create tiled z-stacks 
(typically 3x4 tiles, 20 µm z-depth with 0.25 µm z-steps), a minimum of 5 cells per 
myelinoid was measured. To acquire PNJs, a 63X oil objective (1.4 NA) was used. 
Image analysis was performed using FIJI with the cell counting plugin and Simple 
Neurite Tracer plugin (Longair et al. 2011). Nearest neighbour analysis was 
performed by plotting a 100 µm radius circle around individual cells and counting the 
number of myelinating oligodendrocytes within that area. All cell counts and analysis 
between experimental conditions were performed blinded by either blinding samples 
before image acquisition and/or running an ImageJ macro to blind and randomise files 
(see appendix). 
 
3.9 Transmission electron microscopy  
 
To demonstrate myelin compaction, myelinoids were fixed in phosphate buffer (PB) 
containing 4% PFA and 2% glutaraldehyde for 2 hours, post-fixed in 0.1% 
glutaraldehyde for 24 hours at 4°C and washed in 0.1 M PB (2 x 15 min). Samples 
were transferred to 1% OsO4 in 0.1 M PB for 45 min at RT, washed in 0.1 M PB and 
then dehydrated in increasing concentrations of EtOH for 15 minutes each (50%, 
70%, 90%, 100% x 3). Samples were then incubated in a 1:1 mix of Araldite-DDSA 
(Agar Scientific):acetone for 1 hour then transferred to Araldite-DDSA for overnight 
incubation, before being cured in Araldite embedding mix at 60°C for 48 hours. 
Ultrathin sections (60 nm thick) were cut, stained in Uranyl Acetate, and Lead Citrate 
then viewed using a JEOL JEM-1400 Plus TEM. Images were captured on a GATAN 
OneView camera. 
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3.10 ImageXpress image acquisition and metaxpress 
image analysis of myelin volume  
 
An ImageXpress micro confocal was used to acquire whole-mounted myelinoids for 
automated analysis of myelin volume. Low magnification (4X) scans for each 
microscope slide were taken and acquisition areas were drawn around each 
myelinoid. Z-stacks of 12 µm (1 µm z-step) beginning at the superficial edge of each 
acquisition area were acquired using a 20X plan Apo objective, a 42 µm pin hole 
confocal mode with 10% overlap for stitching.  
A custom module was designed to segment myelin volume in 3D. First, an adaptive 
threshold was used to segment either MBP or CNP staining. The Filter Mask tool was 
then used to remove objects with a Fiber Breadth > 16 µm, a Fiber Length < 10 µm 
and an Area < 45 µm2. Objects were then shrunk by 4 pixels and a subsequent filter 
step removed objects that had an Elliptical Form Factor < 3.7, Fiber Breadth of > 8 
µm, and an Intensity Standard Deviation < 1000. Keep Marked Objects was then used 
to retain objects from the first Filter Mask that overlaid with the second Filter Mask of 
shrunk objects. This step specifically helped remove the non-myelin objects including 
cell bodies and debris. The Find Blobs tool was used to further identify non-myelin 
objects with an approximate width between 8-100 µm, which were then enlarged by 
5 pixels and subtracted from the Filter Mask. This step was repeated with blobs 
approximately 4-6 µm in width. Next, a 3D filter mask was obtained by connecting 
neighbouring z-steps using the Connect Touching Objects tool. A final filter step 
removed 3D objects with a volume ≤ 450 µm3 and a diameter ≤ 45 µm. In order to 
measure NF-H intensity, a simple threshold was performed to segment the total image 
area and Connect by Touching was used to segment the total image volume. DAPI+ 
nuclei were similarly identified using the ‘find round objects’ tool with typical 
dimensions between 5.7 and 9 µm and z-steps were stitched by connect best match. 
The volume of segmented myelin (µm3), integrated intensity of NF-H+ staining, DAPI 
number and SOX10 number were measured within the total image volume, summated 
for each acquisition site. Downstream analysis was performed using RStudio to 
process exported data tables, aggregate measurements for each myelinoid, and 
normalise data to a batch control. 
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3.11 Distribution correlations of myelinoid cell-types 
 
To determine how the regional distribution of different cell-types correlated with each 
other in iPSC myelinoids, automated measurements were gathered from all control 
MI-12 myelinoids processed at the time (51 myelinoids from 11 conversions). In order 
to identify robustly myelinated samples, the maximum myelin score for each myelinoid 
was ranked and the top 50th percentile myelinoids were taken forward for correlation 
analysis (28 myelinoids from 6 conversions). The dataset was filtered to remove 
redundant acquisition sites with fewer than 100 DAPI+ cells. As the dataset was not 
large enough to run a mixed linear model with random effects, a linear model with 
robust standard errors was used. 
 
3.12 Statistical analysis using R  
 
Statistical analyses were performed using RStudio and the generalised mixed models 
plugin glmmTMB (Brooks et al. 2017). Analysis of myelin sheath length over time was 
performed using mean sheath length as the dependent variable. Individual myelinoids 
were included as a random effect (with random intercepts) to accommodate for 
nesting of data (Aarts et al. 2014). Analysis of sheath number and mean sheath length 
per cell were performed with treatment conditions as fixed effects (e.g. TeNT) and 
each myelinoid and cell line were included as random effects. Automated analysis of 
myelin volume was performed with TeNT as a fixed effect and each conversion of 
iPSCs included as a random effect. For correlating automated measurements of cell 
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4.1 Introduction 
 
In vitro generation of iPSC-derived oligodendrocytes has provided a major 
advancement in our ability to ask questions related to human oligodendrocyte biology 
in development, in response to pharmacological manipulation, in the context of 
genetic perturbations (Vasistha et al. 2019; Osipovitch et al. 2018; Ehrlich et al. 2017; 
Ferraiuolo et al. 2016) and to explore the recently identified gene-expression 
differences between both between mouse and human oligodendroglia (Hodge et al. 
2018; Xu et al. 2018) and in human disease (Jäkel et al. 2019). However, there exists 
a paucity of methods to investigate the most critical function of iPSC-derived 
oligodendrocytes: forming myelin. Currently, the most reliable method involves 
transplantation of iPSC derived OPCs into the shiverer mouse brain, which is devoid 
of endogenous compact myelin (Wang et al. 2013; Vasistha et al. 2019). In vitro 
models of myelin development are desired due to the advantages of an accessible 
environment for pharmacological modulation, increased experimental throughput and 
improved reproducibility. Currently, human pluripotent stem cell-derived models have 
so far failed to give rise to robustly myelinating cultures with appropriate myelinated 
axon organisation. Against this background, I set out to generate a humanised model 
of myelination using iPSC-derived cells to understand the cellular processes that 
regulate human myelin development and also permit investigations of normal and 
pathogenic myelin development using patient-derived cell lines. 
As I will describe in this chapter, an iPSC-derived organoid model that demonstrates 
temporal formation of compact myelin was developed following a series of 
unsuccessful approaches in which dissociated iPSC-derived OPCs were added to 
human and rodent neuronal cultures. I characterise the cell-types and temporal 
development of myelin formation within myelinating organoid and assessed the 
thickness and integrity of myelin and the organisation of myelinated axon sub-
domains. Finally, I identify the regional distribution of myelin within these cultures and 
investigate the sub-types of neurons being myelinated in this model. 
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4.2 Results 
 
4.2.1 Generation of iPSC-derived oligodendrocytes 
 
The healthy control human induced pluripotent stem cell (iPSC) lines used for the 
completion of this thesis were CS02iCTR-NTn1 (iPSC1), CS25iCTRL-18n2 (iPSC2), 
which were purchased from Cedars Sinai. These and other cell lines were maintained 
on Matrigel-coated culture plates in E8 medium. iPSCs were positive for pluripotency 
markers TRA-1-60, OCT3/4, and NANOG, and were shown to be karyotypically 
normal (Figure 4.1A). 
In order to generate oligodendrocytes from iPSCs, I used a protocol that was 
established by a previous post-doctoral researcher in the Chandran lab, Dr Dario 
Magnani (Figure 4.1B) (Livesey, Magnani, Cleary, Vasistha, James, Selvaraj, Burr, 
Story, Shaw, Kind, Hardingham, Wyllie & Chandran 2016a). This protocol—similarly 
to others that have been established by different research groups (Wang et al. 2013; 
Douvaras et al. 2014)—involves patterning neuroepithelial cells towards the pMN 
domain of the developing spinal cord, which gives rise to both motor neurons and 
oligodendrocytes during development, in a time-dependent manner (Rowitch 2004). 
Specification of the pMN domain begins by enzymatic detachment of confluent iPSC 
colonies, transfer to orbital shakers to encourage embryoid body formation, and 
patterning with dual SMAD inhibition to direct cells towards neuroectoderm. 
Subsequent exposure to retinoic acid and sonic hedgehog agonist pattern cells 
towards a caudal and ventral fate, respectively. Efficient targeting of the pMN domain 
can be determined by the expression of OLIG2. At week 5, the mitogens PDGF-AA 
and FGF-2 are used to induce oligodendroglial cell-fate and expand the cycling 
population of oligodendrocyte progenitor cells (OPCs). During this period, 
oligodendrocyte progenitor spheroids are mechanically dissociated and re-formed to 
yield a higher proportion of OPCs by expanding the surface area of cells exposed to 
media growth factors. This process also reduces the neuronal contamination of 
cultures by axotomisation and prevents the aggregation of spheroids into large 
clumps. Two to four weeks after oligodendroglial induction, spheroids are 
enzymatically dissociated into single cells and plated on matrigel-laminin-fibronectin-
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coated coverslips, or plates, and maintained in medium devoid of growth factors for 
up to 21 days. Successful generation of iPSC-derived oligodendrocytes at d14 post-
plate down is shown in Figure 4.1C, where OPCs and oligodendrocytes are labelled 
by PDGFR-α and O4, respectively. The full range of cell-types generated from this 
protocol which includes OLIG2+ pMN derived cells, GFAP+ astrocytes, and NF-H+ 
neurons, are shown in Figure 4.1D. 
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Figure 4.1 Generation of iPSC derived oligodendrocytes 
A) Immunocytochemical staining of iPSC colonies demonstrating positive expression of 
pluripotency markers TRA-1-60, OCT3/4 and NANOG, and normal karyotype analysis for two 
different iPSC lines.    
B) Schematic overview of the protocol to generate iPSC-derived oligodendrocytes.   
C) Representative images for other cell-types present in glia-progenitor spheroids including DAPI+ 
nuclei, OLIG2+ pMN derived cells, PDGFRα+ OPCs, MBP+ oligodendrocytes, GFAP+ astrocytes 
and NF-H+ axons.  
D) Representative images of iPSC-derived OPCs and oligodendrocytes.  
All scale bars = 100 µm .  
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4.2.2 Co-culture with iPSC-derived motor neurons 
 
In order to determine whether iPSC-derived oligodendrocytes have the capacity to 
form myelin in vitro, I performed a series of co-culture experiments using different 
neuronal substrates. 
As our aim was to develop an entirely human-derived culture system, I first performed 
two-dimensional co-culture experiments with human iPSC-derived neurons. iPSC-
derived motor neuron (MN) cultures were chosen, as they comprise a purely neuronal 
composition without contamination by glial cells and reflect the appropriate target for 
myelination by pMN-derived oligodendrocytes, in vivo. These cultures were generated 
by Dr Bhuvaneish Selvaraj in the Chandran lab using a protocol that similarly patterns 
iPSC-derived neurospheres towards the pMN domain (see Methods) (Selvaraj et al. 
2018). 
After 16 days, MN spheres were dissociated, plated as single cells and maintained 
for 3 weeks in defined neuronal medium. Oligodendrocyte differentiation medium was 
gradually incorporated over 2 days (final concentration 1:1) prior to the addition of 
OPCs. Following dissociation of oligodendrocyte progenitor spheres, between 50,000 
and 300,000 cells were added to each 24-well-plate well of neurons and maintained 
for an additional 3 weeks in 1:1 neuronal: oligodendrocyte medium, before being fixed 
and stained for Tau, O4 and MBP. Figure 4.2 shows representative images of the co-
culture including magnified images of individual MBP+ oligodendrocytes after 3 weeks 
of co-culture. Whilst some association can be seen between oligodendrocyte 











Figure 4.2 Co-culture with iPSC-derived neurons 
200,000 cells dissociated from oligodendrocyte progenitor spheres were added to 3-week-old 
neuron cultures and co-cultured for 3 weeks.   
Top panel shows the density of respective cell-types (scale 25 µm).   
Lower panels show highly branched oligodendrocytes and linear arrangement of processes 
suggestive of axonal association (arrow), but no myelin formation (scale 10µm);   
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The reasons for failure are unclear. It is possible that a baseline of neuronal activity 
is required to induce myelin formation and that 3- to 5-week-old neurons fall beneath 
this threshold. This is unlikely, however, as rodent-derived oligodendrocytes have 
been shown to ensheath inert fibres that mimic axonal structures (Bechler et al. 2015) 
and one would assume that human oligodendrocytes have the capacity to behave 
similarly. It is possible that, for myelination to take place, human oligodendrocytes 
require long-term culture, which accommodates the protracted period of myelination 
in vivo. Unfortunately, in this culture paradigm, cells began to lift away from the 
coverslip after 3 weeks of co-culture and the experiment could not be continued. 
Indeed, other research groups that have performed similar humanised co-cultures 
have had very limited success at inducing myelin formation and have each been 
limited to 2–4 weeks of co-culture (Kerman et al. 2015; Wang et al. 2013).  
  
  97 
4.2.3 Co-culture with rat dorsal root ganglion neurons 
 
Given that our human:human co-cultures failed to give rise to myelin formation in vitro, 
I resorted to a more established model of in vitro myelination to test whether human 
iPSC-derived oligodendrocytes were capable of in vitro myelination: co-culture with 
embryonic rat dorsal-root ganglion (DRG) neurons.  
Dr Marie Bechler of the ffrench-Constant lab provided training to establish cultures of 
E15.5 rat DRGs. Briefly, E15.5 rat embryos were dissected, and their spinal cords 
were removed. Dorsal root ganglia were plucked individually, dissociated, and plated 
at a density of 200,000 cells per coverslip. Proliferating cells were selectively removed 
by treatment with fluoro-deoxyuridine (FdU) and the cultures were maintained for 
three weeks in the presence of NGF to promote neurite extension. Subsequently, 
oligodendrocyte progenitor spheres were dissociated, as before, and between 
150,000 and 300,000 cells were seeded onto DRG cultures. After 4 weeks of co-
culture, coverslips were fixed and stained for SMI-312, GFAP, and MBP.  
As found in the human neuron co-culture, oligodendrocytes were widely distributed 
among SMI-312+ processes with highly branched morphologies. However, in contrast 
to the above, oligodendrocytes were occasionally associated with thick, linear MBP+ 
processes, aligned with SMI-312+ axons, indicative of early myelin sheaths (Figure 
4.3). The majority of oligodendrocytes observed had 1 or 2 myelin sheaths per cell, in 
addition to numerous thin, arborized non-myelinating processes, reflecting the 
immaturity of myelin formation. Whilst this was encouraging, the survival of co-
cultures was a considerable issue as the dense structure of axons would often peel 
away from the coverslip, terminating the experiment. Over 8 independent 
preparations of DRG cultures, approximately half were viable after 4 weeks of co-
culture. Further optimisation would certainly have improved matters, including the 
addition of FdU to limit the proliferation of human cells, however, success in another 
culture paradigm resulted in progressing from this set-up.  
 
 






Figure 4.3 iPSC-derived oligodendrocyte co-culture with E15.5 DRGs. 
250,000 cells from dissociated oligodendrocyte progenitor spheroids were added to 3-week-
old DRG neuron cultures and maintained for 4 weeks.   
A) representative image of co-culture demonstrating the density of GFAP+ astrocytes, MBP+ 
oligodendrocytes and SMI-312+ axons, scale = 50µm.   
B) Individual oligodendrocytes show early signs of wrapping (arrow heads) and structures 
indicative of myelin sheaths (arrows). Scale = 10µm   
Data collected from N = 4 independent preparations, n = 8 coverslips.  
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4.2.4 Co-culture with shiverer mouse organotypic slice 
cultures 
 
Another routinely used model for examining the myelinating potential of OPCs in vitro 
is their co-culture with shiverer mouse organotypic slice cultures. The advantages of 
shiverer mouse organotypic slice co-cultures over conventional co-culture methods 
include a microenvironment that mimics the appropriate in vivo environment, 
preservation of the relevant cytoarchitecture and cell-types, and their ability to be 
maintained for longer durations (e.g. Bin et al. (2012) maintained their cultures for 
over two months), which contributes to the greater degree of myelination often 
associated with these cultures. Organotypic slice cultures of the shiverer mouse brain 
and spinal cord have been used to assess myelin formation in vitro when co-cultured 
with OPCs from mice, rats, and human fetal material (Bin et al. 2012) and from human 
embryonic stem cell-derived oligodendrocytes (Izrael et al. 2007).  
Dr Navneet Vasistha of the Chandran lab provided technical assistance in optimising 
shiverer mouse organotypic slice cultures. Given that myelin development in 
heterozygous shiverer mice mbp+/  is largely unaffected (Martin et al. 2006), it was 
necessary to use only homozygous mbp /  mice for co-culture experiments. P0-P1 
neonatal mice were therefore genotyped for the presence or absence of the complete 
MBP gene by PCR, using DNA lysed from tail cuts (see Methods). Next, shiverer 
mouse brains were collected from P2-P4 mice and 300µm forebrain sections were cut 
using a vibratome and transferred onto millicell culture inserts and maintained in slice 
culture medium. Over 3 days, the serum content of the slice culture medium was 
reduced as it has been shown to be detrimental for myelin induction by transplanted 
cells (Bin et al. 2012). After 7 days of culture, sections became opaque as they 
stabilised.  
To co-culture hOPCs, oligodendrocyte progenitor spheroids were dissociated as 
before and 250,000 cells were added to each section on day 7 in a total volume of 5µl 
(Figure 4.4A). After 2–4 weeks of co-culture, human cells, identified by the hNu 
antibody, were sparse (Figure 4.4B). MBP+ human cells were present but were few in 
number and extended only flat membranous sheets and not myelin sheaths (Figure 
4.4B). Cell loss and degradation were occasionally found in co-cultured slices, which 
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was possibly due to disruption of the liquid-air interface that is necessary for slice 
culture maintenance. Stereotactic injection of hOPCs into the slice culture would 
potentially improve survival and yield myelin formation over time. However, success 
in an alternative culture set-up resulted in a change in emphasis and no further work 





































Figure 4.4 iPSC-derived oligodendrocyte co-culture with shiverer mouse organotypic 
slice culture. 
Between 10 and 50,000 cells from dissociated oligodendrocyte progenitor spheroids were 
added on top of 7-day-old cortical organotypic slice cultures prepared from P2-P4 pups.  
A) Schematic showing experimental set-up. 
B) Human oligodendrocytes are identified by the Human Nuclei antibody and MBP. 
Oligodendrocytes are sparse and without myelinating processes.   
N = 8 preparations, n = 6 slices each. Scale = 10µm. 
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4.2.5 Intra-spheroid myelination in iPSC-derived cultures 
 
In order to improve the survival of both human cells and slice culture in co-culture, I 
attempted an alternative experimental paradigm that involved migration of OPCs from 
oligodendrocyte progenitor spheroids into the organotypic slice culture. Previously, it 
has been shown that cerebellar organotypic slice cultures prepared from WT newborn 
mice—treated with cytosine arabinoside to suppress myelination—could be rescued 
by overlaying explanted slice cultures that had not been exposed to cytosine 
arabinoside, demonstrating that oligodendrocytes could migrate from an overlaid 
tissue section to myelinate the underlying slice culture (Seil & Blank 1981). A similar 
phenomenon appeared when WT optic nerves were transplanted into shiverer mouse 
cerebellar cultures with resulting MBP+ and compact myelin being found within the 
shiverer slice culture (Billings-Gagliardi et al. 1984). Given that when glial progenitor 
spheroids are dropped onto plastic or glass-coated coverslips, a large number of 
OPCs migrate out of adhered spheroids (In-house observations, Douvaras et al. 
2015), I asked whether dropping intact spheroids onto slice cultures in close proximity 
to the corpus callosum would result in OPC migration into the slice culture and 
myelination of mouse neurons. This strategy would avoid both the mechanical 
dissociation of spheroids and the flooding of slice cultures with excess media. A 
schematic of the experimental set-up and a phase-contrast image of the co-culture is 
shown in Figure 4.5A-B.  
After two weeks in culture, we observed (for the first time) tube-like MBP+ segments, 
indicative of in vivo myelin sheaths, developing within the confines of the spheroid 
placed onto the shiverer cortical slice culture—identified by phase contrast and an 
antibody against human nuclei (hNu) staining (Figure 4.5C). On closer examination, 
individual human myelinating oligodendrocytes could be identified by co-labelling of 
MBP and hNu (Figure 4.5D-E). Intriguingly, the circular arrangement of MBP+ 
structures and the high density of human nuclei observed in this co-culture suggested 
that hOPCs were not migrating out of the transplanted spheroids into the surrounding 
tissue but rather were forming myelin within the margins of iPSC-derived spheroids.  
  







Figure 4.5 iPSC-derived oligodendrocyte progenitor spheroids co-culture with mouse 
shiverer organotypic slice culture. 
Oligodendrocyte progenitor spheroids were added on top of cortical shiverer mouse slice 
cultures without dissociation.   
A) Schematic showing experimental set-up.    
B) Phase contrast and hNu staining shows the demarcation where individual spheroids were 
placed. MBP staining is constrained to the region of hNu+ cells (scale 200µm).   
C) Magnified view of spheroid-slice boundary identified by human nuclei. MBP staining is 
constrained within the perimeter of the sphere (scale = 15µm).   
D-E) Individual human oligodendrocytes associated with myelin sheaths, stained with hNu 
(arrows) and MBP (scale = 10µm). 
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Based on this pattern, I asked whether oligodendrocytes were myelinating mouse 
neurons present in the brain slice or human neurons present within the spheroid. As 
our protocol mimics the developmental trajectory of the pMN domain of the ventral 
telencephalon, motor-neurons are also generated at the early stages of patterning, 
which is followed by a switch from neurogenesis to gliogenesis (Stacpoole et al. 
2013). Therefore, it is possible that intra-spheroid neurons could serve as a substrate 
for myelination, though the neuronal contribution to monocultures derived from 
dissociated spheroids is minimal (Figure 4.1C, Livesey, Magnani, Cleary, Vasistha, 
James, Selvaraj, Burr, Story, Shaw, Kind, Hardingham, Wyllie & Chandran 2016a). 
In order to determine which neuronal population was being myelinated, I adapted the 
culture conditions. Instead of the direct co-culture of oligodendrocyte progenitor 
spheroids and cortical slices (Figure 4.6A), spheroids were transferred either onto cell 
culture inserts to be cultured in isolation (Figure 4.6A) or next to cortical slices without 
direct contact (Figure 4.6B). Analysis at 8 weeks post-plate down demonstrates the 
presence of MBP+ myelinating oligodendrocytes in both isolated spheroids (Figure 
4.6C) and non-contact co-cultured spheroids (data not shown). Numerous MBP+ 
sheaths were identified and showed co-localisation with NF-H+ axons (Figure 4.6D-
E). 
These results led me to conclude that human myelin formation occurs within intact 
three-dimensional iPSC-derived spheroids, hereafter referred to as “myelinoids”, 
cultured on membrane inserts and that this is independent of soluble signals secreted 
by the shiverer cortical slice. Further investigations of iPSC-myelinoids were made in 
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Figure 4.6 Oligodendrocyte progenitor spheroids cultured away from organotypic slice 
culture 
A-B) Schematic of experimental set-up. Oligodendrocyte progenitor spheroids were either 
transferred to cell culture inserts in isolation away from organotypic slice cultures, or next to 
organotypic cultures.   
C) Representative image of a single oligodendrocyte progenitor spheroid in isolation 
(experimental set-up A) showing MBP+ myelin-like staining and NFH+ axons (scale 50µm).  
D) MBP+ structures demonstrate typical myelin morphology (scale 25µm). 
E) MBP+ structures co-localise with NF-H+ axons (scale 10µm).  
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4.2.6 Characterisation of iPSC myelinoids 
 
The result that there was sufficient axonal content in glial progenitor spheroids to give 
rise to myelination was somewhat of a surprise. However, the low neuronal content 
observed in dissociated cultures is likely due to axotomy of neurons during the 
mechanical dissociation of spheroids, the short period of time that cultures were 
maintained (2–3 weeks) and the lack of neuronal-specific growth factors in the culture 
medium that would aid their recovery. Therefore, in order to characterise the starting 
point for iPSC-derived myelinating cultures, I first wanted to characterise the cell-
types observed ‘in-sphero’. 
The induction of myelin formation begins with the transfer of spheroids onto cell 
culture inserts after 2–3 weeks in oligodendrocyte proliferation medium. ‘Myelin 
Induction’ (MI) spheroids therefore were whole-mounted 24-hours after being 
transferred to cell culture inserts and used for immunocytochemical analysis of a 
range of cell-types.  
Similar to the dissociated cultures, MI spheroids contain a large proportion of OLIG2+ 
cells, demonstrating efficient specification of the pMN domain in vitro and a high 
proportion of NESTIN+ neural progenitor cells (Figure 4.7). Oligodendroglial 
patterning was again demonstrated by the dense arrangement of SOX10+ nuclei and 
PDGFRα+ oligodendrocyte progenitor cells, as well as sparsely labelled MBP+ 
oligodendrocytes. Analysis of NF-H staining in MI spheroids revealed a dense 
arrangement of axons that can be seen to circle the periphery of the spheroid, forming 
close parallel tracts. Finally, a high proportion of GFAP+ astrocytes also exists within 
spheroids. This shows that MI spheroids contain a mixture of progenitor and 
differentiated cells across all CNS-derived cell-types, with an abundant axonal 
population that serves as a favourable environment for the in vitro study of human 
myelin development. 
  





Figure 4.7 Myelin Induction (MI) spheroids contain a mixture of CNS-derived cell-types 
iPSC myelinoids were fixed 24 hours after being transferred onto cell culture inserts, stained 
with a range of markers for different cell-types, whole-mounted, and imaged on the 
ImageXpress micro confocal. OLIG2 expression demonstrates pMN domain acquisition; 
NESTIN identifies neural progenitor cells; SOX10 identifies oligodendroglial cells; PDGFR-α 
identifies OPCs; MBP identifies mature oligodendrocytes; NF-H identifies neuronal axons; and 
GFAP identifies astrocytes. Scale 250µm. 
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4.2.7 Temporal development of iPSC-myelinoids 
 
To profile the temporal development of iPSC-myelinoids, MI spheroids were cultured 
in differentiation medium for a further 4, 8, and 12 weeks and subjected to 
immunocytochemistry. These time-points are referred to as MI-4, MI-8, and MI-12, 
respectively. A revised schematic outlining the protocol for iPSC myelinoids is shown 
in Figure 4.8A. 
Firstly, phase contrast images of spheroids were acquired at different time-points 
throughout the culture period and their diameters recorded. Figure 4.8B shows an 
overview of the entire culture process and the change in spheroid diameter over time. 
Between week 5 and MI there is a doubling of spheroid diameter due to the expansion 
of oligodendrocyte progenitor cells in the presence of FGF2. It is at this time-point that 
glial progenitor spheroids are transferred onto cell culture inserts. The subsequent 
increase in spheroid diameter between MI and MI-4 is due to flattening of spheroids 
on the membrane, a process that also occurs in the culture of organotypic slices. 
Subsequently, no further increase in diameter is seen, even when spheroids were 
maintained for an additional 20 weeks. 
It is important to select spheroids of a similar size at the myelination induction phase 
to mitigate any potential variability in myelin formation at later time-points. During the 
generation of glial progenitor spheres, individual spheroid diameters can vary 
significantly. However, as long as there is sufficient supply of material, it is possible 
to be accurate in choosing spheres of a consistent size. Figure 4.8C shows the 
variability in the diameter of spheroids that have been transferred onto cell culture 
inserts (mean MI spheroid diameter = 577 µm). The standard deviation of MI spheroid 
diameter across conversions was 123 µm. However, the mean standard deviation of 
MI spheroid diameter within conversions was 76 µm, demonstrating reduced within-
batch variability in spheroid diameter.   






Figure 4.8 Temporal development of iPSC myelinoids 1 
A) Schematic overview of the revised protocol to generate iPSC myelinoids.   
B) Sphere diameter increases over time and stabilises from MI-4 onwards.   
C) Sphere diameter varies within and between individual conversions. 
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To visualise the temporal development of myelin, iPSC-myelinoids were fixed at MI, 
MI-4, MI-8, and MI-12 and stained for CNP, NF-H, and SOX10 (Figure 4.9). 25 µm z-
stacks were acquired on the ImageXpress spinning disc micro confocal microscope 
and best projection images were stitched together using an image-J macro (see 
Appendix, Chapter 10.2). Representative figures of whole-mounted myelinoids, 
acquired in a similar fashion, are shown throughout this thesis. 
The profile of CNP+ oligodendrocytes across the surface of iPSC-myelinoids changes 
over time. The first four weeks between MI and MI-4 show a large increase in the 
number of CNP+ oligodendrocytes, which are primarily located around the periphery 
of the spheroid. The majority of these cells do not show evidence of myelin formation 
though few have begun to form myelin sheaths. Between MI-4 and MI-8, the number 
of myelinating oligodendrocytes, and of myelin sheaths, has increased, though many 
non-myelinating cells persist around the periphery. Finally, by MI-12, a dense 
arrangement of myelinating oligodendrocytes is observed across the surface of the 
spheroid. Myelin is found always in areas of high axonal density, which is something 
that I have analysed further in Chapter 7. The density of SOX10+ cells, which identifies 
oligodendrocyte progenitor cells as well as differentiated oligodendrocytes, varies 
between spheroids over time but is uniformly distributed across the sphere (see 
Chapter 7). 
Given that these images were acquired from whole-mounted myelinoids and re-
constructed as best projection images from 25µm z-stacks, they do not provide detail 
as to the distribution of myelin within the spheroid. Are oligodendrocytes distributed 
evenly throughout the spheroid or only around the outer areas of the spheroid, as 
visualised in the above images? To answer these questions, cryosections were taken 
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Figure 4.9 Temporal development of iPSC myelinoids 2 
Myelinoids at MI, MI-4, MI-8, and MI-12 were stained for CNP, NF-H, and SOX10, whole-
mounted, and imaged on the ImageXpress micro confocal. Scale = 250µm.  
  112 
4.2.8 Regional distribution of myelin in iPSC myelinoids 
 
In order to determine the distribution of myelin throughout iPSC-derived myelinoids, 
10µm cryosections were cut from MI-12 spheroids and stained for MBP. Images were 
acquired from sections at their largest diameter and their smallest diameter, 
corresponding to the middle and superficial regions of myelinoids, respectively. 
Example images of an MI-12 mid-section and superficial-section are shown in Figure 
4.10A-B.  
To quantify the regional distribution of myelin across cryosections, images were 
thresholded and binarized. Next, a 100µm wide rectangle region of interest (ROI) 
spanning the diameter of the sphere was drawn and an intensity profile was measured 
to count the number of MBP+ pixels as a function of length across each section 
(illustrated in Figure 4.10C). Several intensity measurements were measured per 
section in both the vertical and horizontal axes. Each ROI was binned into 5 equal 
lengths to represent ‘peripheral’, ‘intermediate’, and ‘central’ domains of each region 
of interest, and the intensity profile for each domain was plotted on a graph. 
Figures 4.10D-E show that, while in mid-sectioned myelinoids MBP+ pixels are mostly 
found in the periphery of the section, in superficial sections MBP+ pixels are evenly 
distributed across each domain. These results show that myelin is distributed around 
the periphery of spheroids, with highest intensity profiles in the outer domain of 
spheres and little to no myelin found in the inner regions of the sphere. Comparing 
these findings with the observations made on whole-mounted myelinoids, I have 
drawn a schematic representation of myelin distribution throughout iPSC-myelinoids 
(Figure 4.11). In addition, I have included a depiction of the imaging paradigm for 
whole-mounted myelinoids, which, in essence, aims to capture a z-stack of the 
peripheral domain of myelinoids where myelin is most dense.  
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Figure 4.11 Schematic depiction of myelin distribution in myelinoids 
A) Schematic depiction of the distribution of myelin and NF-H+ axons across iPSC myelinoids.  
B) Imaging set-up for whole-mounted myelinoids captures myelin formation in the outer 1/3rd of 
myelinoids.   
C) Schematic representation of myelin visualised within the ROI from B at MI-4, MI-8, and MI-12. 
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4.2.9 Oligodendrocyte morphology over time 
 
Myelination is a process that requires extensive re-organisation of the cytoskeleton, 
as oligodendrocytes elaborate large swathes of membrane around multiple axons 
simultaneously. Many of the nascent myelin sheaths that are formed are subsequently 
retracted soon after. In the zebrafish, 40% of nascent sheaths are retracted within 5 
hours after the initiation of myelination (Czopka et al. 2013). To capture the 
morphological transitions of iPSC-derived oligodendrocytes, MI-4, MI-8, and MI-12 
myelinoids were stained with CNP, which labels the cell body, processes, and 
internodes of mature oligodendrocytes. Figure 4.12 shows that as oligodendrocytes 
begin to myelinate, they appear to put out many processes (MI to MI-4) and, over 
time, (MI-8 to MI12) the number of processes and myelin sheaths from a single 
oligodendrocyte is considerably reduced. Whilst temporal analysis of myelin formation 
by the same cell was unavailable, these results suggest that iPSC-derived 
oligodendrocytes conform to the expected process of overproduction and retraction 
of nascent sheaths during myelination. 
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4.2.10 Quantifying the temporal development of myelin 
formation 
 
To quantify the temporal relationship between oligodendrocyte differentiation and 
myelination, the number of SOX10+ oligodendrocyte lineage cells and the proportion 
of MBP+ oligodendrocytes at MI-4, MI-8, and MI-12 were assessed. In addition, the 
proportion of myelinating oligodendrocytes was quantified by morphological 
identification of thick, linear MBP+ segments that were characteristic of myelinating 
oligodendrocyte processes. Representative images at MI-4, MI-8, and MI-12 are 
shown in Figure 4.13A. Between MI-4 and MI-12, the proportion of mature 
MBP+SOX10+ oligodendrocytes remain unaltered at approximately 17% (Figure 
4.13B). However, the proportion of mature oligodendrocytes that were observed 
forming at least one myelin sheath increased from 18% at MI-4 to 79% at MI-12 
(Figure 4.13C). 
The same cultures were also used to measured myelin sheath length over time. 20X 
images were acquired in z-stack to ensure whole myelin sheaths were captured in a 
single region of interest. Again, myelin sheaths were identified by their distinct 
morphology to non-myelinating processes and, using the distance between distal 
ends of MBP+ myelin sheaths (Figure 4.13D). Manual tracing of myelin sheath lengths 
showed a 52 % increase between MI-4 and MI-12 (mean 48 ± 35 µm to 74 ± 41 µm) 
(Figure 4.13E).  
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Figure 4.13 Temporal development of oligodendrocyte differentiation, myelination and 
myelin sheath length 
A) Representative images of whole-mounted myelinoids stained with SOX10, MBP, and NF-H 
at MI-4, MI-8, and MI-12, scale = 10µm.   
B) Quantification of the number of mature (MBP+ SOX10+) oligodendrocytes / total number of 
SOX10+ oligodendroglial cells over time (glm with dummy variables for each timepoint, no 
change, 2 sites per myelinoid from n = 45 myelinoids across 2 cell lines and 5 conversions). 
C) Quantification of the number of mature oligodendrocytes that could be seen forming at least 
one myelin sheath (glm with dummy variables for each timepoint p < 0.001, 95% CI: 68% to 90% 
increase between MI-4 to MI-12, 2 sites per myelinoid from n = 45 myelinoids across 2 cell lines 
and 5 conversions).   
Continued overleaf 
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Figure 4.13 Temporal development of oligodendrocyte differentiation, myelination and 
myelin sheath length contd. 
D) Representative images of MBP+ myelin sheaths imaged at 20X between MI-4 to MI-12, 
scale = 50µm.   
E) Frequency distribution plot showing the increase in sheath length between MI-4 and MI-12 
(glm with dummy variables for each timepoint, *** p < 0.001, 95% CI: 44% to 60% increase 
between MI-4 and MI-12, data collected from over 2000 sheaths from 6 myelinoids from the 
same conversion). 
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4.2.11 Compact myelin formation 
 
A critical step in the process of myelin formation is the compaction of myelin lamellae 
wrapped around axons. The evidence that I have demonstrated so far indicates the 
formation of myelin sheaths that co-localise with NF-H. However, to confirm myelin 
wrapping and to determine the thickness and integrity of myelin sheaths, iPSC 
myelinoids between MI-8 and MI-28 were processed for transmission electron 
micrsocopy (TEM). 
Representative images of myelinated axons are shown in Figure 4.14A demonstrating 
the formation of compact and concentric, electron-dense layers of myelin around 
axons of varying size. To determine the thickness of iPSC-derived myelin, g-Ratio 
analysis was performed by measuring the diameters of the myelinated fibre (distance 
between opposing outer myelin sheaths) and of the axon alone and calculating the 
ratio between the two. Figure 4.14B shows the distribution of g-Ratios for individual 
fibres against their corresponding axon diameter. Average g-Ratio across all fibres 
was 0.7 ± 0.01 and showed a reduction over time (mean for MI-8 = 0.82 ± 0.01, mean 
for MI-12 = 0.77 ± 0.03, mean for MI-28 = 0.69 ± 0.09). Theoretical modelling of axon 
structure and function identify an optimal g-Ratio of between 0.6 and 0.77 (Rushton 
1951; Chomiak & Bin Hu 2009), which is in line with measurements made across 
different species, including humans (Saliani et al. 2017). 
These data show that not only are myelin lamellae compacted in iPSC myelinoids but 
that myelin sheaths demonstrate a thickness in line with that seen around axons in 
vivo. 
  








Figure 4.14 Compact myelination and g-ratio analysis 
A) Representative images of myelinated axons under TEM (scale 500 nm) at MI-12.  
B) Scatter plot of axon diameter against g-ratio (axon diameter/fiber diameter) with a 
logarithmic regression curve between MI-8 and MI-28 (43 axons from 3 myelinoids).  
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4.2.12 Organisation of myelinated axon domains 
 
Myelin sheath function requires both compaction of myelin lamellae and the 
organisation of discrete myelinated axon domains for saltatory conduction. The 
assembly of nodes of Ranvier in the CNS occurs via the positioning of several 
cytoskeletal and tethering proteins at sites along the axolemma contacted by 
myelinating oligodendrocytes and is mediated by both contact-dependent and soluble 
factors (Susuki et al. 2013; Snaidero et al. 2014). The formation of PNJs precede 
nodal assembly in the CNS, which in turn is dependent on myelin wrapping  (Wiggins 
et al. 1988; Rasband et al. 1999; Susuki et al. 2013).  
Though more recently, myelin has been attributed with additional functions, including 
more dynamic, activity-dependent roles in CNS development, nodal assembly 
remains the definitive hallmark of myelin. In order to see whether iPSC-myelinoids 
can recapitulate definitive functions of compact myelin in vitro, 10 µm cryosections of 
MI-12 myelinoids were stained for components of the node and paranode. 
PNJ formation in iPSC myelinoids was confirmed by the expression of CASPR at the 
distal ends of myelin sheaths (Figure 4.15A). In addition, CLAUDIN-11+ tight-junctions 
between the cytoplasmic loops of myelin lamellae are equally prominent at the distal 
ends of myelin sheaths, demonstrating myelin wrapping and the sequestration of cell-
type specific proteins into overlapping yet discrete domains (Figure 4.15B). At higher 
magnification, a Schmidt-Lantermann incisures can be seen spiralling through 
compact CNS myelin (Figure 4.15B). 
Many closely opposed PNJs could be seen separated by a small gap, indicative of 
NoRs. Node formation was confirmed by staining for Neurofascin and ANKYRIN G. 
Both major isoforms of Neurofascin can be identified in iPSC myelinoid sections by 
their localisation. Nfasc155, which binds CASPR at the PNJ is found at the distal ends 
of myelin sheaths. Nfasc186, which is central to and initiates NoR assembly by 
recruiting ANKYRIN-G, is expressed brightly within the gap between CASPR+ bands 
(Figure 4.15C). Furthermore, ANKYRIN-G itself is clearly visualised at the node 
between CASPR+ bands (Figure 4.15D). 
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These data show that human myelinating oligodendrocytes in iPSC myelinoids form 
appropriate axoglial interactions that lead to maturation and organisation of 
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4.2.13 Characterisation of neuronal subtypes and myelin
 targeting 
 
The pMN domain of the developing spinal cord gives rise to motor neurons that are 
distinguished by their expression of the LIM-homeodomain transcription factors Islet 
1 and 2 (Islet1/2) and Choline Acetyl Transferase (ChAT), which synthesises the 
neurotransmitter acetylcholine (Thaler et al. 2002). However, in patterning cells as 
three-dimensional spheroids, cells will naturally be exposed to a graded concentration 
of patterning factors—including ventralising smoothened agonist (SAG)—thereby 
resulting in the acquisition of additional domains neighbouring the pMN, which give 
rise to a range of interneuron and astrocyte subtypes (Lai et al. 2016). With this in 
mind, I decided to broadly investigate neuronal subtypes in iPSC myelinoids. Firstly, 
I asked whether interneurons were present in iPSC-myelinoids? And secondly, 
whether interneurons were being myelinated in iPSC myelinoids? 
10µm cryosections of MI-12 myelinoids were stained for ISLET1/2, ChAT, and 
PARVALBUMIN (PV), which is a calcium binding protein that is expressed by a large 
subgroup of GABAergic interneurons (Gonchar & burkhalter 1997). Figure 4.16A 
shows the presence of motor neuron cell bodies by the colocalisation of ISLET1/2 and 
ChAT. Additionally, PV+ cell bodies could be identified; these did not co-localise with 
ISLET1/2 (Figure 4.16B), demonstrating the acquisition of a range of neuronal 
subtypes in iPSC myelinoids. 
Next, sections were stained with NF-H, PV, and MBP to determine the myelination 
status of PV+ neurons. Figure 4.16C demonstrates the presence of myelinated PV+ 
axons (red arrows) as well as the presence of myelinated PV  NF-H+ axons (yellow 
arrows). Quantification of the number of PV+ myelinated axons revealed that 
approximately half of all myelinated axons were PV+ (mean = 52% ± 14.4%, analysed 
from three separate myelinoids, Figure 4.16D). Additionally, cryosections stained with 
CNP and PV revealed that individual oligodendrocytes could myelinate both PV+ and 
PV  axons simultaneously (Figure 4.16E). 
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These data demonstrate 1) the acquisition of multiple neuronal subtypes in iPSC 
myelinoids, 2) that axons of different neuronal subtypes can be myelinated, and 3) 
that oligodendrocytes can myelinate multiple neuronal subtypes simultaneously. 
Indeed, the proportion of myelinated PV+ axons suggest that oligodendrocytes 
indiscriminately myelinate PV+ and PV- axons without bias. It was recently shown in 
the mouse neocortex that some oligodendrocytes can be biased towards inhibitory 
neurons or excitatory neurons, or show no bias at all, suggesting that 
oligodendrocytes can recognise and differentially myelinate neuronal subtypes 
(Zonouzi et al. 2019). Further analysis of the myelination profile of different neuronal 
subtypes would be of great interest in determining the factors that underlie the 
distribution of myelin across the brain and spinal cord. 
It is unclear what the identity of PV+ neurons are. In the ventral horn of spinal cord, 
PV expression is high during development but is absent in both adult rats and humans 
following maturation of the locomotor system (Clowry et al. 2000). PV expression was 
found in a variety of neuronal subtypes in the ventral horn, including Renshaw cells, 
which are premotor inhibitory interneurons that are excited by motor neuron axon 
collaterals and function to inhibit motor neurons (Jankowska 2013). PV expression 
has also been observed in motor neurons themselves (Clowry et al. 2000). However, 
as all newly generated motor neurons express ISLET1/2 (Pfaff et al. 1996) and PV 
expression was not found to overlap with ISLET1/2 in iPSC myelinoids, observed PV+ 
cells are likely to be interneurons. 
PV+ interneurons are also found in the dorsal horn of the spinal cord (Chen et al. 2016) 
and it is possible that incomplete ventral patterning could yield a population of dorsally 
derived interneurons in iPSC myelinoids. However, this is unlikely due to the 
substantial proportion of OLIG2+ observed in dissociated oligodendrocyte progenitor 
spheroids (Livesey, Magnani, Cleary, Vasistha, James, Selvaraj, Burr, Story, Shaw, 
Kind, Hardingham, Wyllie & Chandran 2016b). Further work to precisely identify these 
cells would require staining for other markers including the Ca2+ binding proteins 
Calbindin and Calretinin as well as a range of transcription factors that establish spinal 
cord neuronal diversity (Lai et al. 2016).  
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4.3 Conclusions 
 
The work presented in this chapter outlines the identification of a novel, completely 
humanised in vitro model of compact myelin formation, derived from human 
pluripotent stem cells. I have shown that iPSC-derived spheroids patterned towards 
the pMN domain of the ventral telencephalon generate neurons, astrocytes, and 
oligodendrocyte lineage cells. Following their initial patterning, spheroids that were 
maintained on PTFE-coated inserts for an additional 12 weeks demonstrated 
temporal development of myelin formation with increasing numbers of myelinating 
cells and elongating sheath lengths. iPSC-derived myelin was shown to be compact, 
with organisation of myelin axon domains. In addition, g-Ratio analysis showed 
appropriate myelin thickness mirroring in vivo measurements. The regional 
distribution of myelin within iPSC myelinoids was shown to be primarily located around 
the periphery of iPSC-myelinoids where dense tracts of NF-H+ axons are also found. 
Finally, in characterising the subtypes of myelinated axons, I showed that 
approximately half of all myelinated axons are positive for the interneuron marker PV, 
indicating that oligodendrocytes in this culture model myelinate both excitatory and 
inhibitory neurons without bias.  
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4.4 Discussion 
 
A number of recent papers have demonstrated the development of oligodendrocytes 
in iPSC-derived organoids with the aim of modelling human myelin development 
(Madhavan, Nevin, Shick, Garrison, Clarkson-Paredes, Karl, Clayton, Factor, Allan, 
Barbar, Jain, Douvaras, Fossati, R. H. Miller & Tesar 2018a; Marton et al. 2019; Kim 
et al. 2018). Similar to the work I have shown here, these papers show that organoid-
type cultures can be generated to comprise a range of CNS-derived cells, including 
oligodendrocytes. However, across each of these protocols, myelin formation is 
sparse and evidence for compaction is limited. Furthermore, these cultures fail to 
acquire nodal domain organisation, highlighting the immaturity of these culture 
systems. A critical factor that likely explains the discrepancy between these cultures 
and the work presented here is that each of the reported protocols generated 
forebrain-patterned spheroids via the omission of RA and exposure to different FGFs. 
Human myelin development begins in utero in the cervical spinal cord as early 10–12 
gestational weeks and proceeds both caudally and rostrally to the spinal cord and 
brain (Weidenheim et al. 1996; Hajihosseini et al. 1996). In contrast, cortical myelin 
development is not apparent until after mid-gestation (17-32 gestational weeks) 
(Jakovcevski et al. 2009). Additionally, humans in particular have a protracted 
development of cortical myelination characterised by a delayed period of maturation 
(D. J. Miller et al. 2012). It is therefore likely that recapitulating widespread myelination 
of forebrain patterned cells will require advanced maturity and culture time beyond 
what has been achieved so far.  
The advanced maturity of iPSC myelinoids compared to other protocols is also 
demonstrated in their earlier acquisition of nascent myelin sheaths. For reference, 
iPSC myelinoids demonstrate MBP+ oligodendrocytes at MI (total culture time of 56 
days/8 weeks) and nascent sheath formation at MI-4 (total culture time of 84 days/12 
weeks). Madhavan et al. induce oligodendrogenesis at around day 50 and PLP+ 
oligodendrocytes are observed at around day 84 (14 weeks) with early myelin sheath 
formation evident at day 210 (30 weeks) (Madhavan, Nevin, Shick, Garrison, 
Clarkson-Paredes, Karl, Clayton, Factor, Allan, Barbar, Jain, Douvaras, Fossati, R. 
H. Miller & Tesar 2018a). Marton et al. begin inducing oligodendrogenesis much 
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earlier, at day 25, but do not identify evidence for myelin sheath formation (by 
immunofluorescence) until day 158, though evidence of myelin compaction by TEM 
is shown at day 103 (15 weeks) (Marton et al. 2019). The protocol published by Kim 
et al., which involves the independent formation and subsequent fusion of dorsal and 
ventral-patterned forebrain spheroids, more closely mimics iPSC myelinoid 
timescales as MBP+ oligodendrocytes are identified by day 63 (9 weeks) and thick 
MBP+ sheaths are identified at week 15. The authors suggest the advanced 
oligodendrogenesis is due to their use of BrainPhys medium (STEMCELL 
technologies), which likely contains neuronal growth factors including BDNF due to 
increased c-FOS expression observed in dorsal forebrain organoids (Kim et al. 2019). 
Indeed, BDNF is supplemented in each of the protocols at some point but was omitted 
in the generation iPSC myelinoids.  
Another critical difference in the culture of iPSC myelinoids is in the transfer to cell 
culture inserts where they are maintained at an air-liquid interface. This technique 
presents a number of advantages. Firstly, it avoids the aggregation of spheroids when 
maintained long-term in suspension cultures. Secondly, as myelinoids flatten on the 
membranes, myelinoids acquire an orientation that promotes wide-spread myelination 
across their surface and allows for each myelinoid to be processed similarly, 
contributing to the reproducibility of analysis between cultures from different 
conversions. Finally, comparisons between myelinoids and spheroids maintained in 
suspension cultures for similar durations show that whilst myelin formation does occur 
in suspension cultures, a greater degree of myelin is found in myelinoids transferred 
onto PTFE-membranes. This is possibly due to more efficient gas exchange at the 
air-liquid interface and improved culture conditions that favour increased maturity of 
both neurons and glia. Indeed, a recent publication supports the culture of organoids 
at the air-liquid interface due to improved survival and maturity of neurons assessed 
by TUNNEL staining, axonal tract formation, and dendritic morphology 
(Giandomenico et al. 2018). 
The critical advantage of iPSC myelinoids over currently available methods is the 
widespread acquisition of myelin with typical morphology of myelinated axons, that is, 
compacted to a similar degree as is observed in vivo and that also demonstrates 
appropriate organisation of nodal and paranodal domains. This demonstrates the 
enhanced maturity of iPSC-derived myelin in this culture model. The temporal 
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sequence of myelination involves first myelin wrapping, followed by formation of 
axoglial junctions at the distal ends of elongating sheaths, and finally, nodal assembly 
(Rasband et al. 1999; Susuki et al. 2013). In shiverer mice, whose oligodendrocytes 
wrap axons but fail to generate compact myelin due to the absence of MBP, PNJ 
formation is perturbed (Rasband et al. 1999). It is conceivable therefore that the failure 
to observe PNJs in established organoid models—as noted by (Madhavan, Nevin, 
Shick, Garrison, Clarkson-Paredes, Karl, Clayton, Factor, Allan, Barbar, Jain, 
Douvaras, Fossati, R. H. Miller & Tesar 2018b)—is due to the predominance of loose 
or incomplete myelin wrapping in their cultures. 
Importantly, the robust acquisition of myelinated axons with appropriate three-
dimensional architecture in iPSC myelinoids provides a unique platform for 
investigations into both the biology and pathology of human myelination, from 
oligodendrogenesis right through to compact myelin formation.  
However, one limitation of iPSC myelinoids is that they are patterned caudally and so 
reflect spinal cord-derived cell-types. Intrinsic differences between forebrain and 
spinal cord oligodendrocytes have been identified, (Bechler et al. 2015) and recent 
transcriptomic studies have revealed unappreciated heterogeneity within 
oligodendrocytes isolated from similar regions (Jäkel et al. 2019; Leong et al. 2014). 
Whether or not investigations of factors that influence oligodendrocyte differentiation 
and myelination affect all oligodendrocytes equally is yet to be determined. However, 
with these caveats in mind, application of iPSC myelinoids to study myelin 
development in the context of neurodevelopmental or neurological diseases may still 
be indicative of pathological processes or disease mechanisms, irrespective of 
neuronal (and potentially oligodendrocyte) subtype generation.  
With the description of any new model system, an in-depth characterisation is a 
necessary pre-requisite to experimental manipulation. The data presented here give 
a small window into the temporal development of myelin in iPSC-myelinoids and are 
by no means exhaustive. Further analysis of interneuron subtypes and their 
myelination profile, of synapse formation and the physiological properties of myelinoid 
neurons would provide an excellent foundation to pursue questions around the impact 
of myelin formation on network formation and circuit dynamics. Such questions may 
require advanced techniques to probe cellular physiology, including live imaging 
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reporter constructs of calcium activity, and would require successive rounds of gene-
editing to report on the behaviour of individual cells. Nevertheless, iPSC myelinoids 
provide a novel and unique means of assessing compact human myelin formation in 
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Chapter 5 iPSC myelinoids respond 
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5.1 Introduction 
 
A wealth of information is available on the regulation of rodent OPC proliferation, 
differentiation, and myelination including but not limited to: oxygen tension (Yuen et 
al. 2014), trophic factors (Barres et al. 1993; Brinkmann et al. 2008), integrins 
(Colognato et al. 2002), inflammatory cytokines (Yuen et al. 2013), and neuronal 
activity (Almeida & Lyons 2017). Whilst many of these factors are also regulated by—
or indeed themselves regulate—CNS health and function more generally, deciphering 
their role in oligodendrocyte/myelin development will aid our understanding of normal 
and pathogenic myelination and will support novel treatment strategies for disorders 
with which these factors have been associated, including perinatal hypoxia-ischemia 
(Back et al. 2002), multiple sclerosis (Lock et al. 2002), schizophrenia (Stefansson et 
al. 2002), and glioblastoma (Venkatesh et al. 2019). 
Due to the inaccessibility of human tissue, little is known about the factors that 
regulate human myelination and to what extent human oligodendrocytes mirror their 
rodent counterpart. As many orthologous, classically defined, oligodendroglial genes 
are expressed by human cells, core oligodendroglial functions are likely similar (X. Xu 
et al. 2018; Hodge et al. 2019). However, a small subset of differentially regulated 
genes specifically enriched in human cells may confer functional differences to human 
oligodendrocytes and which may play a role in human disease (Hodge et al. 2019; X. 
Xu et al. 2018; Jäkel et al. 2019). Similar indications have appeared from the study of 
human astrocytes, which have, for example, been attributed with sustaining more 
complex information processing (Vasile et al. 2017).  
Physiologically, human oligodendrocytes appear similar to rodent cells (Livesey et al. 
2016; Stacpoole et al. 2013). However, human oligodendrocytes have revealed 
differential responsiveness to specific trophic and transcription factors (Chandran et 
al. 2003; J. Wang et al. 2014) and intrinsic differences in the proliferation, colonisation, 
and myelination of the demyelinated mouse CNS, compared to rodent-derived cells 
(Sim et al. 2009; Windrem et al. 2008; Windrem et al. 2014; Mozafari et al. 2015; 
Buchet et al. 2011; Chanoumidou et al. 2019). Moreover, as oligodendroglial function 
is inextricably tied to myelin formation, our understanding of this key process in human 
cells is limited by the lack of robust models of human myelination. 
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iPSC myelinoids are well-suited for studies of the regulation of human myelination, 
from oligodendrogenesis through to myelin wrapping, compaction, and sub-domain 
organisation. Pharmacological or physiological manipulations therefore may both 
corroborate findings from other animal models and examine human-specific or 
disease-associated responses. In particular, iPSC myelinoids provide a unique 
platform for interrogating activity-regulated myelin development due to the presence 
of multiple CNS-derived cell types and a defined time-course for wide-spread, 
compact myelin formation. This is important as, whilst MRI studies have demonstrated 
experience-dependent white matter plasticity in the CNS (Scholz et al. 2009; 
Bengtsson et al. 2005; Weber et al. 2019; Schlegel et al. 2012; Sampaio-Baptista et 
al. 2013), the structural information obtained from MRI may be attributed to changes 
across several cell-types. This includes OPC proliferation and differentiation, new 
myelination, and myelin remodelling, as well as affecting axonal diameter, branching, 
and vascular changes (Walhovd et al. 2014; Cassandra Sampaio-Baptista 2017). 
Increased FA in the corpus callosum of rats following a learning and memory task and 
in M1-associated white matter following precise motor skill learning is associated with 
localised increased MBP expression (Blumenfeld-Katzir et al. 2011; Sampaio-
Baptista et al. 2013), indicating that experience-dependent white matter changes by 
MRI may reflect myelin related changes in humans. However, direct evidence to show 
that human oligodendrocytes are responsive to changes in neuronal activity is lacking. 
In order to demonstrate the suitability of iPSC myelinoids for use in such studies, it 
was first necessary to show that human oligodendrocytes in this culture model can 
modulate their myelin deposition predictably in response to previously identified 
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5.2 Results 
 
5.2.1 Characterising the myelinating profile of iPSC-derived 
oligodendrocytes 
 
Prior to pharmacological manipulation of iPSC myelinoids, the myelinating profile of 
oligodendrocytes was characterised. Using the marker CNP to label the cell body, 
processes, and internodes of myelinating oligodendrocytes, large tiled areas of myelin 
in MI-12 myelinoids were acquired using a Zeiss 710 confocal with 40X oil objective. 
The acquisition area was large enough to easily count 5–20 cells per field of view, per 
myelinoid. The number and lengths of myelin sheaths per cell were quantified. Figure 
5.1A is a maximum projection image of an example tile of CNP+ oligodendrocytes. To 
show that myelin sheath length can be accurately captured by CNP staining alone, 
segmented lengths obtained from CNP+ myelin sheaths were overlaid onto the 
corresponding image of CASPR+ PNJs to confirm appropriate alignment between 
these structures (Figure 5.1B). Human myelinating oligodendrocytes generated a 
median of 10 ± 6.82 sheaths per cell (Figure 5.1C). Mean standard deviation per batch 
of myelinoids and per myelinoid was 5.06 and 3.98, respectively, demonstrating 
reduced variability within batches of myelinoids. Mean sheath length per cell was 89.4 
± 23.9 µm (mean SD per myelinoid = 20.8 µm) (Figure 5.1C-D). The lengths of all 
sheaths measured were also plotted as a frequency distribution histogram (population 
mean sheath length = 86 µm ± 52 µm) (Figure 5.1E). Additionally, the log-transformed 
histogram is shown in Figure 5.1F, demonstrating the log-normal distribution of sheath 
lengths). 
Given the variation in both sheath number and sheath lengths, I created a composite 
score for total myelin length per cell by summation of all sheath lengths per cell. 
Though not able to account for differences in axonal diameter or myelin sheath 
thickness, the score provides an approximate measure for the myelinogenic output 
per cell. The total myelin length per cell was found to be 1237.20 ± 803 µm (mean SD 
per batch of myelinoids = 382 µm and mean SD per myelinoid = 326 µm) (Figure 
5.1E).  
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These data show that the myelinating profile of individual oligodendrocytes can be 
readily measured in iPSC myelinoids with reproducible results across two cell lines. 
Using this assay, investigations into those factors that modulate myelin development 
can be made. 
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Figure 5.1 Analysis of myelin sheath number and lengths per cell 
A) Maximum projection image of a representative area acquired for measuring the lengths and 
number of CNP+ sheaths per cell, scale = 100µm.   
B) CNP marks the distal ends of myelin sheaths identified by CASPR+ PNJ (red arrows).   
C) Boxplot of sheath number per cell across two control iPSC lines.   
D) Boxplot of mean sheath length per cell.  
E) Boxplot of total sheath length per cell.  
F) Frequency distribution for all sheath lengths.  
G) Log-transformed frequency distribution for all sheath lengths.   
Data collected from 321 cells from 26 different myelinoids across 8 conversions. 
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5.2.2 Oligodendrocyte density does not influence myelin 
sheath number or length 
 
The myelinogenic capacity of oligodendrocytes has been shown to be influenced by 
surrounding biophysical factors including changes in axonal area (Almeida et al. 
2018) and the number of neighbouring oligodendroglial cells (Chong, Rosenberg, 
Fancy, Zhao, Shen, A. T. Hahn, McGee, Xu, Zheng, L. I. Zhang, Rowitch, Franklin, 
Lu & Chan 2012b). In Kif1bp mutant zebrafish for example, a 50-80% reduction in 
reticulospinal axon area does not limit the number of sheaths per oligodendrocyte. 
Instead, supernumerary oligodendrocytes mistarget myelin to neuronal cell bodies 
(Almeida et al. 2018). In RGC-OPC co-cultures, OPCs cultured in the presence of 
polystyrene beads conjugated with oligodendrocyte membrane to mimic increased 
oligodendrocyte densities show a reduction in the number of internodes per cell as 
well as a reduction in the percentage of myelinating oligodendrocytes per field of view 
(Chong, Rosenberg, Fancy, Zhao, Shen, A. T. Hahn, McGee, Xu, Zheng, L. I. Zhang, 
Rowitch, Franklin, Lu & Chan 2012b).  
In order to determine whether the density of neighbouring oligodendrocytes 
contributes to the myelinogenetic capacity of human myelinating oligodendrocytes in 
iPSC myelinoids, I performed a nearest neighbour analysis. I first counted the lengths 
and number of internodes of individual oligodendrocytes, then plotted a circle 
surrounding each cell with a 100µm radius and counted the number of neighbouring 
CNP+ oligodendrocytes within that area (Figure 5.2A). Figures 5.2B-C show the 
correlation between the number of neighbouring oligodendrocytes and myelin sheath 
number or mean sheath length per cell, respectively. Neither measure significantly 
correlated with the number of neighbouring oligodendrocytes. Therefore, in iPSC 
myelinoids, the density of oligodendrocytes does not affect myelin sheath number or 
length. 
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Figure 5.2 Nearest neighbour analysis of oligodendrocyte density 
A) Illustration of nearest neighbour assay. 100µm radius circles were drawn around 
particular oligodendrocytes whose sheaths had been traced and the number of CNP+ 
oligodendrocytes within that area was counted.   
B) Scatterplot correlating the number of sheaths per cell and the total number of 
neighbouring oligodendrocytes (glm, no significant correlation).   
C) Scatterplot comparing mean sheath length per cell and the total number of 
neighbouring oligodendrocytes (glm, no significant correlation).    
Data from 35 cells from 8 myelinoids across 3 batches. 
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5.2.3 Blebbistatin increases myelin sheath number per cell 
 
Oligodendrocyte membrane extension and subsequent wrapping involves dramatic 
cytoskeletal changes that is dependent on the polymerization of actin and tubulin 
(Wilson & Brophy 1989). Filamentous actin (F-actin) is concentrated at the leading 
edge of membrane protrusions in immature oligodendrocytes and also at the inner 
tongue of myelinating processes (Nawaz, Sánchez, Schmitt, Snaidero, Mitkovski, 
Velte, Brückner, Alexopoulos, Czopka, Jung, Rhee, Janshoff, Witke, Schaap, Lyons 
& Simons 2015a). However, the extension of myelin membrane is dependent on actin 
de-polymerisation, which reduces surface tension and enables myelin wrapping 
(Zuchero et al. 2015). A key regulator of actin dynamics in OPCs is non-muscle 
myosin II, which binds to F-actin in lamellipodia and provides cytoskeletal tension 
necessary for membrane protrusion (H. Wang et al. 2008; Domingues et al. 2017). 
During oligodendrocyte differentiation, Myosin II is downregulated, which coincides 
with F-actin depolymerisation and elaboration of myelin (Domingues et al. 2017). 
Importantly, blocking the function of non-muscle myosin II with the inhibitor 
blebbistatin modulates oligodendrocyte myelination by increasing the number of 
myelin sheaths elaborated per cell (H. Wang et al. 2008). 
To demonstrate that the myelinating profile of individual oligodendrocytes could be 
modulated pharmacologically, I treated cultures with 10µM blebbistatin between MI 
and MI-12. Representative images of blebbistatin-treated myelinoids shows wide-
spread myelination (Figure 5.3A). Blebbistatin treatment resulted in a 44.5 % increase 
in the number of myelin sheaths per cell (mean of 9.8 ± 4.8 sheaths per cell vs 14.2 
± 5.4 in blebbistatin-treated cultures) (Figure 5.3B-C). Mean sheath length per cell 
was reduced by 24 % (100.4 ± 28.5 µm to 76.3 ± 19.4 µm) (Figure 5.3D) and total 
sheath length per cell was not significantly different between the two conditions 
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Figure 5.3 Blebbistatin increases myelin sheath number per cell 
A) Representative images of CNP staining in MI-12 myelinoids treated with 
normal media (Ctrl) or supplemented with 10 µM blebbistatin for 12 weeks (scale 
250µm).  
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  Figure 5.3 Blebbistatin increases myelin sheath number per cell contd. 
B) Skeletonised traces of myelin sheaths from Ctrl and Blebb-treated 
myelinoids (scale 25µm).   
C) Blebbistatin increased sheath number per cell (p = 0.0078, 95% CI: 6.2% to 
84.8% increase).   
D) Blebbistatin reduced mean sheath length per cell (p = 0.0015, 95% CI: 10% 
to 36% reduction).   
E) Blebbistatin did not change total sheath length per cell.  
Data collected from 146 cells from 10 myelinoids across two batches.    
< 0.01 ** generalised mixed model with individual myelinoids included as a 
random effect. 
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5.2.4 TeNT reduces myelin sheath number per cell 
 
Having established that the myelinating profile of individual cells can be modulated 
experimentally, I aimed to test whether iPSC-myelinoids could respond to changes in 
neuronal excitability and modulate their myelinogenetic output accordingly.  
To test whether iPSC-derived myelin development could be modulated by dampened 
neuronal activity, myelinoids were exposed to TeNT to suppress neuronal excitability. 
TeNT-induced cleavage and inactivation of VAMP2 is an efficient method to block 
both spontaneous and action-potential-evoked synaptic and nonsynaptic vesicle 
release (Söllner et al. 1993) (Kim et al. 1984), which has profound effects on myelin 
development (Wake et al. 2011; Mensch et al. 2015; Hines et al. 2015). TeNT has 
also been used to shut down synaptic transmission in stem cell-derived neurons 
(Beske et al. 2016). 
Firstly, the expression of VAMP2 as well as PSD-95 and SYNAPTOPHYSIN was 
confirmed in MI spheroids by RT-PCR, demonstrating that the functional target of 
TeNT, as well as structural components of the synapse, are expressed at the point of 
treatment (Figure 5.4A). iPSC-derived myelinoids were then exposed to TeNT by 
supplementing the culture medium with 3nM TeNT (Sigma, heavy chain and light 
chain connected through an interchain disulphide bond) for 12 weeks between MI and 
MI-12. Myelin development was wide-spread in TeNT-treated myelinoids (Figure 
5.4B).  
Manual tracing of the number and lengths of myelin sheaths per cell (Figure 5.4C) 
demonstrated that, averaged across two independent cell lines and five biological 
replicates, myelin sheath number per cell was reduced by an average of 22 % (mean 
9.1 ± 5.9 to 7.1 ± 3.5 TeNT; p = 0.005, 95% CI: 7% to 35%) (Figure 5.4D). Mean 
sheath length per cell was increased in TeNT-treated cultures (14.1% increase, p = 
0.018, 95% CI: 2.4% to 25% increase) (Figure 5.4E) and there was no overall 
difference in total myelin sheath length per cell (Figure 5.4F).  
To determine the effect of TeNT on oligodendrocyte differentiation, the density of 
myelinating oligodendrocytes was evaluated by nearest neighbour analysis. No 
change was observed in the number of oligodendrocytes per 100µm radius between 
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Ctrl and TeNT-treated cultures (Figure 5.4G). Further breakdown of mean sheath 
number and mean sheath length per cell in TeNT-treated cultures is provided as a 
table in Figure 5.4H.  
These data demonstrate that blockade of vesicular release results in a predictable 
reduction in the myelinogenic output of human oligodendrocytes, providing the first 
evidence that human cells can also undergo activity regulated myelination. 
  
  146 
  
Figure 5.4 TeNT reduces myelin sheath number per cell 
A) RT-PCR confirms the expression of VAMP2, PSD-95 and SYNOTPOPHYSIN in MI myelinoid-derived 
RNA +/- reverse transcriptase (RT).   
B) Representative images of CNP staining in Ctrl and TeNT-treated myelinoids (scale 250µm).  
C) Skeletonised myelin sheaths from Ctrl and TeNT-treated myelinoids (scale 25µm). 




Figure 5.4 TeNT reduces myelin sheath number per cell contd.  
D) Sheath number per cell is reduced in TeNT-treated myelinoids. The breakdown per cell line 
shows: iPSC1; 20% reduction in TeNT myelinoids, mean change 8 to 6.4 sheaths per cell, p = 
0.028, 95% 95% CI: 2.2% to 33.9% reduction. iPSC2; 32% reduction in TeNT myelinoids, mean 
change 15.3 to 10.4 sheaths per cell, p = 0.012, 95% CI: 8.1% to 49.3% reduction. 
E) Mean sheath length per cell in TeNT-treated myelinoids. iPSC1; increase of 11.4 %, p = 0.0322, 
95% CI: 0.97 % to 21.76 %. iPSC2; cultures did not show a difference in mean sheath length per 
cell. 
F) Total sheath length per cell in TeNT-treated myelinoids. iPSC1; no change. iPSC2; 25 % 
reduction, p < 0.01, 95 % CI: 10.4% to 36.9%.  
G) Nearest neighbours analysis shows no change in the number of oligodendrocytes per 100µm 
radius. 
H) Breakdown of sheath number and mean sheath length per cell for each batch of myelinoids. 
The combined effect of TeNT across both cell lines is reported in the main text.  
Data collected from 588 cells from 40 myelinoids from 5 batches across two 2 cell lines. 
< 0.05 * < 0.01 ** generalised mixed model with individual myelinoids included as a random effect. 
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5.2.5 Potassium chloride does not affect myelin sheath 
number per cell 
 
Given that a reduction in synaptic vesicle release led to a decrease in the number of 
myelin sheaths per cell, I next asked whether increasing neuronal activity would 
promote myelin sheath number per oligodendrocyte. In order to stimulate neuronal 
activity, I transiently exposed myelinoids to an increased concentration of potassium 
chloride (KCl), which causes membrane depolarisation by stimulating L-type Ca2+ 
channels and NMDA receptors, leading to action potential firing (Bading et al. 1993) 
and increased synaptic vesicle release (Freyberg et al. 2016). Establishing an 
appropriate treatment paradigm for KCl proved challenging. Whilst bath application of 
KCl to cultured neurons elicits stereotypical response within minutes, experiments 
conducted with organotypic slice cultures, which are arguably more similar to 
myelinoid cultures, display KCl-evoked responses from different concentrations and 
time-scales ranging from tens of minutes to several days (Croft et al. 2017; Chen et 
al. 2005) . However, it has also been shown that in hippocampal neurons, chronic 
depolarization with KCl over 7–13 days results in dampened intrinsic excitability, 
whereby greater currents were required to elicit action potentials (O’Leary et al. 2010). 
In order to stimulate myelinoids whilst avoiding plasticity-mediated adaptations, 
cultures were exposed to 15 mM KCl for 2 hours at a time, either once per week (KCl-
1) or three times per week (KCl-3) for 12 weeks.  
Representative figures of whole-mounted myelinoids from Ctrl and KCl-1 cultures are 
shown in Figure 5.5A. Overall, the number of myelin sheaths per cell was not different 
in KCl-treated cultures compared to myelinoids maintained in control medium (Figure 
5.5B). Mean sheath length per cell was again not affected by KCl treatment overall 
(Figure 5.5C). However, the breakdown for each cell line showed that, for iPSC2 
alone, there was an increase). Total myelin per cell was not significantly different 
between the two conditions for both cell lines (Figure 5.5D).  
Whilst I was unable to directly measure the excitability of neurones in KCl-treated 
myelinoids, these data suggest that KCl treatment had either no effect or a slightly 
negative effect on the myelinogenic output per cell.  




Figure 5.5 High KCl does not affect myelin sheath number per cell 
A Representative images of CNP staining in Ctrl and KCl-1 treated myelinoids (scale 250µm). 
B) Sheath number per cell. iPSC1; no change between Ctrl, KCl-1 or KCl-3. iPSC2; 31.3% 
reduction, mean change of 15.2 to 10.5 sheaths per cell in KCl-1, p = 0.03, 95% CI: 3.5% to 51%. 
C) Mean sheath length per cell. iPSC1; no change between Ctrl, KCl-1 or KCl-3. iPSC2; 26% 
increase in mean sheath length per cell, p = 0.013, 95% CI: 4.9 % to 51%.  
D) No change was found in total sheath lengths per cell between Ctrl and KCl-treated myelinoids. 
Data collected from 498 cells from 33 myelinoids from 3 batches across 2 cell lines. 
< 0.05 * generalised mixed model with individual myelinoids included as a random effect. 
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5.2.6 BDNF increases oligodendrocyte density without 
affecting sheath number per cell 
 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of 
growth factors, which together with nerve growth factor (NGF) and neurotrophin 3 and 
4 (NT-3/4), exert a wide range of actions in both the CNS and PNS via two classes of 
transmembrane receptors: the tropomyosin-related kinase (Trk) receptor B (TrkB) and 
p75 neurotrophin receptor (p75NTR). Neurotrophin signalling regulate numerous 
processes including cell survival, proliferation and differentiation, axon and dendrite 
outgrowth, synaptic activity, and myelination (E. J. Huang & Reichardt 2003; Chan et 
al. 2001; Xiao et al. 2009).  
Regarding neuronal activity, BDNF-TrkB signalling enhances differentiation of neural 
precursors, as well as synapse formation and spontaneous neuronal activity (Ahmed 
et al. 1995; Aguado et al. 2003). In addition, BDNF has been shown to enhance 
quantal neurotransmitter release by increasing the number of docked vesicles in 
hippocampal excitatory synapses (Tyler & Pozzo-Miller 2001).  
BDNF can also directly act upon oligodendroglial cells via TrkB receptors to increase 
the total number of oligodendrocytes, the number of myelinating oligodendrocytes and 
myelin area in rat DRG-OPC co-cultures (Xiao et al. 2010; Lundgaard et al. 2013). 
Indeed, both global haploinsufficiency of BDNF as well as conditional knockout of 
Bdnf in mature (MBP+) oligodendrocytes led to CNS hypomyelination (Vondran et al. 
2010; Xiao et al. 2010; Nicholson et al. 2018), though different patterns of 
hypomyelination were observed (Fletcher et al. 2018). Intriguingly, it was shown that 
loss of TrkB expression in Pdgfr-α+ OPCs blocked activity-regulated 
oligodendrogenesis and myelination in optogenetically-stimulated cortical projection 
neurons (Geraghty et al. 2019). Additionally, BDNF has been shown to modulate the 
mode of myelination to one that is NMDAR-dependent (Lundgaard et al. 2013). Thus, 
BDNF is a pro-myelinating factor in the CNS and potentiates both developmental and 
activity-dependent myelination. 
Against this background, I was interested in asking whether 1) BDNF treatment would 
potentiate myelin formation in iPSC myelinoids and 2) whether BDNF had an effect 
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on myelin sheath number or sheath length, which has not previously been 
investigated. To assess the role of BDNF in iPSC myelinoids, 10 ng/ml BDNF was 
supplemented to the myelination medium between MI and MI-12. 
Representative images of Ctrl and BDNF-treated cultures are shown in Figure 5.6A. 
BDNF-treated myelinoids did not show any difference in myelin sheath number or 
mean sheath length per cell (Figure 5.6B-C). However, the density of 
oligodendrocytes was often so high in BDNF-treated cultures that accurate tracing of 
myelin sheaths per cell in those areas was impossible. This is demonstrated by the 
increased number of total and myelinating oligodendrocytes per 100 µm radius (241% 
increase, p = 0.0026) Figures 2.6D-E). Whilst I have shown that oligodendrocyte 
density does not affect sheath number or sheath length under basal conditions, it is 
possible that BDNF may be acting differentially on oligodendrocytes in areas of high 
oligodendrocyte density. Therefore, the role of BDNF in regulating sheath number and 
sheath length remains inconclusive. 
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5.3 Conclusions 
 
In this chapter, I have characterised the myelinating profile of individual human 
oligodendrocytes with respect to sheath number and length per cell and demonstrated 
that myelin development of single cells can be pharmacologically modulated. 
Specifically, blebbistatin treatment increased sheath number per cell by over 40%. 
Furthermore, I have made preliminary investigations into the role of vesicular release 
in regulating activity dependent myelination by human oligodendrocytes. TeNT-
induced blockade of vesicular release reduced myelin sheath number per cell by 22% 
on average without affecting the density of myelinating oligodendrocytes. However, 
the converse experiment to potentiate neuronal activity via KCl-mediated 
depolarisation did not affect myelin formation by individual cells. Finally, BDNF 
treatment had no effect on sheath number per cell but increased the number of 
oligodendrocytes by approximately 2.5 fold.  
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5.4 Discussion 
 
Early in the myelination process, oligodendrocytes rapidly establish the number of 
axons they myelinate after a dynamic process of forming and retracting nascent 
sheaths on neighbouring axons (Czopka et al. 2013). Live imaging studies have 
demonstrated that the number of internodes per cell can be modulated by changes in 
neuronal activity and is remarkably stable thereafter (Mensch et al. 2015; Hines et al. 
2015; Czopka et al. 2013; Hughes et al. 2018; Hill et al. 2018). A number of 
parameters regulate the conduction velocity of action potential propagation along 
myelinated fibres including axon diameter, periaxonal space, and myelin thickness, 
as well as nodal and internodal length (Halter & Clark 1991; Arancibia Carcamo et al. 
2017). Modulating the number and lengths of internodes along individual axons 
therefore provides a mechanism to fine-tune signal transduction (Young et al. 2013). 
iPSC myelinoids generate on average 11.9 myelin sheaths per cell (median = 10), 
though a number of cells were found to myelinate over 40 axons each. Variability in 
sheath number between cells of the same myelinoid was less than for sheath number 
between myelinoids of the same or different batches. In vivo, sheath number and 
sheath length can vary greatly both between and within CNS regions (Murtie et al. 
2007; Chong, Rosenberg, Fancy, Zhao, Shen, A. T. Hahn, McGee, Xu, Zheng, L. I. 
Zhang, Rowitch, Franklin, Lu & Chan 2012a). Mouse cortical oligodendrocytes 
generate up to 60 sheaths per cell (Chong, Rosenberg, Fancy, Zhao, Shen, A. T. 
Hahn, McGee, Xu, Zheng, L. I. Zhang, Rowitch, Franklin, Lu & Chan 2012a) and rat 
spinal cord oligodendrocytes have been shown to generate as few as 1–2 sheaths 
per cell, possibly due to the presence of large calibre axons (Hildebrand & R. Hahn 
1978; Bjartmar et al. 1994). Further comparisons with other model systems (zebrafish: 
approx. 10 sheaths per cell (Mensch et al. 2015), DRG-OPC co-cultures: approx. 7 
sheaths per cell (H. Wang et al. 2008), rat primary oligodendrocytes on inert 
microfibres: approx. 7 sheath per cell (Bechler et al. 2015), shows that iPSC 
myelinoids generate a physiologically relevant number of myelin sheaths per cell, 
which performs better than other in vitro models. Pio del Rio-Hortega highlighted the 
diversity of myelinating oligodendrocyte morphologies nearly a 100 years ago (Pérez-
Cerdá et al. 2015). That single oligodendrocytes in the spinal cord generate fewer 
sheaths surrounding large diameter axons compared to the many small diameter 
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axons myelinated per cell in the brain, has since been confirmed across all animal 
models studied so far (Hildebrand et al. 1993). Even neighbouring oligodendrocytes 
in iPSC myelinoids can demonstrate differing morphologies. Does this reflect different 
subtypes of oligodendrocytes? Does this reflect different axonal targets? Would 
forebrain-patterned myelinoids generate a greater number of internodes per cell? 
These questions remain outstanding. 
Myelin sheath lengths in iPSC myelinoids are surprisingly long for an in vitro model. 
Mean sheath length per cell was found to be 89 µm and multiple sheaths over 300 
µm were observed. Both co-cultures of rat primary oligodendrocytes with either 
DRGs, shiverer mouse organotypic slice culture or microfibres and zebrafish, 
generate a mean sheath length of approximately 20-40µm (Bechler et al. 2015; 
Mensch et al. 2015). In vivo, oligodendrocytes generate a range of lengths between 
20 and 220µm in mice (Chong, Rosenberg, Fancy, Zhao, Shen, A. T. Hahn, McGee, 
Xu, Zheng, L. I. Zhang, Rowitch, Franklin, Lu & Chan 2012a) and up to 241µm in cats 
(Remahl & Hildebrand 1990). More than likely, the enhanced sheath length observed 
reflects the physiological maturity of iPSC myelinoids, resulting from the dense 
compaction of neurons, astrocytes, and oligodendrocytes over several months. As 
human post-mortem data on CNS internodal length is not available and nor is there a 
comparable culture model derived from rodent cells, it is difficult to determine whether 
species-specific differences might also be contributing to increased sheath length. In 
vivo, internode length varies considerably but has been shown to increase linearly 
with axon diameter (Ibrahim et al. 1995). Given the unremarkable calibre of 
myelinated axons observed in iPSC myelinoids (mean 0.8 µm), it is possible that 
human oligodendrocytes are generating comparatively long myelin sheaths. 
However, another factor is the non-histotypical arrangement of axons and the 
abundance of non-myelinated axon area, which might provide myelin sheaths with 
more space to elongate.  
Pharmacological manipulation of iPSC myelinoids modulated the myelinogenic 
potential of individual oligodendrocytes. Inhibition of non-muscle myosin II with 
blebbistatin increased the number of myelin sheaths per cell by 44.5% and also 
reduced mean sheath length per cell. In DRG co-cultures, blebbistatin treatment was 
associated with a 3 to 4-fold increase in sheath number per cell. However, in their 
system, the authors report that oligodendrocytes under basal conditions only 
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generated 4.8 ± 3.5 sheaths per cell (H. Wang et al. 2008). This low degree of base-
line myelination makes it difficult to compare the percentage increase in sheath 
number per cell observed between the two experiments as the therapeutic window 
was greater for their experiment. Nevertheless, this finding demonstrates that 
pharmacological modulation of human myelination is possible and opens up 
possibilities for future studies. 
The results of the TeNT experiment are in-line with a number of other studies that 
have investigated blockade of synaptic vesicle release on myelin development. TeNT-
treated myelinoids demonstrated an overall reduction in sheath number of 22%. 
However, the percentage reduction varied between individual batches of myelinoids 
with 3 out of 5 batches showing over 30% reduction in sheath number per cell. This 
mirrors in vivo data where TeNT-expressing zebrafish show a 30% reduction in sheath 
number per cell (Mensch et al. 2015). A possible explanation for the reduced effect of 
TeNT treatment in the remaining two batches is that the degree of neuronal activity 
may not have developed to a substantial level in those myelinoids. Given that 
myelination is suspected to proceed via both activity-dependent and independent 
mechanisms (Bechler et al. 2017), the percentage difference in sheath number from 
TeNT exposure is dependent on the initial degree of neuronal activity (and activity-
dependent myelination) present within iPSC myelinoids. Additionally, it has been 
shown that vesicular release-mediated myelin development does not occur in all 
neurons. Whilst expression of TeNT in reticulospinal neurons of the zebrafish 
suppressed myelination along their lengths, myelination was normal along 
commissural primary ascending neurons of the zebrafish expressing TeNT (Koudelka 
et al. 2016). Therefore, it possible that blockade of vesicular release had varying 
effects on the myelination of different neuronal subtypes identified in iPSC myelinoids, 
which could influence overall sheath number per cell by the relative proportion of 
those neurons within each (or batch of) myelinoids. 
In DRG-OPC co-cultures, (Wake et al. 2011) used either 3nM BoNT/A or 3µM TeNT 
for at least 18 hours prior to co-culture to abolish vesicular release and saw the 
number of myelin segments per cell reduce dramatically from approximately 8 to 1 
segment per cell. It is possible that the 1000-fold increase in TeNT concentration used 
in their study would have suppressed myelin development further in iPSC myelinoids. 
However, such a high dose may have been toxic over the long time-course of myelin 
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development in this culture model and, as mentioned, a baseline of activity-
independent myelination is expected and indeed supports the positive viability of 
myelinoids exposed to long-term TeNT treatment. Importantly, whilst Wake et al. 
abolished vesicular release prior to co-culture with OPCs, it was found that TeNT did 
not reduce sheath number per cell by directly acting on oligodendrocytes as 
expressing the TeNT light chain exclusively in zebrafish oligodendrocytes resulted in 
a normal number of myelin sheaths per cell (Mensch et al. 2015). 
TeNT exposure resulted in a slight increase in mean sheath length per cell in iPSC 
myelinoids. This result was not consistent across the two cell lines used for this study 
and is not likely to be of biological significance as the percentage increase per batch 
did not correlate with the percentage difference in sheath number per cell (Figure 
5.4G). Indeed, TeNT expression in the developing zebrafish did not modulate sheath 
length (Hines et al. 2015; Mensch et al. 2015). Finally, there is discrepancy in whether 
TeNT affects the number of myelinating oligodendrocytes. Whilst DRG-OPC co-
cultures showed no difference in oligodendrocyte differentiation, both zebrafish 
studies identify a small but significant reduction in the number of myelinating 
oligodendrocytes (Wake et al. 2011; Hines et al. 2015; Mensch et al. 2015). As the 
density of oligodendrocytes was normal in iPSC myelinoids, it may simply reflect 
differences between zebrafish and in vitro culture models. Nevertheless, this is the 
first demonstration that human myelination responds to regulated vesicular release, 
indicating that human oligodendrocytes might respond to changes in neuronal activity 
during development and learning.  
Having demonstrated myelin-related changes in response to suppressed neuronal 
excitability, I attempted the converse experiment: to potentiate myelin sheath number 
per cell by increasing neuronal activity. Whilst KCl robustly induces depolarization of 
cells and release of synaptic vesicles (Bading et al. 1993; Freyberg et al. 2016), KCl-
treated myelinoids did not show an increase in sheath number per cell. A likely 
explanation is due to overstimulation with KCl in the chosen treatment paradigm that 
results in intrinsic adaptation and dampened excitability of neurons. Indeed, a 
reduction of sheath number per cell was found in iPSC myelinoids treated with KCl in 
a subset of experiments. It was also shown that patterned electrical stimulation, rather 
than continuous KCl depolarization more effectively induced release of BDNF in 
neuronal cultures (Balkowiec & Katz 2000). It would therefore be interesting to test 
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whether reducing KCl treatment to very short exposure times would result in a 
different outcome. 
Finally, whilst oligodendroglial TrkB signalling has been shown to potentiate myelin 
development in a number of ways, the role of BDNF in modulating myelin sheath 
number has not been investigated. Interestingly, neither sheath number nor length 
was affected by BDNF treatment. However, as has been shown previously (Xiao et 
al. 2010; Lundgaard et al. 2013), BDNF induced a robust increase in the density of 
myelinating and total number of oligodendrocytes in iPSC myelinoids. Consequently, 
firm conclusions over the role of BDNF in modulating sheath number per cell is difficult 
to make as the increased density of cells prevented manual tracing of sheaths within 
those dense areas of myelin. Though under basal conditions oligodendrocyte density 
did not affect the myelinating profile of individual cells, it possible that BDNF-TrkB 
signalling may be acting directly to modulate the myelinating profile of individual 
oligodendrocytes, in addition to increasing the number of myelinating 
oligodendrocytes. TrkB signalling was shown to be critical for BDNF-mediated 
increases in the number of myelinating oligodendrocytes (Xiao et al. 2010; Lundgaard 
et al. 2013). However, it is also possible that enhanced neuronal activity from BDNF 
exposure supported the integration of new-born oligodendrocytes, as has been shown 
by both sensory enrichment and motor skill learning (Hughes et al. 2018; McKenzie 
et al. 2014). In order to establish, conclusively, whether BDNF modulates 
myelinogenic output per cell, one could employ a virus-based method to sparsely label 
oligodendrocytes as has been shown previously (Osanai et al. 2016). 
In summary, pharmacological and physiological manipulation of iPSC myelinoids 
leads to predictable outcomes in the morphology of individual oligodendrocytes and 
highlights the plasticity of myelin development in this system for further studies of the 
regulators of myelination. 
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6.1 Introduction 
 
A challenging feature of iPSC myelinoids is the heterogeneity of myelin formation 
across the surface of myelinoids. The analysis of individual oligodendrocyte 
morphology described above was performed with blinding and randomisation. 
Although regions of myelin had to be manually selected for analysis, large tiled areas 
were acquired to further mitigate bias. However, a completely unbiased method of 
measuring myelin volume across entire myelinoids would enable researchers to 
address questions relating to the response of global myelin volume to different 
conditions and support the findings made at higher resolution.  
High content automated image analysis is increasingly being employed to in vitro 
cultures to increase experimental throughput, remove human error and bias, and 
improve reproducibility. However, myelin is a technically challenging structure for 
automated segmentation due to the expression of myelin proteins throughout the cell 
body and the processes of oligodendrocytes. A common method of measuring 
myelination relies on quantifying MBP+ pixels above a certain threshold, or those 
pixels that co-localise with an axonal marker such as NF-H (Kerman et al. 2015; 
Lariosa-Willingham et al. 2016). A major challenge is to avoid the inclusion of non-
compacted MBP+ pixels that would improperly contribute to a score of ‘myelin area’, 
especially when maximum projection images are being used. The development of a 
more stringent segmentation method that is able to account for the three-
dimensionality of myelin would enable more accurate analysis of myelin volume and 
improve the confidence in findings.  
This is of particular relevance to studies investigating small molecule-induced 
potentiation of myelin formation. High-content phenotypic screens aiming to identify 
inducers of oligodendrogenesis have identified a number of compounds that promote 
the differentiation of oligodendrocytes (Deshmukh et al. 2013; Mei et al. 2014; Najm 
et al. 2015; Mei et al. 2016; Early et al. 2018; Hubler et al. 2018). When applied to 
secondary myelination assays, these compounds also promote myelin formation and 
aid functional recovery in experimental mouse models of demyelination. Interestingly, 
a miniaturised 96-well-plate myelination assay derived from embryonic rat cortical 
cells, identified different classes of compounds not found in differentiation screens 
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that promoted myelination (Lariosa-Willingham et al. 2016). Whilst not directly 
comparable, due to the presence of neurons in their culture model, this does support 
the view that differentiation and myelination are distinct cellular processes and that a 
combinatorial treatment that targets each of them is a favourable strategy for treating 
white matter disorders.  
Zebrafish offer an alternative and powerful method with which to perform in vivo 
phenotypic drug discovery and was recently used to identify compounds that 
promoted the number of myelinating oligodendrocytes (Early et al. 2018). However, a 
human stem cell-derived high-content screen of oligodendrocyte differentiation has 
also identified novel classes of compounds that have not previously been associated 
with oligodendrocyte differentiation, indicating that species-specific differences might 
exist in regulating oligodendrogenesis (Magnani, Telford-Cooke et al., manuscript in 
preparation). Indeed, the high failure rate of clinical trials based on experimental data 
suggests that more physiological—and potentially species-specific—models of drug 
discovery/validation are required to improve the development of novel treatments 
(Silva & Haggarty 2019; Garner 2014; McGraw et al. 2017). iPSC myelinoids provide 
a complementary tool that bridges high-throughput models of differentiation with a 
human and physiologically representative environment to test the pro-myelinating 
potential of candidate compounds.  
In order to corroborate findings made at the level of individual oligodendrocytes and 
to enable analysis of global changes in myelination in response to pharmacological 
modulation of myelinoids, I sought to develop a novel automated method of whole-
myelinoid myelin segmentation. 
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6.2 Results 
 
6.2.1 Image acquisition 
 
Using the ImageXpress Micro Confocal microscope, entire myelinoids were imaged. 
First, a low magnification (4 X objective) scan of mounted microscope slides was 
performed and regions of interest (ROI) drawn around DAPI+ myelinoids for 
subsequent image acquisition. Each ROI may be composed of between 9 and 25 
sites (each 20 X site has a maximum area of 0.49 mm2). Automated laser-based 
focussing was used to the superficial edge of the myelinoid in each acquisition site. 
Z-stacks between 12-25 µm (1 µm z-step) beginning at the superficial edge were 
acquired using a 20 X plan Apo objective in 42 µm pin hole confocal mode with 10 % 
overlap for stitching. Practically, a single myelinoid captured across a 4x4 grid in 4 
wavelengths and a 12 µm z-stack may be acquired in approximately 23 minutes and 
is composed of 768 individual images and 5.3 GB of data.  
The representative images presented throughout this thesis were acquired on the 
ImageXpress microscope. An ImageJ macro was used to stitch best projection 
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6.2.2 Image analysis 
 
Using the MetaXpress software, a custom module was developed to detect and 
quantify the number of DAPI+ cells, the number of SOX10+ cells, the volume of 
compact myelin and NF-H+ axonal density.  
In order to segment myelin, an adaptive threshold was first used to segment MBP or 
CNP staining to identify objects above a defined threshold of background intensity. 
The Filter Mask tool was used to selectively remove objects with a Fiber Breadth > 16 
µm, a Fiber Length < 10 µm and an Area < 45 µm2. The Shrink Objects tool was then 
used to shrink objects by 4 pixels and a subsequent filter step removed those objects 
that had an Elliptical Form Factor < 3.7, Fiber Breadth of > 8 µm and an Intensity 
Standard Deviation < 500. Keep Marked Objects was then used to retain objects from 
the first Filter Mask that overlaid with the second Filter Mask of shrunk objects. This 
step specifically helped remove the non-myelin objects including cell bodies and 
debris. The Find Blobs tool was used to further identify non-myelin objects with an 
approximate width between 7.5-100 µm, which were then enlarged by 6 pixels and 
subtracted from the Filter Mask. This step was repeated with blobs approximately 4-
6 µm in width. This step was particularly important when segmenting compact myelin 
from CNP-stained myelinoids as CNP also labels myelinating cell bodies and 
processes. Next, another filtration step removed objects with a Total Area < 50 µm to 
again remove non-myelin objects and prevent the formation of interconnected non-
myelin objects in the next step. The 3D tool Connect Touching Objects was used to 
merge objects between neighbouring z-steps to produce a three-dimensional 
segmentation mask. A final filtration step removed 3D objects with a volume ≤ 400 
µm3 and a diameter ≤ 45 µm. Representative images of myelin segmentation in a 
single acquisition site is shown in Figure 6.1A. 
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Figure 6.1 Automated segmentation of myelin formation 
A) Z-stack series of MBP+ myelin in grey with segmented compact myelin overlaid in 
colour with 1µm steps. 
  165 
The segmentation of DAPI+ and SOX10+ cells was achieved by identifying round 
objects of a diameter between 5-10µm, thresholded against local background 
intensity. Each Z-step was then stitched together by connecting touching objects with 
a displacement of 4µm (Figure 6.2A-B). For axonal density, the integrated intensity of 
NF-H+ staining was used as a proxy measure for the density of NF-H+ axons as it was 
not possible to segment individual axons accurately (Figure 6.2C). To do so, a Simple 
Threshold was used to segment the total image area and the Connect by Touching 
tool was used to produce a volumetric measure for the entire acquisition site. The 
integrated intensity of NF-H+ staining, as well as the total volume of segmented myelin 
(µm3) and the number of SOX10+ and DAPI+ nuclei, were measured within this total 
image volume to produce a single score for each measurement. 
Once again, practically, a single unit of analysis (i.e. a single acquisition site) would 
take approximately 6-7 minutes (1 myelinoid ~ 1.5h). However, using the MetaXpress 
PowerCore software, which enables the use of additional central processing units 
(CPUs), up to 9 units of analysis could be completed simultaneously, greatly 
increasing the analysis throughput. Downstream processing was performed using 
RStudio to process exported data tables, aggregate measurements for each 
myelinoid, and perform statistical analyses. 
An important consideration is that since the initial threshold of either CNP+ or MBP+ 
immunostaining has the biggest downstream effect on total myelin area, it was 
necessary to optimise this for each experiment to account for changes in the staining 
intensity. The same settings were then used for each myelinoid and treatment 
conditions per experiment. All other analysis settings were also maintained. When 
comparisons between multiple experiments were made, the data were normalised to 
the mean value of the control condition for each experiment. 
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Figure 6.2 Automated segmentation of other cell-types 
A) DAPI staining and segmentation.  
B) SOX10 staining and segmentation.  
C) NF-H staining and a box to represent extraction of the integrated 
intensity of NF-H+ pixels across the acquisition volume. 
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6.2.3 Automated analysis of myelinoids over time 
 
In order to demonstrate the specificity of the automated analysis in recognising 
compact myelin, Figure 6.3 shows the myelin volume measured from individual 
myelinoids from MI-4, MI-8, and MI-12 alongside best projection images of those 
same myelinoids. Whilst the MI-4 myelinoid has an abundance of non-myelinating 
oligodendrocytes, only a small volume of compact myelin has been measured, 
thereby providing confidence that automated analysis of myelin volume is 
appropriately attributed. 
Figure 6.4 shows a series of measurements obtained from a range of myelinoids 
across the time-course. Figure 6.4 A and B show the increase in myelin volume over 
time from both CNP and MBP-stained myelinoids. Figure 6.4C-E are ratiometric 
measurements of myelin volume normalised to NF-H intensity and the number of 
SOX10+ nuclei respectively, and Figures 3.4D-H show the change in NF-H intensity, 
DAPI+ cells, SOX10+ cells, and the proportion of SOX10+ cells compared to DAPI over 
the time-course. As demonstrated by the spread of myelin volume between MI-12 
myelinoids, the degree of myelination observed between myelinoids can vary greatly. 
This is mostly accounted for by the heterogeneity between conversions of iPSCs, 
rather than between myelinoids of the same conversion. This is shown in Figure 6.4I, 
which compares the standard deviations of measurements obtained per timepoint and 
per batch. The smaller deviations per batch illustrates the need to account for data 
that is nested (i.e. per myelinoid, batch, or cell line) when performing inferential 








Figure 6.3 Automated analysis of individual myelinoids 
A) Automated analysis of myelin volume over time measured from the same myelinoids shown in 
(B).  
Scale = 250µm 
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Figure 6.4 Automated analysis of myelin development 
A) CNP+ myelin volume increased by over 40-fold between MI-4 and MI-8 (p = 0.009) and by over 
80-fold by MI-12 (p < 0.001).  
B) MBP+ myelin volume increased by 2.9-fold between MI-4 and MI-8 (p = 0.02) and by 6.4-fold 
by MI-12 (p < 0.001).   
C) Myelin volume / NF-H+ intensity increased by 9-fold between MI-4 and MI-8 (p < 0.001) and 
by over 15-fold by MI-12 (p < 0.001).  
D) NF-H+ intensity fluctuated minimally between timepoints with no change between MI-4 and MI-
12. However, MI-8 myelinoids showed a 0.5-fold reduction compared to MI-4 (p < 0.001).  
continued overleaf. 
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Figure 6.5 contd. Automated analysis of myelin development 
E) Myelin volume / SOX10+ nuclei increased by over 90-fold between MI-4 and MI-8 (p < 
0.001) and by over 400-fold by MI-12 (p < 0.001).  
F) There was no change in DAPI+ nuclei across the timepoints measured.  
G) SOX10+ nuclei steadily reduced in number over time with 0.4-fold as many SOX10+ 
nuclei at MI-12 than there was at MI-4 (p < 0.001).  
H) Proportion of SOX10+/DAPI+ nuclei steadily reduced in number over time reaching 
0.25X the starting population at MI-4 (p < 0.001). 
Data collected from 23 myelinoids across 7 batches. 
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6.2.4 TeNT reduces global myelin volume 
 
Having demonstrated that our automated analysis could faithfully measure myelin 
volume across myelinoids, we sought to use this method to compare myelin volume 
between experimental conditions.  
I was interested in determining the effect of TeNT on global myelin volume as it has 
previously been shown that expression of the TeNT light chain resulted in a 40 % 
reduction in the number of myelinated axons in the spinal cord of zebrafish (Mensch 
et al. 2015). Additionally, given that we see a 22% reduction in the number of myelin 
sheaths per cell and no change in the density of myelinating oligodendrocytes, one 
might expect that global myelin volume would be equally disrupted.  
Representative images show the distribution of CNP+ myelin, NF-H+ axons, and 
SOX10+ nuclei in Ctrl and TeNT-treated myelinoids (Figure 6.6A). Across two cell 
lines, exposure to TeNT led to an overall reduction in myelin volume by 41% (p = 
0.019, 95% CI: 8% to 62% reduction) (Figure 6.6B). On a subset of experiments, 
myelinoids that had been immunostained with MBP could also be used to measure 
myelin volume. Analysis of MBP+ myelin volume mirrored the results using CNP 
showing a 39% reduction in myelin volume in TeNT-treated cultures (p = 0.054) 
(Figure 6.6C). This result also demonstrates the specificity of the automated analysis 
in removing CNP+ oligodendrocyte cell bodies and processes from the final mask to 
leave only compact myelin, which is easily visualised with MBP due to its 
accumulation in the sheath proper.  
There was no change in NF-H+ intensity between Ctrl and TeNT-treated myelinoids 
across both cell lines (Figure 6.6D) and so the ratio between myelin volume and NF-
H+ intensity was expectedly reduced (32% reduction, p = 0.028, 95% CI: 4% to 52% 
reduction) (Figure 6.6E). Whilst there was no overall difference in the number of 
SOX10+ nuclei between Ctrl and TeNT myelinoids. Breakdown per cell line showed 
that the number of SOX10+ cells was reduced in iPSC2 (15% reduction, p = 0.031, 
95% CI: 9.5% to 87% reduction) (Figure 6.6F). However, as we were only able to 
attain one iPSC-conversion for this cell line, it is difficult to draw a hard conclusion 
from this. The four other iPSC-conversions used in this experiment were from another 
cell line (iPSC1) and do not show a difference in the number of SOX10+ nuclei. Finally, 
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the ratio between myelin volume and SOX10 number was unchanged between Ctrl 
and TeNT-treated myelinoids (Figure 6.6G). 




Figure 6.6 TeNT reduces global myelin volume 
A) Representative images from CNP+ myelin, NF-H+ axons and SOX10+ 
oligodendroglia from same myelinoid. Scale = 250µm.   
Contd. overleaf 
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Figure 6.5 TeNT reduces global myelination contd.  
B) CNP+ myelin volume was reduced in TeNT-treated myelinoids. iPSC1; 36% 
reduction, p = 0.056. iPSC2; 64% reduction, p = 0.068. The overall effect reported 
in the main text is greater due to increased strength of generalised mixed model. 
C) MBP+ myelin volume was reduced in TeNT-treated myelinoids (39% reduction, 
p = 0.05).  
D) NF-H+ intensity was not different between Ctrl and TeNT-treated myelinoids. 
E) CNP+ myelin volume / NF-H+ intensity was reduced in TeNT-treated 
myelinoids. iPSC1: 35% reduction, (p = 0.043, 95% CI: 1.4% to 57% reduction). 
iPSC2: 65% reduction, (p = 0.041, 95% CI: 4% to 87% reduction).  
F) Quantification of SOX10+ number. iPSC1; no change. iPSC2; 15% reduction, 
(p = 0.031, 95% CI: 9.5% to 87% reduction).  
G) No change in CNP+ myelin volume / SOX10+ nuclei in TeNT-treated 
myelinoids. 
Data collected from 40 myelinoids from 5 batches across two 2 cell lines.  
< 0.05 * generalised mixed model with each batch of myelinoids included as a 
random effect.  
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6.2.5 BDNF treatment increases global myelin volume 
 
As discussed above, BDNF has been shown to potentiate myelin volume and can 
directly act upon oligodendrocytes via their expression of TrkB. In iPSC myelinoids 
BDNF treatment increased the density of myelinating oligodendrocytes but had no 
effect on myelin sheath number or mean sheath length per cell (Figure 5.6) In order 
to see whether the increased density of myelinating oligodendrocytes contributed 
towards a greater myelin content overall, automated analysis of myelin volume was 
performed.  
Figure 6.7A shows representative images of DAPI, SOX10, CNP, and NF-H staining 
in Ctrl and BDNF-treated myelinoids. Analysis of DAPI+ nuclei showed no difference 
between the two treatment groups (Figure 6.7B) and whilst a trend towards an 
increase in the number of SOX10+ nuclei is seen in BDNF-treated cultures, neither 
SOX10+ number nor the proportion of SOX10 / DAPI nuclei were significantly different 
between the two conditions (Figure 6.7C-D). However, BDNF treatment did increase 
myelin volume by 83 %. NF-H intensity was unchanged and thus the ratio of myelin 
volume / NFH intensity was also increased, by 75 %. There was no change in the ratio 
of myelin volume / SOX10+ nuclei. This is likely due to the increasing trend of SOX10+ 
cells in BDNF treated myelinoids. 
Thus, BDNF acts to potentiate myelination in iPSC myelinoids by increasing the 
density of myelinating oligodendrocytes and total myelin, similarly to rodent derived 
cultures (Xiao et al. 2010).   
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Figure 6.7 BDNF increases total myelin volume 
A) Representative images of Ctrl and BDNF-treated myelinoids showing DAPI+ nuclei, MBP+ myelin, 
NF-H+ axons SOX10+ oligodendroglia (scale 340µm).  
B-D) There was no change in the number of DAPI+ nuclei (B), SOX10+ nuclei (C) or the proportion of  
Contd. overleaf 
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Figure 6.6 BDNF increases total myelin volume contd.  
oligodendroglial cells (D) in BDNF treated myelinoids.  
E) BDNF increased myelin volume by 83% (p = 0.0067) #.  
F)There was no change in the ratio of myelin volume to SOX10+ nuclei) in BDNF treated myelinoids. 
G) There was no change in NF-H+ intensity) in BDNF treated myelinoids.  
H) BDNF increased the ratio of myelin volume to NF-H intensity by 75% (p = 0.0131, 95% CI: 12% 
to 274% increase) ##.  
Data collected from 26 myelinoids across 3 conversions. # mixed linear model with treatment as 
fixed effect and each conversion as a random effect. ## glm with treatment as fixed effect and each 
conversion as a random effect. * < 0.05, ** < 0.01  
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6.3 Conclusions 
 
In this chapter, I have demonstrated the development of an automated method of 
image acquisition and image analysis that permits unbiased quantification of myelin 
development in iPSC myelinoids. Using the ImageXpress micro confocal and a 
custom designed MetaXpress image analysis pipeline, it is possible to measure DAPI+ 
number, SOX10+ number, myelin volume, and NF-H+ intensity in a three-dimensional 
environment.  
With this platform, I have shown that myelin development increases between MI and 
MI-12, that global myelin volume is reduced in TeNT-treated myelinoids and is 
potentiated in BDNF-treated myelinoids, corroborating the pattern of myelination by 
individual oligodendrocytes in all conditions. 
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6.4 Discussion 
 
To overcome the limitation of pixel-based analysis of myelin volume, I have developed 
a more robust and volumetric method that rapidly identifies compact areas of myelin 
and avoids retention of non-sheath-like objects by filtering segmentation masks on 
their elliptical shape, identifying and removing cell bodies and associated process, 
and filtering neighbouring objects based on their combined area across z-stacks. 
Recently, a deep-learning protocol for high-throughput analysis of myelination was 
reported that was capable of single cell resolution (Y. K. T. Xu et al. 2019). Such 
reports encourage wide-spread adoption of powerful and sophisticated methods of 
data analysis that will improve the reproducibility and generalise findings between 
studies. However, since this tool was not available at the time, the data presented in 
this chapter are based on the ImageXpress pipeline that I have outlined.  
Automated segmentation of myelin in iPSC myelinoids reflects the myelin content 
observed by eye in individual myelinoids. By combining intensity thresholds with size 
and shape filtration of segmented objects, both pre-myelinating oligodendrocytes with 
dim and thin processes or those with expansive sheet-like membrane protrusions 
were excluded, leaving only bright, thick, and linear myelin sheaths. Furthermore, 
similar measurements of myelin volume between CNP-labelled and MBP-labelled 
myelin reflects the specificity of this analysis in identifying internodal myelin. Using 
this method, I’ve shown that myelin volume increases over the time-course. 
Furthermore, the number of SOX10+ cells goes down expectedly over time, reflecting 
the in vivo scenario where the majority of oligodendrocytes that differentiate do not 
survive (Barres et al. 1992; Hughes et al. 2018). Therefore, automated analysis of 
myelin development provides an accurate representation of CNS myelin 
development. 
Using this assay, I was also able to corroborate earlier findings of activity regulated 
myelin development in iPSC myelinoids. TeNT exposure was shown to reduce total 
myelin volume—a phenotype that would be expected following a reduction in the 
number of sheaths per cell whilst maintaining normal numbers of myelinating 
oligodendrocytes. That NF-H intensity was not changed by TeNT treatment supports 
the normal viability of neurons after long-term exposure to TeNT. A reduction in 
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SOX10+ nuclei was found for one of the cell lines used. However, as mentioned, since 
only one conversion of myelinoids was made using this cell line, it is difficult to 
conclusively say whether this is a true effect of TeNT exposure. Nevertheless, these 
results support the opinion that iPSC-derived cultures participate in activity-regulated 
myelination by the global reduction in myelin volume following blockade of vesicular 
release, which can be explained by a reduction in the number of myelin sheaths per 
cell. 
In the previous chapter, I demonstrated that BDNF treatment resulted in an increase 
in the number of myelinating oligodendrocytes with normal sheath number and 
lengths per cell. Therefore, as one might predict, total myelin volume was also 
increased in BDNF treated myelinoids, similar to what has been shown using rodent 
derived cultures (Xiao et al. 2010). In their study, using Campenot chambers that 
physically separate the cell bodies of DRGs and oligodendrocytes, Xiao et al. showed 
that the BDNF-dependent increase in myelin observed was via direct action on 
oligodendrocytes. In this study however, BDNF is likely acting on multiple cell types 
and may also potentiate myelination by increasing neuronal activity.  
Overall, this chapter reports a novel automated pipeline for unbiased quantification of 
myelin and that changes in total myelin volume reflect those at the level of individual 
oligodendrocytes.  
  





Chapter 7 A platform for testing pro-
myelinating compounds 
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7.1 Introduction 
 
Oligodendrocyte or myelin disruption contributes to several neurological disorders 
including perinatal hypoxia (Buser et al. 2012); the childhood leukodystrophies 
(Powers 2004); neurodevelopmental disorders such autism spectrum disorder (Ameis 
& Catani 2015), schizophrenia (Fitzsimmons et al. 2013; Hakak et al. 2001), and major 
mental illness (Haroutunian et al. 2014); and neurodegenerative disorders such as 
multiple sclerosis (Noseworthy et al. 2000), motor neurone disease (Kang et al. 2013), 
Huntington’s disease (B. Huang et al. 2015; J. Zhang et al. 2018), and Alzheimer’s 
disease (Bartzokis 2011). However, in contrast to the prevailing view of CNS tissue 
regeneration, myelin can be repaired spontaneously following damage. 
Remyelination is neuroprotective against inflammatory damage, restores efficient 
conduction velocity to denuded axons, and is associated with functional recovery 
(Franklin & ffrench-Constant 2017).  
Though mature oligodendrocytes are capable of myelin remodelling (Snaidero et al. 
2014; Auer et al. 2018) and despite recent evidence suggests that they contribute to 
repair in humans and large animal models (Yeung et al. 2019; Duncan et al. 2018) 
(see chapter 2.6), the dominant view from mouse studies is that remyelination 
proceeds via the following distinct stages: resident OPC recruitment and colonisation 
of demyelinated lesions, differentiation into mature oligodendrocytes, myelin 
wrapping, and reorganisation of myelinated axon subdomains (Franklin & ffrench-
Constant 2017). During ageing, the efficiency of remyelination progressively declines. 
This has significant consequences for chronically demyelinating diseases such as 
multiple sclerosis, where remyelination ultimately fails, leading to neurodegeneration 
and accumulating disability. Enhancing remyelination is therefore of substantial 
clinical interest. Significantly, the regenerative capacity of OPCs in adult mice was 
shown to be enhanced when stimulated with the milieu of a young mouse during 
heterochronic parabiosis (Ruckh et al. 2012) and, more recently, by the fasting 
mimetic, metformin (Neumann et al. 2019). These studies initially indicated, and 
subsequently demonstrated, that the reduced differentiation potential of aged OPCs 
could be reversed pharmacologically and that the oligodendrocyte lineage may be 
tractable for the treatment of disease (Franklin et al. 2012).  
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However, given the complex series of signalling pathways driving each of the steps 
involved in (re)myelination—as well as the abundance of inhibitory factors that arise 
in disease (Franklin & ffrench-Constant 2017)—the identification of compounds that 
modulate each of these processes in turn will enable treatments to be tailored to 
particular disease pathology. This is relevant for disorders such as multiple sclerosis 
where neuropathological studies have indicated heterogeneity between lesions and 
disruption at multiple stages in the repair process. For example, over 30% of multiple 
sclerosis lesions were found to contain low numbers of OPCs, which is suggestive of 
recruitment failure (Boyd et al. 2013), whilst others have substantial numbers of OPCs 
but few differentiated oligodendrocytes, and still others show an abundance of pre-
myelinating oligodendrocytes (Lucchinetti et al. 2000; Chang et al. 2002). 
Furthermore, remyelinated axons are typified by short and thin myelin sheaths 
(Prineas & Connell 1979; Duncan et al. 2017). 
The abundance of multiple sclerosis lesions demonstrating impaired differentiation 
has led to several high-content phenotypic screens that aimed to identify inducers of 
oligodendrocyte differentiation as a mode to promote remyelination (Deshmukh et al. 
2013; Mei et al. 2014; Najm et al. 2015; Mei et al. 2016; Early et al. 2018; Lariosa-
Willingham et al. 2016; Hubler et al. 2018). Several hit compounds have since been 
validated in vivo and one, clemastine fumarate, was recently shown to have beneficial 
effects on optic nerve conduction velocity in a double-blind clinical trial (Green et al. 
2017). Significantly, clemastine fumarate has also demonstrated positive effects in 
treating other animal models of disease, including Williams syndrome and perinatal 
hypoxia, as well as in a human adult with hypoxic brain injury (Barak et al. 2019; F. 
Wang et al. 2018; Cree et al. 2017).  
Mostly, these studies have relied on purified cultures of primary rodent- or mouse ES-
derived OPCs. This is an important consideration given the differences in the timing 
and scale of human oligodendrogenesis and the possible exclusion of compounds 
that promote myelin wrapping. Indeed, both a miniaturised myelination assay derived 
from embryonic rat cortical cells and an in vivo screen of myelinating oligodendrocytes 
in developing zebrafish identified classes of compounds that promoted myelination, 
which were not found in OPC differentiation screens (Lariosa-Willingham et al. 2016; 
Early et al. 2018). Furthermore, a human iPSC-derived high-content screen of 
oligodendrocyte differentiation has also identified pro-differentiating compounds in 
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drug classes not previously reported, which indicates that species-specific differences 
might exist in the regulation of oligodendrogenesis (Magnani, Telford-Cooke et al., 
manuscript in preparation). Whilst these studies are not directly comparable, due to 
the use of different cellular and animal models, these findings support the view that 
differentiation and myelination are distinct cellular processes and that a combinatorial 
treatment that targets each of them is a favourable strategy for treating white matter 
disorders. Moreover, due to the high attrition of neuroscience-related drug discovery, 
it has been suggested that more physiologically complex—and potentially species-
specific—models of drug discovery/validation are required to support the 
development of novel treatments (Silva & Haggarty 2019; Garner 2014; McGraw et 
al. 2017).  
iPSC myelinoids, when paired with an automated and unbiased method of quantifying 
myelin volume, provide a unique opportunity to test the oligodendrogenic and 
myelinogenic propensity of candidate compounds in a human model of myelination. 
In this chapter, I sought to determine whether automated analysis could be used to 
measure drug-induced changes in oligodendrogenesis and myelination in iPSC 
myelinoids. First, I determined how the regional densities of different cell-types 
correlated with each other, in order to identify a potential bottleneck or rate-limiting 
step in myelinoid myelin formation. Next, I treated myelinoids with miconazole nitrate, 
a previously identified potent inducer of oligodendrocyte differentiation (Najm et al. 
2015), and SGCCBP30, a pro-differentiating compound that was identified in an in-
house automated screen of iPSC-derived oligodendrocyte differentiation.  
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7.2 Results 
 
7.2.1 Myelination is driven by high axonal density 
 
As discussed, myelination takes place in the periphery of myelinoid cultures, which 
provides a large area of myelin that can be easily visualised in 3D in whole-mounted 
myelinoids. However, even within this compartment, myelin appears randomly 
distributed across the surface of myelinoids. I was interested, therefore, in 
determining whether the density of DAPI+ cells, SOX10+ cells, or NF-H+ intensity was 
associated with changes in myelin volume and drew correlations between these 
markers from automated measurements of robustly myelinated myelinoids (see 
Methods).  
Figure 7.1A shows an example myelinoid with uniform expression of SOX10 and 
extensive myelination that appears constrained to areas of high NF-H density. Figures 
7.1B-E show scatter plots correlating the densities of different cell-types. Summary 
statistics show that DAPI+ and SOX10+ nuclei are closely distributed, with an adjusted 
R2 = 0.76, and that myelin volume is not dependent on high numbers of SOX10+ cells 
(R2 = 0.07) but rather high NF-H+ intensities (R2 = 0.6). Finally, a more sophisticated 
analysis with adjustment for the number of oligodendroglial cells present shows that 
myelin volume is predicted by axonal density (R2 = 0.67, p < 2.2e-16). 
These data suggest that myelin formation is highly dependent on axonal density and 
that the density of axons may act as a rate-limiting step in myelinoid myelin 
development, should dense axonal area become saturated with myelin. This is a 
useful consideration for the analysis of compounds whose mechanism of action is 
unknown, as off-target effects on neurons and axonal density may indirectly modulate 
myelin formation. Furthermore, potentiating oligodendrocyte differentiation in the 
absence of high axonal density may underrepresent the promyelinative capacity of 
drug compounds. 
  





























Figure 7.1 Distribution correlations of myelinoid cell-types 
A) Representative images of different cell-types within myelinoids overlaid by 
example grid representing individual acquisition sites for automated analysis 
(scale 250µm).  
B) Correlation between SOX10+ oligodendroglial cells and total DAPI+ nuclei. 
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Figure 7.1 Distribution correlations of myelinoid cell-types contd. 
C) Correlation between SOX10+ oligodendroglial cells and NF-H+ intensity. 
D) Correlation between myelin volume and SOX10+ oligodendroglial cells. 
E) Correlation between Myelin volume and NF-H+ intensity.   
Each dot represents a single square grid (acquisition site). Over 500 data points 
were analysed from 28 myelinoids at MI-12 across 6 conversions. Linear model 
with robust standard errors. 
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7.2.2 Miconazole nitrate 
 
Miconazole nitrate is an antifungal agent that was found to potentiate OPC 
differentiation from mouse pluripotent epiblast stem cells in vitro and which alleviated 
disease severity in the experimental autoimmune encephalomyelitis (EAE) mouse 
model of progressive multiple sclerosis (Najm et al. 2015). Miconazole nitrate, similar 
to several recently identified pro-differentiating compounds, exerts its effects on OPC 
differentiation by targeting CYP51A, an essential enzyme involved in cholesterol 
biosynthesis (Hubler et al. 2018). 
Given the extensive timeframe required for myelinoid myelination, choosing an 
appropriate treatment strategy proved challenging. Figure 7.2 shows the results from 
a single experiment in which myelinoids were cultured continuously with increasing 
concentrations of miconazole (MIC) for 12 weeks between MI and MI-12 (Figure 
7.2A). This treatment strategy had a dose-dependent toxic effect on myelinoids 
Illustrated by the representative images of MBP+ myelin and the quantification of 
SOX10+ cell numbers, myelin volume, and NF-H intensity (Figure 7.2B-C).   
An alternative strategy which involved 8 weeks of treatment between MI and MI-8 
showed that, whilst there was widespread myelination in drug-treated myelinoids, 
there was no difference in the number of SOX10+ cells, nor in the ratio of myelin 
volume to either SOX10 number or NF-H+ intensity between the two groups (Figure 
7.3).  
These data show that treatment with miconazole nitrate did not enhance 
oligodendrocyte differentiation in iPSC myelinoids and that long-term exposure of 
miconazole had a toxic influence on cell viability. 
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Figure 7.2 Optimising drug treatment paradigm 
A) Schematic outlining 12-week miconazole treatment paradigm.  
B) Representative images of MBP+ myelin from MI-12 myelinoids following dose-response 
(scale = 340µm).  
C-E) SOX10+ nuclei, myelin volume and NF-H+ intensity each showed a dose-dependent 
reduction indicative of drug-induced toxicity.  
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Figure 7.3 Miconazole nitrate did not increase myelin volume in iPSC myelinoids 
A) Schematic outlining 8-week 1µM miconazole treatment paradigm.  
B) Representative images of MBP+ myelin from DMSO and MIC-treated MI-8 myelinoids (scale 250µm). 
C) No difference in the number of SOX10+ nuclei between DMSO and MIC-treated myelinoids.  
D) Myelin volume was reduced in MIC-treated myelinoids (52 % reduction p = 0.046). 
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Figure 7.3 Miconazole nitrate did not increase myelin volume in iPSC myelinoids contd. 
E) No difference was found in NF-H+ intensity between DMSO and MIC-treated myelinoids.  
F) No difference was found in myelin volume normalised to either SOX10+ cell number or NF-
H+ intensity between DMSO and MIC-treated myelinoids.  
Data collected from 18 myelinoids across 2 conversions.  
< 0.05 * linear mixed model with each batch of myelinoids included as a random effect. 
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7.2.3 SGCCBP30 
 
For another study in the Chandran lab (separate to this thesis), Dr Dario Magnani 
established a high-content phenotypic screen to identify compounds that promoted 
the differentiation of iPSC-derived oligodendrocytes. A novel epigenetic modulator of 
oligodendrocyte differentiation was identified, SGCCBP30, that greatly increased the 
number of mature oligodendrocytes (Magnani, Telford-Cooke et al., manuscript in 
preparation). A CBP/P300 histone acetyltransferase, SGCCBP30 is a structural 
analogue of another compound, C646, that was independently identified to increase 
oligodendrocyte numbers in the dorsal spinal cord of developing zebrafish (Early et 
al. 2018). 
To determine whether SGCCBP30 (hereafter referred to as SGC) increased the 
number of oligodendrocytes and total myelin volume in iPSC myelinoids, cultures 
were exposed to a short dose-response of SGC between MI and MI-8. After 4 weeks 
of culture, SGC-treated myelinoids demonstrated a widespread increase in the 
number of SOX10+ nuclei and the proportion of oligodendroglial cells identified by 
SOX10+ / DAPI+ nuclei (Figure 7.4). A substantial increase in the number of 
oligodendrocytes was observed by eye at MI-4 though no myelination is observed 
(Figure 7.4B). Analysis at MI-8 revealed that both the increased proportion of SOX10+ 
nuclei and the increased number of oligodendrocytes are maintained (Figure 7.5D-
E). However, there was no increase in compact myelin compared to DMSO-treated 
cultures (Figure 7.5F-G). Whilst these data suggest that SGC treatment robustly 
increased oligodendrocyte number and detrimentally effected myelin formation, a 
major caveat of this experiment is that the degree of myelination observed in control 
cultures was minimal. Unfortunately, this was reflective of a wider cell culture problem 
that led to a reduction in myelinoid quality and a failure to generate myelinating 
cultures for the remainder of this PhD. Therefore, conclusive demonstration of small 
molecule-mediated potentiation of myelin formation in iPSC myelinoids was not 
possible.  
Nevertheless, these results show that it is possible to measure changes in the number 
of oligodendroglial cells and of compact myelin in a human stem cell-derived culture 
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model, using automation thereby providing a platform for investigating the effect of 
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Figure 7.4 SGCCBP30 increases oligodendrogenesis at MI-4 
A) Schematic illustration of 8-week drug treatment paradigm for SGC.  
B) Representative images from the same myelinoid of DAPI, SOX10, MBP, and NF-H staining in Ctrl and 
1µM SGC-treated myelinoids (scale = 250µm).  
C) There was no significant difference in DAPI number between control and SGC-treated myelinoids. 
D) SOX10 number significantly increases in a dose-dependent fashion in SGC-treated myelinoids: 77% 
increase at 0.5µM (p < 0.001, 95% CI: 30% to 240% increase), 73% increase at 1µM (p < 0.001, 95% CI: 
26% to 239% increase).   
E) The proportion of SOX10 / DAPI+ nuclei also increased in a dose-dependent fashion in SGC-treated 
myelinoids: 59% increase at 0.5µM (p < 0.001, 95% CI: 31% to 92% increase), 76% increase at 1µM (p < 
0.001, 95% CI: 26% to 215% increase).  
Data collected from 47 myelinoids across 3 conversions and averaged across 2 cell lines. 
< 0.001 *** generalised mixed model with each conversion of myelinoids included as a random effect.  
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Figure 7.5 SGCCBP30 increases oligodendrogenesis at MI-8 
A) Schematic illustration of 8-week drug treatment paradigm for SGC.  
B) Representative images from the same myelinoid of DAPI, SOX10, MBP, and NF-H staining in Ctrl and 
1µM SGC-treated myelinoids (scale = 250µm).  
C) There was no significant difference in DAPI number between control and SGC-treated myelinoids. 
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Figure 7.5 SGCCBP30 increases oligodendrogenesis at MI-8 contd.  
D) SOX10 number significantly increases in a dose-dependent fashion in SGC-treated myelinoids: 
55% increase at 0.5µM (p = 0.002, 95% CI: 17% to 205% increase), 38% increase at 1µM (p = 
0.0049, 95% CI: 0% to 90% increase).   
E) The proportion of SOX10 / DAPI+ nuclei also increased in a dose-dependent fashion in SGC-
treated myelinoids: 32% increase at 0.5µM (p = 0.018, 95% CI: 4.7% to 65% increase), 57% increase 
at 1µM (p < 0.001, 95% CI: 26% to 200% increase).  
F) No change in myelin volume between DMSO and SGC-treated myelinoids.  
G) No change in NF-H+ intensity between DMSO and SGC-treated myelinoids.  
Data collected from 42 myelinoids across three 3 conversions and averaged across two cell lines.  
p < 0.05 * p < 0.01 ** p < 0.001 *** generalised mixed model with each conversion of myelinoids 
included as a random effect. 
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7.3 Conclusions 
 
In this chapter, I assessed the application of iPSC myelinoids as a platform for the 
validation of prodifferentiating/promyelinating compounds. I demonstrated that small 
molecule induced oligodendrogenesis can be measured using the automated pipeline 
outlined in the previous chapter. Specifically, 4- or 8-week exposure of myelinoids to 
SGCCBP30, a CBP/P300 histone acetyltransferase, increased the proportion of 
SOX10+ nuclei. Further work is required to confirm whether this compound has a 
promyelinating effect in iPSC myelinoids. I also demonstrate the close association of 
myelination with high axonal densities. Whilst only preliminary, these results support 
the use and experimental optimisation of iPSC myelinoids in candidate studies of 
potentiators of human oligodendrogenesis and myelin development.   
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7.4 Discussion 
 
The potential application of myelinoids—paired with an automated quantitative 
analysis of myelination—as a platform for testing promyelinating compounds was 
examined. However, similarly to the promotion of neuronal activity, pharmacological 
potentiation of myelination elicits practical considerations. Most drug screens are 
performed at either 1 or 10 µM for short periods of time over the course of days—not 
weeks—and there is limited data available on the half-life or EC50 of drug compounds 
for cell culture assays. One approach that has been employed to model 
oligodendrogenesis in three dimensional cultures was to transiently expose spheroids 
to drug compounds during glial patterning to inflate the number of OPCs, which 
eventually yielded high numbers of MYRF+ oligodendrocytes with continued culture 
(Madhavan et al. 2018). However, rather than simply potentiating oligodendrogenesis, 
myelinoids permit the identification of compounds that modulate the myelinating 
potential of single oligodendrocytes as well as the total volume of myelin, as I have 
shown with blebbistatin, TeNT, and BDNF treatment. This is important as, given the 
complex signalling pathways involved late in (re)myelination and that many lesions 
are occupied by pre-myelinating oligodendrocytes not engaged in remyelination, the 
assumption that myelin wrapping and myelinated axon sub-domain (re)organisation 
will naturally follow oligodendrocyte differentiation may not be justified (Chang et al. 
2002; Nawaz, Sánchez, Schmitt, Snaidero, Mitkovski, Velte, Brückner, Alexopoulos, 
Czopka, Jung, Rhee, Janshoff, Witke, Schaap, Lyons & Simons 2015b; Franklin & 
ffrench-Constant 2017). The identification of compounds that, either alone or in 
combination, lead to enhanced myelin volume is therefore key. 
Here, I exposed myelinoids to different compounds chronically for 4, 8, or 12 weeks. 
I found that 12 weeks of chronic exposure to miconazole had a detrimental effect on 
myelin development. However, given that these data came from only two conversions 
of myelinoids, further work repeating this experiment with measurements at MI-4 and 
MI-8 will hopefully provide further clarity.  
In contrast to miconazole nitrate, exposure of myelinoids to SGCCBP30 did promote 
oligodendrogenesis. Analysis at both MI-4 and MI-8 showed a significantly increased 
proportion of SOX10+ cells. Representative images also demonstrated a robust 
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increase in the number of MBP+ oligodendrocytes. However, the effect of SGC in 
promoting myelin formation was not able to be addressed due to concurrent tissue 
culture problems outside of our control, leading to a failure of iPSC myelinoids to form 
myelin—even in control conditions. Unfortunately, this failure was maintained in a 
number of subsequent conversions, rendering any further analysis of drug-treated 
myelinoids impossible. Though frustrating, such complications in stem cell-derived 
cultures are not uncommon. Nevertheless, the data demonstrated here shows that 
automated analysis of drug-induced oligodendrogenesis in iPSC myelinoids is a 
suitable and complementary assay to existing capacities.  
Finally, analysis of individual acquisition sites across the surface of myelinoids shows 
that myelin volume is significantly correlated with axonal density (NF-H intensity). 
Axonal density has previously been identified to regulate the fraction of myelinating 
oligodendrocytes in co-culture (Lundgaard et al. 2013). Additionally, increasing the 
number of normal target axons in the developing spinal cord of zebrafish led to an 
increase in total myelin content without affecting the number of oligodendrocytes 
(Almeida et al. 2011). However, in iPSC myelinoids, it appears that it is the initiation 
of myelination that is dependent on high axonal density. One explanation for this could 
be that those non-myelinated, sparse axons possess a calibre below the threshold for 
myelination (approximately 0.2µm) (Lee et al. 2012; Goebbels et al. 2016). Whilst 
rare, the observation of myelinoids with seemingly saturated levels of myelin within 
constrained regions of axonal density identifies a potential ceiling effect in the 
enhancement of myelination in some cultures. This could be resolved by considering 
earlier time-points for analysis. Compounds that accelerate the rate of myelin 
formation will equally be of significant interest.  
Future considerations 
Future studies relating to the use of myelinoids in investigations of pro-myelinating 
compounds should consider alternative treatment paradigms that I performed during 
the course of my PhD study, but are not presented in this thesis. For example, if the 
mechanism of action is known to target early stage progenitor cells, transient 
exposure early-on, followed by continued culture for 6-7 weeks may be suitable, as 
was employed by (Madhavan et al. 2018). However, for compounds expected to 
target late oligodendrocyte progenitors and pre-myelinating oligodendrocytes, a 
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repetitive treatment strategy that continually targets differentiating oligodendrocytes 
might be better suited with drug exposure once per week, thereby limiting drug-
induced toxicity whilst continually targeting newly differentiated oligodendrocytes 
throughout the time-course. Future studies should also consider the use of a 
fluorescent reporter line under the control of MBP or MYRF to quickly screen for drug 















Chapter 8 Disease modelling  
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8.1 Introduction 
 
A major application of this model system, which takes advantage of the source 
material, is the generation of myelinoids from patient-derived iPSCs for in vitro 
modelling of neurological disorders.  
Disparities exist between humans and mice in terms of evolutionary divergence, 
anatomical disproportions, developmental time-courses, divergent gene expression 
profiles, and physiology, which are thought to contribute to the incomplete 
recapitulation of human disorders in rodent models of disease (S L Eaton 2017; Xu et 
al. 2018). Whilst animal models remain an instrumental tool with which to investigate 
cellular mechanism, disease pathogenesis, and preclinical studies of therapeutic 
interventions and drug safety, the rate of translation between drug trials and 
development of therapies is very low—particularly for neurological disorders (Garner 
2014; McGraw et al. 2017). Both methodological flaws in animal studies and disease-
specific differences between animals and humans have been shown to contribute to 
translational failure (van der Worp et al. 2010). Large animal models have been 
suggested to better recapitulate the human condition due to the relatively advanced 
genetic homology observed, especially in primates, and the presence of naturally 
occurring neurological disorders in pigs and sheep (S L Eaton 2017). However, the 
availability and advanced lifecycle of these animals precludes the wide-spread 
adoption of them for research purposes.  
Though reductionist in nature, human iPSC derived cultures offer a powerful resource 
that complements animal studies. With an accessible in vitro environment for 
physiological interrogation and drug delivery, a theoretically unlimited supply of 
material, the ability to compare familial and sporadic forms of disease, and integration 
with clinical and pathology information, iPSC-derived cultures are well-suited for both 
mechanistic studies and drug-discovery purposes. A number of studies have revealed 
disease-associated phenotypes, novel drug targets, and drug combinations using 
patient-derived iPSCs (Silva & Haggarty 2019). Patient-derived iPSCs have been 
used to draw mechanistic insight into disease (Selvaraj et al. 2018), and iPSC-based 
discovery and screening has led to the initiation of a clinical trial for ALS (Wainger et 
al. 2014; McNeish et al. 2015). Organoid cultures provide an additional method for 
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studying the interaction of different cell-types and the function of cells in a more 
physiologically relevant environment. Indeed, organoid cultures have so far been 
employed to model disorders including microcephaly (Lancaster et al. 2013), Costello 
syndrome (Krencik et al. 2017), major psychiatric disease (Johnstone et al. 2019), 
Timothy syndrome (Birey et al. 2017), and Miller-Dieker syndrome (Iefremova et al. 
2017). Therefore, stem cell-derived cultures have great potential in terms of stand-
alone discovery, as well as to complement animal models by demonstrating the 
efficacy of compounds in a human cellular environment and, thus, supporting the 
progression of candidate hits to clinical trial.  
However, whilst in vitro modelling with patient-derived material provides an 
opportunity to study the effect of disease-causing mutations on cell- and non-cell 
autonomous processes, it has not been possible to model functional oligodendroglial-
axon interactions and the consequences of disease-causing mutations on this 
structure in vitro until now.  
Mutations in several genes specific to myelinating glia have been associated with 
neurodevelopmental disorders, leukodystrophies and congenital hypomyelinating 
neuropathies (CHN) (Nave et al. 2007; Vallat et al. 2016; Inoue et al. 2002; Powers 
2004a). These mutations result in myelin pathology but also negatively impact on the 
wider CNS and can present clinically with hypotonia, weakness, areflexia, slow nerve 
conduction and often culminate in early mortality. For example, there have been 
several reports of severe neurodevelopmental disorders arising through distinct 
mechanisms that result in disrupted NoR or PNJ formation. Mutations in GLDN and 
LGI4, which encode secreted cell adhesion molecules involved in NoR formation, lead 
to lethal arthrogryposis (Maluenda et al. 2016; S et al. 2017) and mutations in 
CNTNAP1 result in a rare CHN with paranodal lesions due to the loss of CASPR 
expression (Vallat et al. 2016). Recently, a novel mutation was described that also 
resulted in PNJ disruption due to a recessive homozygous nonsense mutation 
(NM_015090.3 c.2491C>T, p.Arg831Ter) in the NFASC gene (Smigiel et al. 2018). 
Importantly, this mutation was shown to selectively disrupt the transcription of glial 
Nfasc155 without affecting axonal isoforms (Nfasc186 and Nfasc140), which are 
implicated in the assembly and maintenance of the NoR (Smigiel et al. 2018; Zhang 
et al. 2015). A severe clinical phenotype that included hypotonia, amimia and areflexia 
was reported, and immunocytochemical staining of a skin biopsy demonstrated 
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disrupted paranode formation by the absence of both Nfasc155 and CASPR at the 
paranode.  
Mice that lack both major isoforms of NFASC are embryonically lethal. However, 
specific loss of glial Nfasc155 disrupts paranode formation and results in a severe 
motor coordination phenotype and premature death by 17 days. Nfasc155 /  mice 
demonstrate widespread myelination and intact nodal clustering of voltage-gated Na+ 
channels (Sherman et al. 2005). However, conduction velocity is estimated to be 
reduced by 50% (Roche et al. 2014). The clinical severity of Nfasc155 /  mice is 
somewhat surprising, as simply disrupting paranode formation only leads to mild 
motor symptoms, as has been shown in Caspr /  mice. What additional functions 
Nfasc155 might be carrying out is currently unknown.  
Oligodendroglial or myelin pathology are also observed across classical 
neurodegenerative diseases where the contribution of glial pathology to disease onset 
and progression remains unclear (Kang et al. 2013; Huang et al. 2015; Nasrabady et 
al. 2018). ALS has previously been described in this thesis as a progressive and fatal 
neurodegenerative disease characterised by the loss of upper and lower motor 
neurons. Oligodendrocyte pathology is prevalent in ALS (Kang et al. 2013; Lee et al. 
2012; Ebstein et al. 2019). However, the mechanism by which oligodendroglia 
contribute to disease pathogenesis is not understood. Though the majority (90%) of 
ALS cases are sporadic, a striking similarity in key pathological features and 
phenotype largely indistinguishable from that of familial ALS (fALS) emphasises the 
value of studying fALS for drawing mechanistic insight into this fatal disease.  
TDP-43—as has already been described above—is an integral DNA/RNA binding 
protein involved in RNA splicing, translation, and transport (Ratti & Buratti 2016). 
Whilst TARDBP mutations account for ~3% of fALS and ~1.5% of sporadic ALS cases 
(Lagier-Tourenne & Cleveland 2009), a defining pathological hallmark for the majority 
of ALS cases is the accumulation of large TDP-43+ cytoplasmic aggregates in both 
neurons and glial cells (Neumann et al. 2006; Arai et al. 2006; Mackenzie et al. 2010), 
highlighting the importance of this protein in disease pathogenesis. The impact of 
TARDBP mutations on oligodendrocyte function remains unknown. Furthermore, 
whether TARDBP mutations lead to TDP-43 loss of function or toxic gain of function 
remains unclear and has been challenging to study with animal models of TDP-43 
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knockdown and overexpression as TDP-43 auto-regulates its mRNA levels through a 
negative feedback loop (Ayala et al. 2011). Patient-derived iPSCs therefore provide 
a unique opportunity to study the impact of ALS-causing mutations in TARDBP—
expressed at endogenous levels—within a disease-susceptible genetic landscape.  
In order to demonstrate the utility of iPSC myelinoids in modelling neurological 
disorders in vitro, I sought to recapitulate a monogenic disorder of myelinated axon 
organisation (Nfasc155 deficiency) and investigated myelin formation in the context 
of an ALS-causing mutation using patient-derived and gene-corrected iPSCs. 
  




8.2.1 Nfasc-155-/- patient-derived myelinoids recapitulate 
paranodal dysfunction 
 
In order to demonstrate that iPSC-myelinoids are able to phenocopy known features 
of a myelin disease and to emphasise the unique ability of myelinoids to appropriately 
organise myelinated axon domains, we sought to model a recently reported case of a 
severe neurodevelopment disorder that resulted from a homozygous NFASC 
mutation which is predicted to specifically affect expression of the glial isoform 
Nfasc155 (Smigiel et al. 2018). Fibroblasts from the proband were reprogrammed and 
two clonal iPSC lines were obtained in collaboration with Professor Peter J. Brophy 
at the University of Edinburgh, Dr Robert Smigiel at Wroclaw Medical University, 
Poland and Cedars-Sinai. iPSCs were confirmed to be karyotypically normal and 
presence of the NFASC mutation was confirmed by PCR amplification and Sanger 
sequencing of ctrl and Nfasc155 /  DNA (Figure 8.1A). 
Myelinoids generated from patient-derived iPSCs demonstrated intact widespread 
myelination, as has been previously been shown in Nfasc155 /  mice  (Sherman et al. 
2005) (Figure 8.1B). To assess paranode formation, 10 µm cryosections were 
obtained from Cs00ink-n1 (Nfasc155 /  clone 1), Cs00ink-n2 (Nfasc155 /  clone 2), and 
control MI-12 myelinoids. Figure 8.1C-D show that, whilst nodal expression of 
Nfasc186 and ANKYRIN-G were comparable between control and Nfasc155 /  
myelinoids, patient-derived cultures lacked expression of glial Nfasc155 and its 
binding partner, CASPR, at the paranode. The expression of CLAUDIN-11 (which is 
not dependent on PNJ assembly) at the distal ends of Nfasc155 /  myelin sheaths 
demonstrates normal tight-junction formation between myelin lamellae, indicating that 
myelin wrapping is intact in patient-derived cultures (Figure 8.1E). 
These data mirror those from the patient biopsy, as well as those from Nfasc155 /  
mice and show that iPSC-myelinoids can recapitulate the key cellular pathology of a 
compact myelin disorder, in vitro.  
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Figure 8.1 Nfasc155-/- myelinoids show disrupted paranode formation contd. 
B) Representative images of Nfasc155 /  myelinoids at MI-12 (scale = 250µm). 
C) 10 µm cryosections stained with a pan-Neurofascin antibody shows normal nodal 
expression of Nfasc186 but loss of Nfasc155 and CASPR expression at PNJ in 
patient-derived myelinoids (scale = 5µm).  
D) 10µm cryosections stained with ANKYRIN-G and CASPR shows normal clustering 
of nodal domain and loss of PNJs in patient-derived myelinoids (scale = 5µm) 
E) 10µm cryosections stained with CLAUDIN-11 shows normal expression at tight 
junctions at the distal ends of MBP+ internodes, demonstrating myelin wrapping. 
Data collected from > 10 nodes each from 4 separate myelinoids (scale = 5µm). 
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8.2.2 Gene targeting and correction of mutant TARDBP in 
patient-derived iPSCs 
 
In order to investigate the impact of TARDBPG298S on oligodendrocyte biology and 
myelination, I first generated an isogenic gene-corrected cell line via CRISPR/Cas9 
gene targeting. 
The TARDBPG298S mutation results from a c.892G>A substitution that gives rise to a 
rare but particularly aggressive form of fALS (Corcia et al. 2012). Both TARDBPG298S 
and TARDBPM337V iPSCs were generated in-house from patient-derived fibroblasts 
obtained from Professor Chris Shaw, King’s College London. To correct the G298S 
mutation, a CRISPR/Cas9-mediated targeting strategy was employed to integrate a 
180bp ssODN carrying the correct gene sequence at exon 6 of the TARDBP gene 
(Figure 8.2A).  
TARDBPG298S is an autosomal dominant mutation. Therefore, guide RNAs were 
designed to selectively bind the mutant allele and induce a double-stranded break 
(DSB) close to the mutation site (Figure 8.2A). Guide RNA design was performed by 
by Dr Bhuvaneish Selvaraj in the Chandran lab. Further experiments involving 
plasmid construction, gene-correction and screening was performed by myself. To 
test the gRNA-Cas9 targeting efficiency, gRNAs were cloned into a pSp-Cas9-2A-
GFP plasmid and, together with a vector conferring puromycin resistance, were 
transfected into TARDBPG298S iPSCs. Following puromycin treatment, DNA was 
extracted from the transfected cells and a T7 endonuclease assay was performed on 
the PCR-amplified target locus. T7 endonuclease selectively cleaves heterologous 
base pairs, which are regularly introduced following non-homologous end joining 
(NHEJ), the dominant—yet error-prone—repair response to DSBs. Figure 8.2B 
demonstrates successful gene targeting and formation of heterologous base pairs by 
the formation of two products corresponding to 191bp and 262bp. Note, as an 
autosomal dominant mutation, G298S itself introduces heterologous base pairs 
following denaturation and reannealing of PCR products, which results in T7 
endonuclease-mediated cleavage in the patient-derived untransfected DNA (Figure 
8.2B).  
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A 180bp ssODN containing the WT genomic sequence with 90bp arms flanking either 
side of the cut site was designed and ordered as single-stranded DNA from Integrated 
Device Technologies. To limit repeat DSB formation following ssODN integration, 
redundant nucleotides at the 3' end of the gRNA binding site (c.903C>T and 
c.906T>C) were substituted to create 'silent mutations' that reduced the binding 
efficiency of gRNAs without modifying the coding sequence. To create the isogenic 
control line, 800,000 TARDBPG298S iPSCs were transfected with the pSp-Cas9-2A-
GFP plasmid, the pMTL23-gRNA7 vector, the EGFP-Puro vector, and the ssODN, 
using the Lonza 4D nucleofector (programme #CA137). The concentration of each 
transfected reagent is provided in the methods. Transfected hiPSCs were split 
between two wells of a 6wp and, the next day, treated with puromycin for 24 hours. 
To isolate clonal populations of targeted cells, between 1000 and 5000 cells were 
plated onto matrigel- or laminin 511-coated 10 cm dishes as single cells and cultured 
for 1 week. Using an EVOS imaging system, 480 individual colonies were picked and 
passaged into matrigel-coated 96-well plates and, after 10 days, were passaged 1:2 
using EDTA to give 3 sets of replica plates. From 1 set of plates, DNA was isolated 
from each well (see methods) and the target locus amplified by PCR. Confirmation of 
ssODN integration was achieved by restriction digestion and gel electrophoresis. The 
silent mutation c.906T>C within the gRNA-binding site of the ssODN introduced a 
novel BsaJ1 restriction site that produced a 191bp product identified by gel 
electrophoresis (Figure 8.2C).  
Thirty one (6.5%) clones demonstrated integration of the ssODN via BsaJ1 restriction 
digestion. Of those, 3 (0.6%) were devoid of indel mutations, identified by Sanger 
sequencing. Two of the three correctly targeted clones displayed monoallelic 
integration of the ssODN on the mutant allele and one displayed biallelic integration 
of the ssODN. Figure 8.2 shows the Sanger sequencing results from the parental 
G298S cell line, a gene-corrected G298G cell line with monoallelic integration of the 
ssODN, and a second gene-corrected G298G cell line with biallelic integration of the 
ssODN. The remaining clones exhibited indel mutations on either the mutant or WT 
allele that resulted in disruptive missense mutations downstream of the DSB site. 
Karyotype analysis demonstrated no chromosomal abnormalities in either the 
parental TARDBPG298S or the gene-corrected TARDBPG298G cell lines. These data 
demonstrate successful gene-correction of TARDBPG298S ALS patient-derived iPSCs.  





Figure 8.2 Targeted gene correction of TARDBP G298S ALS patient-derived iPSCs 
A) Schematic overview of G298S mutation and targeting strategy for integration of ssODN.  
B) T7 endonuclease assay shows the expected sizes of cleaved products, demonstrating appropriate 
targeting of Cas9.  
C) Gel electrophoresis of BsaJ1 restriction digest dependent on ssODN integration. Neither control 
DNA from another cell line, nor untransfected DNA show cleavage by BsaJ1 (Ctrl and Φ). # shows 
monoallelic integration of ssODN and * shows biallelic integration of ssODN.   
D) Sanger sequencing traces of TARDBP exon 6 showing presence of the G298S mutation in the 
parental line and correction in two different clones. G298G-1 shows monoallelic integration of ssODN 
on the mutant allele with integration of silent mutations (blue and red arrows). G2982G-2 shows 
biallelic integration of ssODN. 
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8.2.3 TARDBPG298S mutation does not affect myelin formation  
 
Drs Samantha Barton and Dario Magnani investigated the impact of TARDBPG298S on 
oligodendrocyte function. They found that TARDBPG298S derived oligodendrocytes 
develop TDP-43+ inclusions, which are resolved following targeted gene-correction. 
However, despite the presence of a TDP-43 proteinopathy, no differences were seen 
in oligodendrocyte maturation, morphology, or function between mutant and control 
oligodendrocytes (Barton, Magnani et al., manuscript in preparation). 
In order to probe the impact of mutant TDP-43 in myelin formation, myelinoids were 
generated from the mutant and gene-corrected G298G iPSCs (with biallelic ssODN 
integration), as well as from a second patient-derived cell line harbouring the 
TARDBPM337V mutation. Figure 8.3A demonstrates efficient myelin induction across 
the three cell lines. 
Analysis of sheath number per cell at MI-12 showed no difference between the two 
mutant TDP-43 cell lines and the isogenic gene-corrected cell line (Figure 8.3B). 
Mean sheath length per cell and the frequency distribution of sheath lengths were 
equally unaffected across the three cell lines (Figure 8.3C-D). Nearest neighbour 
analysis showed that whilst there was a trend for an increase in the number of 
myelinating and total oligodendrocytes per 100µm radius between the mutant vs 
gene-corrected and M337V cell line, this did not reach significance (36% increase in 
number of myelinating oligodendrocytes in G298S vs G298G, p = 0.0898 and 26% 
increase in the total number of oligodendrocytes in G298S vs G298G, p = 0.1911).  
These data demonstrate that myelinoids can be derived from ALS patient-derived 
iPSCs, which shows normal myelination. This mirrors data derived in-house from 
dissociated cultures of iPSC-derived oligodendrocytes showing that the TARDBPG298S 
has no detrimental effect on the maturation or function of oligodendrocytes.  
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Figure 8.3 TARDBPG298S mutation does not impact myelin development 
A) Representative images of CNP+ myelin from G298S, G298G and M337V myelinoids (scale 250µm). 
B) No difference was found in sheath number per cell between the three lines *.  
C) No difference was found in mean sheath length per cell between the three lines *.  
D) Frequency distribution of all sheath lengths shows no differences between the three lines *.  
E) The number of myelinating (E) and total (F) oligodendrocytes per 100µm radius was the same for all three 
lines *.  
Data were collected from 20 myelinoids from three separate conversions (1 conversion only for M337V).  
* p < 0.05, glm with each cell line as fixed effects and each conversion as a random effect.  




This chapter concerned the use of iPSC myelinoids in modelling disease. I 
demonstrated that myelinoids generated from patient-derived cell lines carrying a 
monogenic disease-causing mutation that causes Nfasc155 deficiency are able to 
accurately phenocopy the key pathology of human patients and mouse models. 
Specifically, whilst nodal organisation of Nfasc186 was intact in mutant myelinoids, 
PNJ formation was disrupted and paranodal expression of Nfasc155 and CASPR was 
absent.  
 
In order to investigate whether ALS-causing mutations in the gene for TDP-43 would 
specifically disrupt myelin development in iPSC myelinoids, I performed 
CRISPR/Cas9 gene targeting on a patient-derived cell line in order to generate an 
isogenic gene-corrected control cell line. Using these tools, I found that presence of 
the disease-causing mutation does not affect sheath number per cell, sheath length, 
or oligodendrocyte density. These results were comparable to another ALS patient-
derived cell line carrying a different TARDBP mutation.  
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8.4 Discussion 
 
iPSC-based modelling of different CNS disorders is gaining traction due to continual 
development of protocols that yield both more restricted and more diverse cell-types 
and regionality (Kelava & Lancaster 2016). Whilst organoids have been used to model 
healthy and pathological cell-cell interactions in vitro (Krencik et al. 2017), arguably, 
no other interaction is as complex as the axo-myelin unit. Modelling human compact 
myelin formation in vitro is, therefore, a substantial step forward that enables studies 
of pathogenic myelination in the context of environmental, pharmacological, or genetic 
perturbations. 
In this chapter, I have demonstrated that patient-derived myelinoids carrying a 
missense mutation in the NFASC gene reveal specific disruption to the organisation 
of myelinated axon domains, which accurately mirrors the human condition. These 
data show, for the first time, that disorders of compact myelin can be phenocopied in 
a human stem cell-derived culture model, thus paving the way for further studies of 
pathogenic myelin development for disorders that urgently require therapeutic 
interventions (Powers 2004b). Additionally, given that Nfasc155 /  mice prematurely 
die between P17-P20, investigations into the long-term impact of Nfasc155 deficiency 
or other lethal glial mutations on nodal domain stability and axonal health may be well 
served using iPSC myelinoids (Pillai et al. 2009; Roche et al. 2014). 
Interest has been placed on the role of oligodendrocytes in contributing to the 
pathogenesis of ALS (Kang et al. 2013; Nonneman et al. 2014; Philips et al. 2013; 
Barton et al. 2019). TDP-43 is of significant interest to the ALS field due to the 
presence of TDP-43+ inclusions in nearly all ALS cases and the discovery of several 
ALS-causing mutations in the TARDBP gene. The mechanism by which TDP-43-
dependent neurodegeneration occurs remains unclear: whilst aggregation of TDP-43 
in nuclear and cytoplasmic aggregates are thought to sequester the protein and lead 
to a toxic loss of function (Vanden Broeck et al. 2014), certain gain of function 
properties have been described—in which age-dependent neurodegeneration occurs 
without loss of normal TDP-43 levels (Arnold et al. 2013; Ebstein et al. 2019). 
Ubiquitous TDP-43 knockdown, as well as either MN or oligodendrocyte-specific 
depletion of TDP-43, leads to age-dependent neurodegeneration (Yang et al. 2014; 
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Wu et al. 2012; Iguchi et al. n.d.; Wang et al. 2018). However, given that TDP-43 is 
essential for cell survival and knock-out animals are not viable (Wu et al. 2010; 
Kraemer et al. 2010), more appropriate modelling of mutant TDP-43 at physiological 
levels of expression are likely to be of greater relevance to the human condition. 
Recently, it was shown that endogenous expression of two common TARDBP 
disease-associated alleles (M337V and G298S) results in age-dependent MN 
degeneration, demonstrating that physiological levels of mutant TDP-43 are sufficient 
to initiate disease (Ebstein et al. 2019). The authors, however, did not comment on 
whether oligodendroglial pathology was present in these mice. 
TDP-43 mutant myelinoids did not shown any clear functional differences in myelin 
development compared to the gene-corrected control. This is surprising, given the 
evidence supporting a role for oligodendrocyte pathology in ALS. It is possible that 
mutant TDP-43 does not produce as overt a phenotype as do TDP-43 conditional 
knock-outs and that, given this is a late-onset disease, defects in iPSC myelinoids 
may become apparent with extended culture time. Given the emphasis of 
excitotoxicity in the pathophysiology of ALS (Van Den Bosch et al. 2006), it would be 
interesting to test whether exposing myelinoids to elevated levels of neuronal activity 
would exacerbate a myelin-related phenotype compared to isogenic gene-corrected 
controls. However, as discussed previously, boosting neuronal activity in iPSC 
myelinoids is not straightforward.  
Nevertheless, these data show that iPSC myelinoids offer a tractable platform for in 
vitro modelling of human disease. 
  






Chapter 9 Discussion 
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In this thesis, I set out to establish a robust, human iPSC-derived, in vitro model of 
myelination that would enable investigations into the biology and pathology of myelin 
development using patient-derived iPSCs and that would serve as a platform to 
identify pharmacological modulators of human oligodendrogenesis and myelination.  
I set out to address the paucity of in vitro models of human myelination and 
established an organoid-like culture model that demonstrates substantial myelin 
formation with physiologically appropriate thickness and organisation of myelinated 
axon architecture. I showed that iPSC myelinoids can be generated from a number of 
healthy and patient-derived cell lines, that myelin development is temporally and (to 
an extent) spatially predictable, and that myelin formation can be pharmacologically 
modulated both at the level of individual cells and across entire myelinoids. An 
automated method of measuring myelin volume enabled comparisons between 
whole-myelinoid changes in myelin volume and the myelinogenic output of individual 
cells. 
I characterised the maturation and temporal profile of myelin formation and examined 
the myelinating profile of individual cells and the subtypes of neurons that are 
myelinated in this system. Furthermore, using this platform, I demonstrated—for the 
first time—that human myelinating oligodendrocytes respond to regulation of axonal 
vesicular release, indicating that human myelin development is also regulated by 
changes in neuronal activity and showed that myelinoids recapitulated a monogenic 
disease of myelinated axon organisation, demonstrating the feasibility of modelling 
human neurodevelopmental disorders in vitro. Finally, I generated a gene-corrected 
isogenic control from an ALS patient-derived cell line carrying a TDP-43 mutation 
(TARDBPG298S) and showed that presence of this mutation had no effect on 
oligodendrogenesis or myelin development in iPSC myelinoids.  
An integral component of this thesis that directly relates to the wider context of the 
field is that robust, compact myelin formation is a critical component of 
oligodendroglial function and is something that should not be overlooked in organoid, 
pharmacological or genetic studies of oligodendrocyte biology. Cerebral organoids 
have advanced dramatically in recent years to include oligodendrocytes, microglia or 
functional networks between CNS and peripheral tissue (Abud et al. 2017; 
Giandomenico et al. 2019; Faustino Martins et al. 2020). However, functional 
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maturation of the nervous system requires myelination, which has largely been 
overlooked in the above studies. Axonal transport, axon calibre, neuronal gene 
expression, cytoskeletal composition and posttranslational modification of 
cytoskeletal proteins are all impacted by compact myelination, as demonstrated in 
studies of the dysmyelinating shiverer mouse (Brady et al. 1999). To date, 
organoid/spheroid cultures comprising oligodendrocytes show only limited myelin 
ensheathment and compaction whilst structural organisation of paranodal and nodal 
domains is not recapitulated (Madhavan, Nevin, Shick, Garrison, Clarkson-Paredes, 
Karl, Clayton, Factor, Allan, Barbar, Jain, Douvaras, Fossati, R. H. Miller & Tesar 
2018a). The model described in this thesis contains compact and appropriately 
organised myelinated axons and thus represents a significant step towards 
establishing functionally mature iPSC-derived neural networks. As discussed in 
Chapter 4.4, regional and developmental variation in the timing of human myelination 
may account for the maturation differences between these findings and those of 
previous studies. The caudalisation of our cultures with retinoic acid generates spinal 
cord-patterned tissue, which contrasts with previous studies that generated cortical-
patterned spheroids by the omission of retinoic acid (Madhavan, Nevin, Shick, 
Garrison, Clarkson-Paredes, Karl, Clayton, Factor, Allan, Barbar, Jain, Douvaras, 
Fossati, R. H. Miller & Tesar 2018a; Marton et al. 2019). During human development, 
the emergence of ventral spinal-cord derived oligodendrocytes occurs as early as 10 
gestational weeks (gw) in utero and is followed by the appearance of myelinated fibres 
up to 4 weeks later (Weidenheim et al. 1993). In contrast, MBP+ forebrain-derived 
oligodendrocytes are identified around 17-20 gw but emerge several months before 
the onset of cortical myelination (Back et al. 2002; Jakovcevski et al. 2009). It would 
follow that considerably longer culture times would be required for forebrain-patterned 
cultures to show—beyond myelin ensheathment—the assembly of nodal structures. 
One way to potentially accelerate compact myelin formation in forebrain-patterned 
cultures would be to promote neuronal maturation through extended exposure to 
growth factors such as BDNF. This would be particularly exciting as cerebral 
organoids generate a diverse range of neuronal subtypes that have greater relevance 
to the study of neurodevelopmental diseases compared to spinal cord patterned 
myelinoids. Ultimately, a goal in the neuroscience community will be to generate 
iPSC-derived cultures comprising distinct brain regions as well as central and 
peripheral tissues connected by functional networks. Whether or not such tracts would 
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segregate into rudimentary white and grey matter regions would be very interesting. 
Such a model would enable manifold questions to be asked surrounding axon 
targeting, network maturation, activity regulated myelination and oligodendrocyte 
heterogeneity, to name but a few examples. 
The formation of compact myelin is also important in the context of drug discovery. 
Screening for compounds that might promote remyelination is technically challenging 
and has so far been addressed by identifying modulators of oligodendrocyte 
differentiation in enriched cultures of oligodendrocyte progenitor cells. However, the 
presence of neurons induces significant changes in glial gene expression and function 
(Hasel et al. 2017) and both a miniaturised myelination assay and zebrafish screen of 
myelinating oligodendrocytes identified distinct classes of pro-myelinating 
compounds not found in OPC differentiation screens (Early et al. 2018; Lariosa-
Willingham et al. 2016). One may consider, therefore, the capability of testing drug-
induced changes in human myelination with iPSC myelinoids to demonstrate putative 
action of candidate promyelinating compounds. The automated platform for 
measuring total myelin volume developed during this thesis will be essential for such 
studies through unbiased and higher throughput analysis.  
Additionally, appropriate axo-glial interaction, as demonstrated in this model, enables 
the study of several biological processes and disease mechanisms may now be 
examined. These include the long-term impact of disrupted paranode formation on 
nodal stability and the trophic support of axons and its potential perturbation in ALS. 
There are also areas in which this model system could be improved and parts of this 
work that could be extended. Firstly, a source of variability in myelinoid cultures comes 
from sphere diameter, which varies both within and between batches of myelinoids. 
Changes in sphere diameter will impact the concentration of patterning factors that is 
exposed to neural precursor cells within the developing spheroid. One method that 
has been employed in other organoid models to circumvent this is to seed single 
iPSCs into 96-well-plates or specialised plastic-wear to generate uniformly sized 
spheroids (Marton et al. 2019). Secondly, the culture of myelinoids on cell culture 
inserts in 6-well-plates limits their use in high throughput applications such as 
phenotypic drug screening. Miniaturisation with 24-well-plate cell culture inserts would 
be most analogous to the current method. However, adaptations that would enable 
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long-term culture of spheroids in 96- or 384-well-plates without the use of inserts 
would be most advantageous.   
Unfortunately, during this PhD, I was not able to characterise the extent of network 
formation in myelinoid cultures or directly demonstrate reduced neuronal activity in 
TeNT-treated cultures. To do so, one may use multi-electrode arrays, which have 
been used to study network formation and firing synchrony in organoid cultures 
(Giandomenico et al. 2019). This would significantly add to the characterisation of this 
model and to the study of myelinated axon physiology. Whether changes in network 
formation can be identified with ongoing myelination would be of interest and a 
valuable assay in modelling various diseases.  
Finally, the data presented in this thesis raise a number of questions that would be 
interesting to address in the future: 
1) Why do human stem cell-derived oligodendrocytes take so long to myelinate? 
Human myelin development is prolonged in comparison to other species (D. J. Miller 
et al. 2012; Yeung et al. 2014). However, even the initiation of myelin formation 
following oligodendrocyte differentiation has been shown to be delayed in humans 
(Jakovcevski et al. 2009). These differences appear to be cell-intrinsic, as human 
OPCs transplanted into the shiverer mouse maintain a protracted period of 
proliferation and delayed myelination compared to transplanted rodent-derived cells 
(Dietz et al. 2016). In iPSC myelinoids, it is surprising to see so many premyelinating 
oligodendrocytes at MI-4 and so little myelin at MI-8. It is likely that, similar to the in 
vivo scenario, oligodendrocytes are overproduced during myelinoid development and 
that changes in axonal properties dictate the initiation of myelination. Live-cell imaging 
studies have demonstrated the rapid development of myelin sheaths by zebrafish 
oligodendrocytes (Czopka et al. 2013). Oustanding questions include: do human 
oligodendrocytes similarly establish internodes quickly, after the initiation of 
myelination? Or, is the process of sheath stabilisation, retraction, and eventual 
myelination equally prolonged in humans? If so, are human oligodendrocytes more 
vulnerable to environmental stressors during the myelination programme? Finally, 
what are the transcriptional changes that accompany the initiation of myelin formation, 
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and are there species-specific differences compared to rodent-derived myelinating 
cultures? iPSC myelinoids are well-suited to answering these questions through the 
generation of an MBP promoter-driven reporter line. Surprisingly, the transcriptomic 
changes underlying the initiation of CNS myelination are not currently known and—
given the protracted and temporally regulated programme of myelination in 
myelinoids—picking apart the different stages of myelin development for such studies 
should be relatively straight forward. 
2) Does myelin targeted to different subtypes of neurons differ in length or 
thickness and does interneuron myelin deposition change in the context of 
neuropsychiatric disease? 
I have shown that oligodendrocytes in myelinoids myelinate PV+ interneurons with 
equal frequency to that of PV  axons, suggesting no neuronal subtype bias in axon 
selection. Furthermore, individual oligodendrocytes were shown to myelinate both 
excitatory and inhibitory axons simultaneously. However, whether or not differences 
in sheath length or thickness exist between neuronal subtypes is a question which is 
currently outstanding. Both interneuron and myelin-related pathologies have been 
implicated in neuropsychiatric disorders, including schizophrenia (J Stedehouder 
2017). Therefore, to investigate abnormal myelin development, it would be of great 
interest to interrogate interneuron myelination in control myelinoids (in the absence 
and presence of TeNT, to rule out selection bias of active axons) and in schizophrenia 
patient-derived myelinoids. Interestingly, I also identified evidence of myelinated 
neuronal cell bodies in iPSC myelinoids (Figure 9.1). Studies in zebrafish revealed 
the surprising frequency with which this phenomenon occurs under normal conditions 
and that it can be exacerbated when oligodendrocyte number excessively outweighs 
axonal area (Almeida et al. 2018). Another molecule, Jam2, was identified as a 
somatodendritic inhibitor of myelination. When Jam2 was knocked out, extensive 
myelination of Pax2+ dorsal spinal cord interneuron cell bodies in both zebrafish and 
mouse was observed (Redmond et al. 2016). Myelinated neuronal cell bodies in iPSC 
myelinoids were shown to be positive for PV, suggesting that the mistargeting of 
myelin to inhibitory neuron cell bodies is an evolutionarily shared phenomenon, which 
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provides an assay that may be useful for studies investigating myelin mistargeting in 
different diseases.  




Figure 9.1 Myelinated neuronal cell bodies 
A) Myelinated cell bodies were identified by acquiring serial z-steps by confocal microscopy to 
show CNP+ myelin surrounding NeuN+ neuronal cell bodies (scale 5µm). 
B) Myelinated cell bodies were found to be positive for PV (scale 5µm).  
C) CNP+ oligodendrocytes can be found to extend processes that form normal myelin sheaths 
as well as spherical objects indicative of cell bodies (arrow), scale = 10µm. 
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3) Does increasing neuronal activity in iPSC myelinoids lead to an increase in 
sheath number per cell?  
I have shown that TeNT reduces the number of myelin sheaths per cell, as well as 
causing a global reduction in myelin volume in iPSC myelinoids. Several groups have 
demonstrated the reverse phenotype, whereby potentiating neuronal activity 
increased the number of myelin sheaths per cell, the number of oligodendrocytes, and 
total myelin (Mensch et al. 2015; Gibson et al. 2014). However, such studies are 
typically performed over a short period of time and my efforts at increasing neuronal 
activity in myelinoids proved challenging. Intermittent KCl treatment did not increase 
myelin sheath number or total myelin volume. Myelinoids were exposed to KCl in 2-
hour intervals, once or three times per week, for 12 weeks. It is possible that this 
paradigm led to chronic depolarization of neurons and a reduction in their intrinsic 
excitability (O’Leary et al. 2010). Future work may consider much shorter exposure 
times to KCl (e.g. 1-minute exposure, three times per week). Alternatively, 
optogenetic tools may provide greater temporal control of over neuronal activation, as 
has been shown previously (Gibson et al. 2014). However, in such a closed system, 
identifying the appropriate strength and frequency of optogenetic stimulation will 
inevitably be challenging. 
4) What treatment strategy is best suited for potentiating oligodendrogenesis and 
myelin formation in iPSC myelinoids?  
A more complete discussion of this question can be found in Chapter 7. Just as the 
promotion of neuronal activity, the pharmacological potentiation of myelination throws 
up practical considerations. Most drug screens are performed at either 1 or 10 µM for 
short periods of time, over the course of days—not weeks—and there is limited data 
available on the half-life or EC50 of drug compounds for cell culture assays. One 
approach used to model oligodendrogenesis in three dimensional cultures involved 
transiently exposing spheroids to drug compounds during glial patterning to inflate the 
number of OPCs. This led to increased numbers of oligodendrocytes with continued 
culture (Madhavan, Nevin, Shick, Garrison, Clarkson-Paredes, Karl, Clayton, Factor, 
Allan, Barbar, Jain, Douvaras, Fossati, R. H. Miller & Tesar 2018b). However, rather 
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than simply potentiating oligodendrogenesis, myelinoids permit the identification of 
modulators of the myelination process. Therefore, drug exposure should overlap with 
peak myelin formation, which is between MI-8 to MI-12. In this thesis, I exposed 
myelinoids to different compounds chronically for 4, 8, or 12 weeks. I found that 12 
weeks of chronic exposure to miconazole had a detrimental effect on myelin 
development. However, both 4- and 8-week exposure to SGCCBP30 increased the 
number of SOX10+ cells and MBP+ oligodendrocytes. Unfortunately, it was not 
possible to explore this further due to technical problems with the cell cultures that 
affected myelin formation in iPSC myelinoids. Future studies should consider the use 
of a fluorescent reporter line under the control of MBP or MYRF to quickly screen for 
drug effects and to identify appropriate treatment paradigms. 
5) How might microglia contribute to myelin development and disease in iPSC 
myelinoids?  
Microglia are essential regulators of CNS development and have important functions 
in stimulating neurogenesis, network wiring, and phagocytosing apoptotic cells (Ueno 
et al. 2013; Squarzoni et al. 2014; Sierra et al. 2010). Microglia also play an integral 
role in myelin development by regulating oligodendrocyte cell numbers (Hagemeyer 
et al. 2017) and in remyelination by clearing myelin debris and orchestrating pro- and 
anti-inflammatory cues that drive the repair process (Miron et al. 2013). I was 
interested in adapting myelinoid cultures so as to ask questions such as: can microglia 
be integrated into myelinoids? What effect might microglia have on myelin 
development? Would it be possible to model demyelination and remyelination in 
microglia-containing myelinoids? To begin this process, iPSC-derived microglia were 
generated by Dr. Poulomi Banerjee (manuscript in preparation) and were added onto 
myelinoids at MI by seeding 50,000 cells in a total of 5 µl of media. Microglia could be 
seen surrounding myelinoids, with some having landed on top and others surrounding 
the base. It was hoped that microglia would migrate into the myelinoid via chemotaxic 
signalling. Three days after co-culture, myelinoids were fixed, sectioned, and stained 
for microglia markers. Figure 9.2 shows the presence of multiple IBA-1+ microglia 
within myelinoids that are exhibiting ramified and amoeboid morphologies and 
expressing TMEM-119 or P2YRY12, reflecting homeostatic and activated states, 
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respectively (Bennett et al. 2016). This preliminary data demonstrates successful 
integration of microglia into myelinoids, which will allow us to interrogate their role in 
the development and degradation of myelin. Future questions investigating whether 
microglia generated from different patient-derived cell lines show differences in their 
regulation of myelin development would be of great interest. 
  







Figure 9.2 Myelinoid-microglia co-culture 
A) Widespread integration of iPSC derived microglia in myelinoids at MI (scale 50µm) 
B) 3D projection of single microglia demonstrating highly ramified projections (scale 10µm). 
C-D) iPSC microglia display activated (P2RY12) and quiescent (TMEM119) markers (scale 5µm). 
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In summary, this thesis describes the successful development of an in vitro model of 
myelination using human iPSCs that displays appropriate hallmarks of maturity. Using 
this platform, I have shown that human myelination can be modulated by 
pharmacological and physiological manipulation, including changes in neuronal 
activity. I have developed an automated, unbiased, and whole-spheroid analysis of 
myelin volume and have used this pipeline to corroborate findings made at the level 
of individual oligodendrocytes. Finally, using patient-derived cell lines, I showed the 
feasibility of modelling human myelin disorders in vitro. It is hoped that this model will 
be of interest to myelin researchers for application in studies of the physiology and 
pathology of myelin development.  
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10.1 ImageJ macro for blinding and randomising 
filenames 
 
// This macro renames files with an identifying experimental name + a random 
number. 
// A .csv table is created in the output directory with both blinded and original filename 
 
print("\\Clear"); 
dir=getDirectory("Select a folder of files");  
newDir=getDirectory("select an output folder to save files");   
list=getFileList(dir); 




Dialog.addString("Provide an identifying name for the experiment",identifyingname); 
Dialog.show(); 
identifyingname = Dialog.getString(); 
 
f = name; 
makeTable(); 
 
for (i=0; i<list.length; i++){ 
 k=i+1;   
 filename=dir+list[i]; 
 newName= newDir+ identifyingname + random + ".lsm"; 
 print(f, k+"\t"+filename+"\t" +newName+"\t"); 
 File.copy(filename, newName); 
} 
 
function makeTable() { 
name = "[Blind table]"; 
 run("New... ", "name="+name+" type=Table"); 
 f = name; 
 print(f, "\\Headings:#\tfilename\tnewName\tdir\tnewDir"); 
} 
selectWindow("Blind table"); 
saveAs("results", newDir +"Blinded_fileNames.csv");    
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10.2 ImageJ macro for stitching and exporting best 
projection images from ImageXpress 
 
// This macro organises best projection images exported from the ImageXpress 
microscope. 
// It transfers images across all sites from each well into individual Well+Channel 
subfolders (maximum 4 wavelengths). 
// The macro user then selects which subfolder of images to stitch together and the 
fused image is displayed 
// and saved in new Directory. 
// This macro uses the grid coordinates to stitch tiles together. Ensure you know the 
grid coordinates before running macro. 
// Author: Owen Gwydion James s1470204@sms.ed.ac.uk 
// Dementia Research Institute, Chancellor's Building, University of Edinburgh 
// 26-2-2018 
 
dir=getDirectory("Choose ImageXpress plate folder eg.747");     
newDir=getDirectory("Where do you want to save the output images?");  




for(i=0; i<list.length; i++){ 
  if(endsWith(list[i],".tif") || endsWith(list[i], ".TIF")){ 
    
  //Retrieves well name from file name 
  indexWell=indexOf(list[i], "_");     
   //Example filename = "........._A01_s1_w1.......tif" 
  wellName=substring(list[i],indexWell+1,indexWell+4 ); 
  listOfWell = Array.concat(listOfWell, wellName); 




 // Extracting unique well name from well array (uses the sorted well array) 
 sortedListOfWell=Array.sort(listOfWell); 
 uniqueWell=newArray(sortedListOfWell[0]); 
  for (k=1; k<sortedListOfWell.length; k++){ 
   if (sortedListOfWell[k] != sortedListOfWell[k-1]){ 
   uniqueWell=Array.concat(uniqueWell, sortedListOfWell[k]); 
   Array.print(uniqueWell); 
}} 
 
 // PadZero for siteName (replaces s_1 with s_01) 
 for(i=0; i<list.length; i++){ 
  if(endsWith(list[i],".tif") || endsWith(list[i], ".TIF")){ 
   indexSite=indexOf(list[i], "_s"); 
   indexEndSite=indexOf(list[i], "_w"); 
   siteName=substring(list[i],indexSite+2,indexEndSite ); 
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   fullSiteName=substring(list[i], indexSite, indexEndSite); 
   lengthOfSiteName=lengthOf(siteName); 
   print(siteName); 
   print(fullSiteName); 
   print(lengthOfSiteName); 
    if (lengthOfSiteName==1){ padZero= "0"; } 
    if (lengthOfSiteName==2){ padZero= ""; } 
    if (lengthOfSiteName>2){exit("Error padding zero");} 
      firstPart=substring(list[i], 0, 
indexSite+2); 
      secondPart=substring(list[i], 
indexSite+2, lengthOf(list[i])); 
     
 newName=firstPart+padZero+secondPart; 
      print(newName); 
      File.rename(dir+list[i], dir+newName); 
}} 
 
// Identify files with different wavelengths and copy into new subfolders 
 
m=0; i=0; j=0; 
for (m=0; m<uniqueWell.length; m++){       
 
//For each unique well name (eg.A01) process the following:  
 
 for(i=0; i<list.length; i++) { 
  if(endsWith(list[i],".tif") || endsWith(list[i], ".TIF")){ 
  indexChannel=indexOf(list[i], "_w");  
  firstChannelPart=substring(list[i], 0, indexChannel+2); 
  channelName=substring(list[i],indexChannel+1,indexChannel+3 ); 
  print(channelName); 
  matchWell=".*_"+uniqueWell[m]+".*"; 
    
if((matches(list[i], ".*_w1.*")) && (matches(list[i], matchWell) && (matches(list[i], 
".*thumb.*") != 1))){     
 
//finds files of wavelength 1 
 
 print(list[i]); 
   
 newDirName=newDir+"Well_"+uniqueWell[m]+"_Channel_1"; 
 File.makeDirectory(newDirName);       
 print(newDirName);         
 File.copy(dir+list[i], newDirName+File.separator+list[i]);   
  
//Copies files into new directory 
   } 
 
if((matches(list[i], “.*_w2.*”)) && (matches(list[i], matchWell) && (matches(list[i], 
“.*thumb.*”) != 1))){   
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//Same again for wavelength 2 
 
 print(list[i]); 
   
 newDirName=newDir+"Well_"+uniqueWell[m]+"_Channel_2"; 
    File.makeDirectory(newDirName); 
    print(newDirName);   
    File.copy(dir+list[i], newDirName+File.separator+list[i]); 
   } 
 if((matches(list[i], ".*_w3.*")) && (matches(list[i], matchWell) && 
(matches(list[i], ".*thumb.*") != 1))){   
 
//Same again for wavelength 3 
  
 print(list[i]); 
   
 newDirName=newDir+"Well_"+uniqueWell[m]+"_Channel_3"; 
    File.makeDirectory(newDirName); 
    print(newDirName);   
    File.copy(dir+list[i], newDirName+File.separator+list[i]); 
   } 
 if((matches(list[i], ".*_w4.*")) && (matches(list[i], matchWell) && 
(matches(list[i], ".*thumb.*") != 1))){   
 
//Same again for wavelength 4 
  
 print(list[i]); 
   
 newDirName=newDir+"Well_"+uniqueWell[m]+"_Channel_4"; 
    File.makeDirectory(newDirName); 
    print(newDirName);   
    File.copy(dir+list[i], newDirName+File.separator+list[i]); 
   } 






// Creating a list of the Well+Channel subfolders  
 newDirlist=getFileList(newDir);  
 wellChannelList=newArray(); 
  for(j=0; j<newDirlist.length; j++){ 
   if(matches(newDirlist[j], ".*.tif.*") != 1){ 
   wellChannelList=Array.concat(wellChannelList, newDirlist[j]); 
   Array.print(wellChannelList); 
}} 
 
//Automated determining of tile configuration. In nearly all cases, Xtile is greater than 
//Ytile. Beware of this assumption. 
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 Xtile = 3;         
    Ytile = 3; 
} 
if(copiedList.length==12){ 
 Xtile = 4;         
    Ytile = 3; 
} 
if(copiedList.length==16){ 
 Xtile = 4;         
    Ytile = 4; 
} 
if(copiedList.length==20){ 
 Xtile = 5;         
    Ytile = 4; 
} 
if(copiedList.length==25){ 
 Xtile = 5;         
    Ytile = 5; 
} 
if(copiedList.length==30){ 
 Xtile = 6;         
    Ytile = 5; 
} 
if(copiedList.length==36){ 
 Xtile = 6;         





for(f=0; f<wellChannelList.length; f++){ 
 tempDir=newDir+wellChannelList[f]; 
  print("the TempDir is: "+ tempDir); 
  ChoiceIndex=indexOf(tempDir, "Well"); 
  ChoiceNameEnd=lengthOf(tempDir); 
  ChoiceName=substring(tempDir, ChoiceIndex, ChoiceNameEnd-1); 
  
//Extracts the name of the chosen file to be used for saving stitched image 
   
print("the choiceName is: "+ ChoiceName); 
  File.makeDirectory(tempDir);      
  File.isDirectory(tempDir);       
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  tempList=getFileList(tempDir); 
  Array.print(tempList); 
 
  for(i=0; i<tempList.length; i++){ 
 
// identifies the full site name and replaces with variable {ii} 
 
  if(endsWith(tempList[i],".tif") || endsWith(tempList[i], ".TIF") && 
(matches(tempList[i], ".*Stitched.*") != 1)){ 
    currentName=tempDir+tempList[i]; 
    indexSiteX=indexOf(tempList[i], "_s"); 
    indexEndSiteX=indexOf(tempList[i], "_w"); 
    firstPart=substring(tempList[i], 0, indexEndSiteX+3); 
    shortenedName=firstPart + ".tif"; 
    print("the ShortenedName is: " + shortenedName); 
    newTempName=tempDir+shortenedName;  
  tempSiteName=substring(tempList[i], indexSite, indexEndSite); 
     
 genericFileName=replace(shortenedName, tempSiteName, "_s{ii}"); 
    File.rename(currentName, newTempName); 
    print("the generic File Name is: " + genericFileName);
      
    }} 
 
// run grid/collection stitching 
 
 run("Grid/Collection stitching", "type=[Grid: row-by-row] order=[Right & Down                
] grid_size_x=Xtile grid_size_y=Ytile tile_overlap=10 first_file_index_i=1 
directory=[&tempDir] file_names=[&genericFileName] 
output_textfile_name=TileConfiguration.txt fusion_method=[Linear Blending] 
regression_threshold=0.30 max/avg_displacement_threshold=2.50 
absolute_displacement_threshold=3.50 computation_parameters=[Save memory 
(but be slower)] image_output=[Fuse and display]"); 
  
saveAs("tiff", newDir + shortenedName + "_Stitched_image" + ".tif");  
   
} 
 
for(x=0; x<wellChannelList.length; x++){ 
 print(wellChannelList[x]); 
 File.isDirectory(newDir+wellChannelList[x]+File.separator);  
 File.delete(newDir+wellChannelList[x]+File.separator);   
 File.isDirectory(newDir+wellChannelList[x]+File.separator);   
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